TERT immunogenic composition and treatment method using the same
By using a composition encoding a nucleic acid molecule and an immune checkpoint inhibitor that encodes a TERT antigen, the immune response is stimulated, and the problem of limited effectiveness of existing cancer treatment methods is solved, and effective treatment and prevention of various cancer types is achieved.
Patent Information
- Application Number
- CN201780073893.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2017-03-07
- Filing Date
- 2017-09-29
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2038-05-26
AI Technical Summary
Existing cancer treatments have limited effectiveness in preventive and therapeutic aspects, and more effective compositions and methods are needed to delay disease progression and reduce mortality from cancer.
Immunogenic compositions containing nucleic acid molecules encoding shared TERT antigens are used in combination with immune checkpoint inhibitors for the treatment or prevention of various types of cancer, and the composition is introduced into the subject through electroporation and other methods.
This method can effectively stimulate immune response, enhance its resistance to cancer cells, delay cancer progression and reduce mortality. It is suitable for a variety of cancers such as melanoma, head and neck cancer, prostate cancer, etc.
Smart Images

Figure CN110573173B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 62 / 402,695, filed on September 30, 2016, and U.S. Provisional Application No. 62 / 468,124, filed on March 7, 2017, which are hereby incorporated by reference in their entirety. Technical Field
[0003] Disclosed herein are compositions and methods for treating cancer, and in particular immunogenic compositions that treat tumors and provide protection against tumor growth. Background Art
[0004] Cancer is one of the main causes of death worldwide, and is the second most common cause of death in the U.S., accounting for almost 1 in every 4 deaths.Cancer arises from a single cell that has been transformed from a normal cell into a tumor cell. Such a transformation is typically a multi-stage process, progressing to a malignant tumor from a precancerous lesion. Various factors contribute to this progress, including aging, genetic contributions and exposure to external agents such as physical carcinogens (for example, ultraviolet radiation and ionizing radiation), chemical carcinogens (for example, components of asbestos, tobacco smoke, etc.) and biological carcinogens (for example, some viruses, bacteria and parasites).
[0005] Prevention, diagnosis, and treatment of cancer can take many different forms. Prevention can include screening for predisposing factors (e.g., specific gene variants), behavioral changes (e.g., smoking, diet, and physical activity), and antiviral (e.g., human papillomavirus, hepatitis B virus) vaccinations. Treatment can include chemotherapy, radiotherapy, and surgical removal of tumors or cancerous tissue. Although many preventive and therapeutic methods are available, such methods generally achieve limited success in effectively preventing and / or treating current cancers.
[0006] Therefore, there is a need to identify and develop compositions and methods for preventing and / or treating cancer to facilitate clinical management of protection against disease progression. In addition, there is a need for more effective treatments to delay disease progression and / or reduce mortality in subjects with cancer. Summary of the invention
[0007] In one embodiment, the present invention relates to an immunogenic composition comprising a nucleic acid molecule encoding a consensus TERT antigen. In one embodiment, the consensus TERT antigen comprises an amino acid sequence selected from the group consisting of: a) an amino acid sequence selected from the group consisting of: SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, and SEQ ID NO: 56, b) an amino acid sequence having 95% or greater identity to an amino acid sequence selected from the group consisting of: SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, and SEQ ID NO: 56, and c) a fragment of an amino acid sequence selected from the group consisting of: SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, and SEQ ID NO: 56, wherein the fragment comprises at least 95% of the full-length amino acid sequence.
[0008] In one embodiment, the immunogenic composition further comprises one or more nucleotide sequences encoding one or more amino acid sequences selected from the group consisting of: a) an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO;58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70; b) an amino acid sequence having 95% or greater identity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO;58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70 NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO;58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, and c) a fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO;58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, wherein the fragment comprises at least 95% of the full-length amino acid sequence.
[0009] In one embodiment, the immunogenic composition further comprises a nucleotide sequence encoding one or more antigens selected from the group consisting of: MAGE A1, gp100, viral antigens, and combinations thereof. In one embodiment, the viral antigen is an antigen from hepatitis B virus (HBV), hepatitis C virus (HCV), or human papillomavirus (HPV). In one embodiment, the HBV antigen is an HBV core antigen or an HBV surface antigen, or a combination thereof. In one embodiment, the HCV antigen is an HCV NS34A antigen, an HCV NS5A antigen, an HCV NS5B antigen, an HCV NS4B antigen, or a combination thereof. In one embodiment, the HPV antigen is an HPV 6 type E6 antigen, an HPV 6 type E7 antigen, an HPV 11 type E6 antigen, an HPV 11 type E7 antigen, an HPV 16 type E6 antigen, an HPV 16 type E7 antigen, an HPV 18 type E6 antigen, an HPV 18 type E7 antigen, or a combination thereof.
[0010] In one embodiment, the immunogenic composition further comprises an immune checkpoint inhibitor.
[0011] In one embodiment, the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: a) a nucleotide sequence selected from the group consisting of: SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53 and SEQ ID NO:55, b) a nucleotide sequence having 95% or greater identity to a nucleotide sequence selected from the group consisting of: SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53 and SEQ ID NO:55, and c) a fragment of a nucleotide sequence selected from the group consisting of: SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53 and SEQ ID NO:55, wherein the fragment comprises at least 95% of the full-length nucleotide sequence.
[0012] In one embodiment, the immunogenic composition comprises one or more nucleotide sequences selected from the group consisting of: a) a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69; b) a nucleotide sequence having 95% or greater identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69; NO:21, SEQ ID NO:23, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67 and SEQ ID NO:69, and c) a fragment of a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67 and SEQ ID NO:69, wherein the fragment comprises at least 95% of the full-length nucleotide sequence.
[0013] In one embodiment, the nucleic acid molecule is a plasmid.
[0014] In one embodiment, the immunogenic composition comprises one or more plasmids.
[0015] In one embodiment, the immunogenic composition further comprises an adjuvant. In one embodiment, the adjuvant is IL-12, IL-15, IL-28 or RANTES.
[0016] In one embodiment, the present invention relates to a method for treating or preventing cancer in a subject in need thereof, the method comprising administering to the subject an immunogenic composition comprising a nucleic acid molecule encoding a common TERT antigen. In one embodiment, the administration method comprises an electroporation step. In this one embodiment, the method further comprises administering to the subject an immune checkpoint inhibitor.
[0017] In one embodiment, the immunogenic composition and the immune checkpoint inhibitor are administered to the subject in a single formulation. In one embodiment, the immunogenic composition and the immune checkpoint inhibitor are administered to the subject separately.
[0018] In one embodiment, the cancer is selected from the group consisting of melanoma, head and neck cancer, prostate cancer, liver cancer, cervical cancer, recurrent respiratory papillomatosis (RRP), anal cancer, blood cancer, ovarian cancer, and combinations thereof.
[0019] In one embodiment, the present invention relates to a nucleic acid molecule comprising one or more nucleotide sequences selected from the group consisting of: a) a nucleotide sequence selected from the group consisting of: SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53 and SEQ ID NO:55, b) a nucleotide sequence having 95% or greater identity with a nucleotide sequence selected from the group consisting of: SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53 and SEQ ID NO:55, and c) a fragment of a nucleotide sequence selected from the group consisting of: SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53 and SEQ ID NO:55, wherein the fragment comprises at least 95% of the full-length nucleotide sequence.
[0020] In one embodiment, the nucleic acid molecule further comprises one or more nucleotide sequences selected from the group consisting of: a) a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69; b) a nucleotide sequence having 95% or greater identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69; NO:21, SEQ ID NO:23, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67 and SEQ ID NO:69, and c) a fragment of a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67 and SEQ ID NO:69, wherein the fragment comprises at least 95% of the full-length nucleotide sequence.
[0021] In one embodiment, the nucleic acid molecule is a plasmid.
[0022] In one embodiment, the present invention relates to an amino acid molecule comprising one or more amino acid sequences selected from the group consisting of: a) an amino acid sequence selected from the group consisting of: SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54 and SEQ ID NO:56, b) an amino acid sequence having 95% or greater identity with an amino acid sequence selected from the group consisting of: SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54 and SEQ ID NO:56, and c) a fragment of an amino acid sequence selected from the group consisting of: SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54 and SEQ ID NO:56, wherein the fragment comprises at least 95% of the full-length amino acid sequence.
[0023] In one embodiment, the amino acid molecule further comprises one or more amino acid sequences selected from the group consisting of: a) an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO; 58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70; b) an amino acid sequence having 95% or greater identity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO; NO:22, SEQ ID NO:24, SEQ ID NO;58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, and c) a fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO;58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, wherein the fragment comprises at least 95% of the full-length amino acid sequence. Sequence Listing <110> Weiner, David Yan Jian <120> HTERT immunogenic compositions and treatment methods using the same <130> 206108-0065-00-WO.606815 <150> US 62 / 402,695 <151> 2016-09-30 <150> US 62 / 468,124 <151> 2017-03-07 <160> 70 <170> PatentIn Version 3.5 <210> 1 <211> 1608 <212> DNA <213> Artificial Sequence <220> <223> Common tyrosinase <400> 1 atggattgga cttggatctt atttttagtt gctgctgcta ctagagttca ttctgactgg 60 acttggattc tgttcctggt cgccgccgct acccgagtgc attccgaaaa agagtgttgc 120 ccaccttggt ctggagatcg aagcccatgc ggacagctga gtgggcgggg atcatgtcag 180 aacatcctgc tgagcaatgc ccccctggga cctcagttcc ccttcaccgg cgtggacgat 240 agagagtctt ggcccagtgt cttttacaac aggacttgcc agtgtagcgg gaatttcatg 300 ggcttcaact gcggcaattg taagttcggc ttttgggggc caaactgcac cgagcggaga 360 ctgctggtga ggcgcaatat cttcgatctg tccgcccccg aaaaggacaa attctttgcc 420 tatctgaccc tggctaagca cacaattagc tccgattatg tcatccccat tggaacatac 480 ggccagatga aaaacggcag cactcctatg tttaacgata tcaatatcta cgacctgttc 540 gtgtggatgc attactatgt ctccatggac gctctgctgg gcgggtctga gatctggcgg 600 gacattgatt tcgcacacga agctccagca tttctgccct ggcataggct gttcctgctg 660 cgctgggagc aggaaatcca gaagctgact ggggacgaga actttaccat tccctattgg 720 gattggcggg acgccgagaa atgcgatatc tgtactgacg aatacatggg aggccagcac 780 cccaccaacc ctaatctgct gtcacctgcc agcttctttt ctagttggca gatcgtgtgc 840 agccggctgg aggaatacaa ctcccaccag agcctgtgca atgggactcc agagggacca 900 ctgcgacgaa accctggaaa tcatgataag agccgaaccc ctcgactgcc atcaagcgcc 960 gacgtggagt tttgcctgtc cctgacacag tatgaaagcg gcagcatgga taaagccgct 1020 aacttctctt ttaggaatac cctggaaggg ttcgcaagtc cactgacagg aatcgccgac 1080 gcttcacagt cctctatgca caacgctctg catatctaca tgaatggcac aatgtcacag 1140 gtgcagggga gcgcaaacga tcctatcttc ctgctgcacc atgccttcgt ggactccatt 1200 tttgagcagt ggctgagaag gcaccgccca ctgcaggagg tgtatcctga agcaaacgcc 1260 ccaatcggcc ataatcgcga atcttatatg gtccccttta tccctctgta ccgaaacgga 1320 gatttcttta ttagttcaaa ggatctgggc tacgactata gttacctgca ggacagcgat 1380 cctgactcct tccaggacta tatcaaatct tacctggagc aggcctctag aatttggagt 1440 tggctgctgg gagcagcaat ggtgggagct gtcctgaccg ctctgctggc aggactggtg 1500 tccctgctgt gccggcacaa gagaaaacag ctgcccgagg aaaagcagcc actgctgatg 1560 gaaaaagaag actaccactc actgctgtac cagacccacc tgtgataa 1608 <210> 2 <211> 517 <212> PRT <213> Artificial Sequence <220> <223> Common Tyrosinase <400> 2 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Glu Lys Glu Cys Cys Pro Pro Trp Ser Gly Asp Arg Ser Pro 20 25 30 Cys Gly Gln Leu Ser Gly Arg Gly Ser Cys Gln Asn Ile Leu Leu Ser 35 40 45 Asn Ala Pro Leu Gly Pro Gln Phe Pro Phe Thr Gly Val Asp Asp Arg 50 55 60 Glu Ser Trp Pro Ser Val Phe Tyr Asn Arg Thr Cys Gln Cys Ser Gly 65 70 75 80 Asn Phe Met Gly Phe Asn Cys Gly Asn Cys Lys Phe Gly Phe Trp Gly 85 90 95 Pro Asn Cys Thr Glu Arg Arg Leu Leu Val Arg Arg Asn Ile Phe Asp 100 105 110 Leu Ser Ala Pro Glu Lys Asp Lys Phe Phe Ala Tyr Leu Thr Leu Ala 115 120 125 Lys His Thr Ile Ser Ser Asp Tyr Val Ile Pro Ile Gly Thr Tyr Gly 130 135 140 Gln Met Lys Asn Gly Ser Thr Pro Met Phe Asn Asp Ile Asn Ile Tyr 145 150 155 160 Asp Leu Phe Val Trp Met His Tyr Tyr Val Ser Met Asp Ala Leu Leu 165 170 175 Gly Gly Ser Glu Ile Trp Arg Asp Ile Asp Phe Ala His Glu Ala Pro 180 185 190 Ala Phe Leu Pro Trp His Arg Leu Phe Leu Leu Arg Trp Glu Gln Glu 195 200 205 Ile Gln Lys Leu Thr Gly Asp Glu Asn Phe Thr Ile Pro Tyr Trp Asp 210 215 220 Trp Arg Asp Ala Glu Lys Cys Asp Ile Cys Thr Asp Glu Tyr Met Gly 225 230 235 240 Gly Gln His Pro Thr Asn Pro Asn Leu Leu Ser Pro Ala Ser Phe Phe 245 250 255 Ser Ser Trp Gln Ile Val Cys Ser Arg Leu Glu Glu Tyr Asn Ser His 260 265 270 Gln Ser Leu Cys Asn Gly Thr Pro Glu Gly Pro Leu Arg Arg Asn Pro 275 280 285 Gly Asn His Asp Lys Ser Arg Thr Pro Arg Leu Pro Ser Ser Ala Asp 290 295 300 Val Glu Phe Cys Leu Ser Leu Thr Gln Tyr Glu Ser Gly Ser Met Asp 305 310 315 320 Lys Ala Ala Asn Phe Ser Phe Arg Asn Thr Leu Glu Gly Phe Ala Ser 325 330 335 Pro Leu Thr Gly Ile Ala Asp Ala Ser Gln Ser Ser Met His Asn Ala 340 345 350 Leu His Ile Tyr Met Asn Gly Thr Met Ser Gln Val Gln Gly Ser Ala 355 360 365 Asn Asp Pro Ile Phe Leu Leu His His Ala Phe Val Asp Ser Ile Phe 370 375 380 Glu Gln Trp Leu Arg Arg His Arg Pro Leu Gln Glu Val Tyr Pro Glu 385 390 395 400 Ala Asn Ala Pro Ile Gly His Asn Arg Glu Ser Tyr Met Val Pro Phe 405 410 415 Ile Pro Leu Tyr Arg Asn Gly Asp Phe Phe Ile Ser Ser Lys Asp Leu 420 425 430 Gly Tyr Asp Tyr Ser Tyr Leu Gln Asp Ser Asp Pro Asp Ser Phe Gln 435 440 445 Asp Tyr Ile Lys Ser Tyr Leu Glu Gln Ala Ser Arg Ile Trp Ser Trp 450 455 460 Leu Leu Gly Ala Ala Met Val Gly Ala Val Leu Thr Ala Leu Leu Ala 465 470 475 480 Gly Leu Val Ser Leu Leu Cys Arg His Lys Arg Lys Gln Leu Pro Glu 485 490 495 Glu Lys Gln Pro Leu Leu Met Glu Lys Glu Asp Tyr His Ser Leu Leu 500 505 510 Tyr Gln Thr His Leu 515 <210> 3 <211> 1668 <212> DNA <213> Artificial Sequence <220> <223> Common tyrosinase-related protein 1 <400> 3 atggactgga cctggattct gttcctggtc gccgccgcaa cccgcgtgca ttcctctgcc 60 ccaaaactgc tgtctctggg atgtatcttc tttccactgc tgctgttcca gcaggcacgc 120 gcccagtttc cacgacagtg cgcaaccgtc gaggccctga ggagcgggat gtgctgtcca 180 gacctgtcac ccgtgagcgg acctggcaca gatcgctgcg gaagctcctc tgggcgggga 240 agatgtgagg ccgtgactgc tgactcacgg ccccacagcc ctcagtaccc acatgatggc 300 agggacgatc gcgaagtgtg gcccctgcga ttctttaacc ggacttgcca ctgtaacggc 360 aatttctccg ggcataattg cggaacctgt agacctggat ggaggggcgc cgcttgtgac 420 cagcgcgtgc tgatcgtccg gagaaacctg ctggatctgt ctaaggagga gaagaaccac 480 ttcgtccgag ctctggacat ggcaaagaga accacacatc ctctgtttgt gatcgccacc 540 aggcgcagcg aggaaattct ggggccagat ggaaacacac cccagttcga gaacatctca 600 atctacaatt atttcgtgtg gacccactac tatagcgtca agaaaacatt cctgggcgtg 660 gggcaggaga gtttcggaga agtggacttt tcacatgagg gccccgcttt tctgacatgg 720 caccggtacc atctgctgag actggaaaag gatatgcagg agatgctgca ggaacctagt 780 ttctcactgc catattggaa ctttgcaaca ggaaaaaacg tgtgcgacat ctgtactgac 840 gatctgatgg gcagcagatc caacttcgat tctacactga tttccccaaa tagcgtgttc 900 agccagtgga gggtggtctg cgactccctg gaggactacg ataccctggg caccctgtgc 960 aattctactg aagatgggcc catccgacgg aaccctgccg gaaatgtggc taggccaatg 1020 gtccagcgcc tgcctgagcc acaggacgtg gcccagtgcc tggaagtcgg cctgttcgat 1080 actccccctt tttattctaa cagtacaaac tctttccgca acactgtcga gggctacagt 1140 gaccctaccg ggaaatatga tccagccgtg cggagtctgc acaacctggc tcatctgttc 1200 ctgaatggaa ctggcgggca gacccacctg tccccaaatg accctatttt tgtcctgctg catactttca ccgacgccgt gtttgatgag tggctgagaa ggtacaacgc agatatcagc acctttccac tggaaaatgc ccccattggc cacaaccggc agtatat ggtgcctttc tggccacccg tcacaaacac tgagatgttt gtgactgctc cagacaatct ggggtacacc tatgaaatcc agtggccctc cagagagttc tctgtgcctg aaatcattgc tattgcagtg gtcggcgcac tgctgctggt ggccctgatc tttgggaccg ctagctacct gattagggca 1560. cgccgatcca tggacgaggc caaccagccc ctgctgacag atcagtacca gtgctatgcc gaagagtatg aaaagctgca gaaccctaac cagtccgtcg tgtgataa <210> 4 <211> 554 <212> PRT <213> Artificial Sequence <220> <223> Thanksgiving license plate license plate1 <400> 4 Met Asp Trp Thr Trp Free Mp3 Download 1 5 10 15 His Ser Ser Ala Pro Lys Leu Leu Ser Leu Gly Cys Ile Phe Phe Pro 20 25 30 Leu Leu Leu Phe Gln Gln Ala Arg Ala Gln Phe Pro Arg Gln Cys Ala 35 40 45 Thr Val Glu Ala Leu Arg Ser Gly Met Cys Cys Pro Asp Leu Ser Pro 50 55 60 Val Ser Gly Pro Gly Thr Asp Arg Cys Gly Ser Ser Ser Gly Arg Gly 65 70 75 80 Arg Cys Glu Ala Val Thr Ala Asp Ser Arg Pro His Ser Pro Gln Tyr 85 90 95 Pro His Asp Gly Arg Asp Asp Arg Glu Val Trp Pro Leu Arg Phe Phe 100 105 110 Asn Arg Thr Cys His Cys Asn Gly Asn Phe Ser Gly His Asn Cys Gly 115 120 125 Thr Cys Arg Pro Gly Trp Arg Gly Ala Ala Cys Asp Gln Arg Val Leu 130 135 140 Ile Val Arg Arg Asn Leu Leu Asp Leu Ser Lys Glu Glu Lys Asn His 145 150 155 160 Phe Val Arg Ala Leu Asp Met Ala Lys Arg Thr Thr His Pro Leu Phe 165 170 175 Val Ile Ala Thr Arg Arg Ser Glu Glu Ile Leu Gly Pro Asp Gly Asn 180 185 190 Thr Pro Gln Phe Glu Asn Ile Ser Ile Tyr Asn Tyr Phe Val Trp Thr 195 200 205 His Tyr Tyr Ser Val Lys Lys Thr Phe Leu Gly Val Gly Gln Glu Ser 210 215 220 Phe Gly Glu Val Asp Phe Ser His Glu Gly Pro Ala Phe Leu Thr Trp 225 230 235 240 His Arg Tyr His Leu Leu Arg Leu Glu Lys Asp Met Gln Glu Met Leu 245 250 255 Gln Glu Pro Ser Phe Ser Leu Pro Tyr Trp Asn Phe Ala Thr Gly Lys 260 265 270 Asn Val Cys Asp Ile Cys Thr Asp Asp Leu Met Gly Ser Arg Ser Asn 275 280 285 Phe Asp Ser Thr Leu Ile Ser Pro Asn Ser Val Phe Ser Gln Trp Arg 290 295 300 Val Val Cys Asp Ser Leu Glu Asp Tyr Asp Thr Leu Gly Thr Leu Cys 305 310 315 320 Asn Ser Thr Glu Asp Gly Pro Ile Arg Arg Asn Pro Ala Gly Asn Val 325 330 335 Ala Arg Pro Met Val Gln Arg Leu Pro Glu Pro Gln Asp Val Ala Gln 340 345 350 Cys Leu Glu Val Gly Leu Phe Asp Thr Pro Pro Phe Tyr Ser Asn Ser 355 360 365 Thr Asn Ser Phe Arg Asn Thr Val Glu Gly Tyr Ser Asp Pro Thr Gly 370 375 380 Lys Tyr Asp Pro Ala Val Arg Ser Leu His Asn Leu Ala His Leu Phe 385 390 395 400 Leu Asn Gly Thr Gly Gly Gln Thr His Leu Ser Pro Asn Asp Pro Ile 405 410 415 Phe Val Leu Leu His Thr Phe Thr Asp Ala Val Phe Asp Glu Trp Leu 420 425 430 Arg Arg Tyr Asn Ala Asp Ile Ser Thr Phe Pro Leu Glu Asn Ala Pro 435 440 445 Ile Gly His Asn Arg Gln Tyr Asn Met Val Pro Phe Trp Pro Pro Val 450 455 460 Thr Asn Thr Glu Met Phe Val Thr Ala Pro Asp Asn Leu Gly Tyr Thr 465 470 475 480 Tyr Glu Ile Gln Trp Pro Ser Arg Glu Phe Ser Val Pro Glu Ile Ile 485 490 495 Ala Ile Ala Val Val Gly Ala Leu Leu Leu Val Ala Leu Ile Phe Gly 500 505 510 Thr Ala Ser Tyr Leu Ile Arg Ala Arg Arg Ser Met Asp Glu Ala Asn 515 520 525 Gln Pro Leu Leu Thr Asp Gln Tyr Gln Cys Tyr Ala Glu Glu Tyr Glu 530 535 540 Lys Leu Gln Asn Pro Asn Gln Ser Val Val 545 550 <210> 5 <211> 1614 <212> DNA <213> Artificial Sequence <220> <223> Common tyrosinase-related protein 2 <400> 5 atggactgga cctggattct gttcctggtc gccgctgcta cccgcgtgca ttcatctcct 60 ctgtggtggg gatttctgct gtcttgcctg ggatgcaaga tcctgccagg agcacaggga 120 cagttccccc gggtgtgcat gaccgtcgac tctctggtga acaaagagtg ctgtcctagg 180 ctgggagccg aaagcgccaa cgtgtgcggc tcccagcagg gacgaggaca gtgtactgag 240 gtgcgcgcag atacccgacc atggagtgga ccctacattc tgaggaacca ggacgatcgc 300 gaactgtggc cccgaaagtt ctttcaccgg acatgcaaat gtactggaaa cttcgccggc 360 tataattgcg gggactgtaa gtttggctgg accgggccca actgcgagag aaagaaaccc 420 cctgtgatca ggcagaatat tcattctctg agtcctcagg agcgggaaca gttcctgggc 480 gcactggacc tggccaagaa aagagtccac ccagattacg tgatcaccac acagcattgg 540 ctgggactgc tgggccctaa cgggacacag ccacagtttg ccaattgctc cgtctatgac 600 ttcttcgtgt ggctgcacta ctattctgtg cgggatacac tgctgggacc aggccgaccc 660 taccgagcaa tcgacttcag ccatcaggga ccagcctttg tgacttggca cagatatcat 720 ctgctgtgcc tggagcggga tctgcagaga ctgattggca acgaatcctt cgctctgccc 780 tactggaact ttgcaaccgg gcggaatgag tgcgacgtgt gcacagatca gctgttcgga 840 gccgctagac ctgacgatcc aactctgatc tcaagaaata gcaggtttag ctcctgggag 900 accgtctgcg actctctgga cgattacaac cacctggtga ccctgtgcaa tggaacatat 960 gaaggcctgc tgcggagaaa ccagatgggc cgcaatagta tgaagctgcc caccctgaaa 1020 gacattcgag attgtctgtc actgcagaag ttcgacaacc cacccttctt tcagaattcc 1080 accttctctt ttaggaacgc cctggagggg tttgacaaag ctgatggaac actggatagt 1140 caggtcatgt cactgcacaa cctggtgcat tcattcctga acgggactaa tgccctgcct 1200 cacagcgcag ccaatgaccc aatctttgtg gtcctgcata gcttcaccga cgctattttt 1260 gatgagtgga tgaagaggtt caaccctcca gctgatgcat ggccccagga actggcacct 1320 atcggacaca accgcatgta caatatggtc cccttctttc cccctgtgac aaatgaggaa 1380 ctgtttctga cttctgacca gctgggctac agttatgcta ttgatctgcc cgtgagcgtc 1440 gaggaaacac ccgggtggcc tactaccctg ctggtggtca tgggcactct ggtggctctg 1500 gtcgggctgt tcgtgctgct ggcatttctg cagtataggc gcctgcgcaa aggatacacc 1560 ccactgatgg aaacccacct gtcctccaag agatacaccg aagaagcatg ataa 1614 <210> 6 <211> 536 <212> PRT <213> Artificial Sequence <220> <223> Common tyrosinase-related protein 2 <400> 6 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Ser Pro Leu Trp Trp Gly Phe Leu Leu Ser Cys Leu Gly Cys 20 25 30 Lys Ile Leu Pro Gly Ala Gln Gly Gln Phe Pro Arg Val Cys Met Thr 35 40 45 Val Asp Ser Leu Val Asn Lys Glu Cys Cys Pro Arg Leu Gly Ala Glu 50 55 60 Ser Ala Asn Val Cys Gly Ser Gln Gln Gly Arg Gly Gln Cys Thr Glu 65 70 75 80 Val Arg Ala Asp Thr Arg Pro Trp Ser Gly Pro Tyr Ile Leu Arg Asn 85 90 95 Gln Asp Asp Arg Glu Leu Trp Pro Arg Lys Phe Phe His Arg Thr Cys 100 105 110 Lys Cys Thr Gly Asn Phe Ala Gly Tyr Asn Cys Gly Asp Cys Lys Phe 115 120 125 Gly Trp Thr Gly Pro Asn Cys Glu Arg Lys Lys Pro Pro Val Ile Arg 130 135 140 Gln Asn Ile His Ser Leu Ser Pro Gln Glu Arg Glu Gln Phe Leu Gly 145 150 155 160 Ala Leu Asp Leu Ala Lys Lys Arg Val His Pro Asp Tyr Val Ile Thr 165 170 175 Thr Gln His Trp Leu Gly Leu Leu Gly Pro Asn Gly Thr Gln Pro Gln 180 185 190 Phe Ala Asn Cys Ser Val Tyr Asp Phe Phe Val Trp Leu His Tyr Tyr 195 200 205 Ser Val Arg Asp Thr Leu Leu Gly Pro Gly Arg Pro Tyr Arg Ala Ile 210 215 220 Asp Phe Ser His Gln Gly Pro Ala Phe Val Thr Trp His Arg Tyr His 225 230 235 240 Leu Leu Cys Leu Glu Arg Asp Leu Gln Arg Leu Ile Gly Asn Glu Ser 245 250 255 Phe Ala Leu Pro Tyr Trp Asn Phe Ala Thr Gly Arg Asn Glu Cys Asp 260 265 270 Val Cys Thr Asp Gln Leu Phe Gly Ala Ala Arg Pro Asp Asp Pro Thr 275 280 285 Leu Ile Ser Arg Asn Ser Arg Phe Ser Ser Trp Glu Thr Val Cys Asp 290 295 300 Ser Leu Asp Asp Tyr Asn His Leu Val Thr Leu Cys Asn Gly Thr Tyr 305 310 315 320 Glu Gly Leu Leu Arg Arg Asn Gln Met Gly Arg Asn Ser Met Lys Leu 325 330 335 Pro Thr Leu Lys Asp Ile Arg Asp Cys Leu Ser Leu Gln Lys Phe Asp 340 345 350 Asn Pro Pro Phe Phe Gln Asn Ser Thr Phe Ser Phe Arg Asn Ala Leu 355 360 365 Glu Gly Phe Asp Lys Ala Asp Gly Thr Leu Asp Ser Gln Val Met Ser 370 375 380 Leu His Asn Leu Val His Ser Phe Leu Asn Gly Thr Asn Ala Leu Pro 385 390 395 400 His Ser Ala Ala Asn Asp Pro Ile Phe Val Val Leu His Ser Phe Thr 405 410 415 Asp Ala Ile Phe Asp Glu Trp Met Lys Arg Phe Asn Pro Pro Ala Asp 420 425 430 Ala Trp Pro Gln Glu Leu Ala Pro Ile Gly His Asn Arg Met Tyr Asn 435 440 445 Met Val Pro Phe Phe Pro Pro Val Thr Asn Glu Glu Leu Phe Leu Thr 450 455 460 Ser Asp Gln Leu Gly Tyr Ser Tyr Ala Ile Asp Leu Pro Val Ser Val 465 470 475 480 Glu Glu Thr Pro Gly Trp Pro Thr Thr Leu Leu Val Val Met Gly Thr 485 490 495 Leu Val Ala Leu Val Gly Leu Phe Val Leu Leu Ala Phe Leu Gln Tyr 500 505 510 Arg Arg Leu Arg Lys Gly Tyr Thr Pro Leu Met Glu Thr His Leu Ser 515 520 525 Ser Lys Arg Tyr Thr Glu Glu Ala 530 535 <210> 7 <211> 1008 <212> DNA <213> Artificial Sequence <220> <223> Common Melanoma - associated Antigen 4 <400> 7 atggattgga catggattct gttcctggtc gccgccgcaa ctagagtgca ttcatcatca 60 gagcagaagt cacagcattg taaacctgag gaaggcgtcg aggctcagga ggaagcactg 120 ggactggtgg gagctcaggc accaaccaca gaggaacagg aggccgctgt gagctcctct 180 agtccactgg tccccggcac tctggaggaa gtgcctgcag cagagagcgc cggaccccct 240 cagagtccac agggagcctc agctctgccc actaccatca gcttcacatg ctggaggcag 300 cctaacgagg gctcaagctc ccaggaggaa gaggggcctt ctactagtcc agacgcagag 360 agcctgttcc gggaagccct gtccaataag gtggatgagc tggcccactt tctgctgcgg 420 aagtacagag ctaaagaact ggtcaccaaa gcagagatgc tggaacgagt gatcaagaac 480 tataaacggt gcttccctgt gatttttgga aaggcctcag agagcctgaa aatgatcttc 540 ggcattgacg tgaaggaagt cgatccagct tctaatacat acactctggt gacatgtctg 600 ggcctgagtt atgacggact gctgggcaac aatcagattt ttcccaaaac cgggctgctg 660 atcattgtgc tgggcacaat cgccatggag ggggattccg cttctgaaga ggaaatttgg 720 gaggaactgg gcgtgatggg agtctacgac gggcgcgagc acaccgtgta cggagaacca 780 cgaaagctgc tgacccagga ttgggtccag gagaactacc tggaatatcg gcaggtgccc 840 gggtccaatc ctgcaagata cgagtttctg tggggaccca gggcactggc cgagacatct 900 tatgtgaaag tcctggaaca tgtggtcagg gtgaacgctc gcgtgcgaat tgcctaccca 960 agcctgcgcg aagccgctct gctggaagaa gaggaaggag tgtgataa 1008 <210> 8 <211> 334 <212> PRT <213> Artificial Sequence <220> <223> Melanoma-associated antigen 4, common <400> 8 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Ser Ser Glu Gln Lys Ser Gln His Cys Lys Pro Glu Glu Gly 20 25 30 Val Glu Ala Gln Glu Glu Ala Leu Gly Leu Val Gly Ala Gln Ala Pro 35 40 45 Thr Thr Glu Glu Gln Glu Ala Ala Val Ser Ser Ser Ser Pro Leu Val 50 55 60 Pro Gly Thr Leu Glu Glu Val Pro Ala Ala Glu Ser Ala Gly Pro Pro 65 70 75 80 Gln Ser Pro Gln Gly Ala Ser Ala Leu Pro Thr Thr Ile Ser Phe Thr 85 90 95 Cys Trp Arg Gln Pro Asn Glu Gly Ser Ser Ser Gln Glu Glu Glu Gly 100 105 110 Pro Ser Thr Ser Pro Asp Ala Glu Ser Leu Phe Arg Glu Ala Leu Ser 115 120 125 Asn Lys Val Asp Glu Leu Ala His Phe Leu Leu Arg Lys Tyr Arg Ala 130 135 140 Lys Glu Leu Val Thr Lys Ala Glu Met Leu Glu Arg Val Ile Lys Asn 145 150 155 160 Tyr Lys Arg Cys Phe Pro Val Ile Phe Gly Lys Ala Ser Glu Ser Leu 165 170 175 Lys Met Ile Phe Gly Ile Asp Val Lys Glu Val Asp Pro Ala Ser Asn 180 185 190 Thr Tyr Thr Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu 195 200 205 Gly Asn Asn Gln Ile Phe Pro Lys Thr Gly Leu Leu Ile Ile Val Leu 210 215 220 Gly Thr Ile Ala Met Glu Gly Asp Ser Ala Ser Glu Glu Glu Ile Trp 225 230 235 240 Glu Glu Leu Gly Val Met Gly Val Tyr Asp Gly Arg Glu His Thr Val 245 250 255 Tyr Gly Glu Pro Arg Lys Leu Leu Thr Gln Asp Trp Val Gln Glu Asn 260 265 270 Tyr Leu Glu Tyr Arg Gln Val Pro Gly Ser Asn Pro Ala Arg Tyr Glu 275 280 285 Phe Leu Trp Gly Pro Arg Ala Leu Ala Glu Thr Ser Tyr Val Lys Val 290 295 300 Leu Glu His Val Val Arg Val Asn Ala Arg Val Arg Ile Ala Tyr Pro 305 310 315 320 Ser Leu Arg Glu Ala Ala Leu Leu Glu Glu Glu Glu Gly Val 325 330 <210> 9 <211> 381 <212> DNA <213> Artificial Sequence <220> <223> Consensus Growth Hormone-Releasing Hormone <400> 9 atggactgga cctggattct gttcctggtg gctgccgcaa ctcgcgtgca ttctcctctg 60 tgggtgttct tctttgtgat tctgactctg tctaacagct cccactgcag tccccctcca 120 cccctgaccc tgcgaatgcg gagatacgcc gacgctatct tcacaaattc ctatagaaag 180 gtgctgggac agctgtctgc taggaaactg ctgcaggata ttatgtcacg ccagcagggc 240 gagagcaacc aggaacgagg cgcaagggcc cgactggggc ggcaggtcga cagcatgtgg 300 gccgagcaga agcagatgga actggaaagc atcctggtcg cactgctgca gaaacatagc 360 cgaaatagcc agggatgata a 381 <210> 10 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> Growth hormone releasing hormone <400> 10 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Pro Leu Trp Val Phe Phe Phe Val Ile Leu Thr Leu Ser Asn 20 25 30 Ser Ser His Cys Ser Pro Pro Pro Pro Leu Thr Leu Arg Met Arg Arg 35 40 45 Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln 50 55 60 Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly 65 70 75 80 Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu Gly Arg Gln Val 85 90 95 Asp Ser Met Trp Ala Glu Gln Lys Gln Met Glu Leu Glu Ser Ile Leu 100 105 110 Val Ala Leu Leu Gln Lys His Ser Arg Asn Ser Gln Gly 115 120 125 <210> 11 <211> 411 <212> DNA <213> Artificial Sequence <220> <223> Source: Melan-A <400> 11 atggactgga catggattct gttcctggtc gctgctgcta caagggtgca ttccccacgg gaggacgccc acttcatcta tggataccca aagaaaggcc acgggcattc ttacaccaca gctgaggaag ccgctggaat cggcattctg acagtgatcc tgggggtcct gctgctgatt ggatgctggt actgtcggag aaggaacggc tatagagcac tgatggacaa gagcctgcac gtgggaactc agtgcgcact gacccgccga tgtccacagg agggattcga ccatcgggat agcaaggtct ccctgcagga gaaaaattgc gaacccgtgg tccctaatgc cccacccgct tacgaaaaac tgtccgcaga gcagagccca ccaccttatt caccttgata a <210> 12 <211> 135 <212> PRT <213> Artificial Sequence <220> <223> Source: Melan-A <400> 12 Met Asp Trp Thr Trp Free Mp3 Download 1 5 10 15 His Ser Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys 20 25 30 Gly His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly 35 40 45 Ile Leu Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr 50 55 60 Cys Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His 65 70 75 80 Val Gly Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe 85 90 95 Asp His Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro 100 105 110 Val Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gln 115 120 125 Ser Pro Pro Pro Tyr Ser Pro 130 135 <210> 13 <211> 597 <212> DNA <213> Artificial Sequence <220> <223> Consensus NY-ESO-1 <400> 13 atggactgga catggattct gtttctggtg gctgccgcaa ctagagtgca ttcacaggcc 60 gctggacagg gaactggagg ctcaaccgga gacgcagatg gccctggcgg gccaggggtg 120 cccgacggac ctggaggcaa cgctggggga cccggggagg ccggagctac aggcggggga 180 ggccctcagg gagccggcgc cgccagagcc agcggacccc ggggcggggc accccggggg 240 cctcacggcg gggcagcatc aggcctgaat ggatgctgtc gatgcggagc acggagacct 300 gagagcaggc tgctggaatt ctacctgact atgccttttg ccaccccaat ggaggcagaa 360 ctggcaaggc gctccctggc tcgggacgca ccccctctgc cagtgcccgg cgtcctgctg 420 aaggaattca ccgtctctgg caacatcctg accattaggc tgacagctgc agatcatcgc 480 cagctgcagc tgtctatcag ctcctgtctg cagcagctga gtctgctgat gtggattacc 540 cagtgctttc tgcccgtctt cctggctcag cctccttccg gacagcgccg atgataa 597 <210> 14 <211> 197 <212> PRT <213> Artificial Sequence <220> <223> Consensus NY-ESO-1 <400> 14 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Gln Ala Ala Gly Gln Gly Thr Gly Gly Ser Thr Gly Asp Ala 20 25 30 Asp Gly Pro Gly Gly Pro Gly Val Pro Asp Gly Pro Gly Gly Asn Ala 35 40 45 Gly Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Gly Gly Pro Gln Gly 50 55 60 Ala Gly Ala Ala Arg Ala Ser Gly Pro Arg Gly Gly Ala Pro Arg Gly 65 70 75 80 Pro His Gly Gly Ala Ala Ser Gly Leu Asn Gly Cys Cys Arg Cys Gly 85 90 95 Ala Arg Arg Pro Glu Ser Arg Leu Leu Glu Phe Tyr Leu Thr Met Pro 100 105 110 Phe Ala Thr Pro Met Glu Ala Glu Leu Ala Arg Arg Ser Leu Ala Arg 115 120 125 Asp Ala Pro Pro Leu Pro Val Pro Gly Val Leu Leu Lys Glu Phe Thr 130 135 140 Val Ser Gly Asn Ile Leu Thr Ile Arg Leu Thr Ala Ala Asp His Arg 145 150 155 160 Gln Leu Gln Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu 165 170 175 Met Trp Ile Thr Gln Cys Phe Leu Pro Val Phe Leu Ala Gln Pro Pro 180 185 190 Ser Gly Gln Arg Arg 195 <210> 15 <211> 687 <212> DNA <213> Artificial Sequence <220> <223> Consensus NY-ESO-2 <400> 15 atggactgga catggattct gtttctggtc gccgccgcaa cacgggtgca ttctcaggcc 60 gaggggcagg gaactggagg ctcaaccgga gacgcagatg gacctggcgg gccaggcatc 120 cccgacggac ctggaggcaa cgccggggga cctggggagg ccggagctac aggcgggaga 180 ggcccaaggg gcgcaggggc cgctagggcc agtggacccc gcggaggcgc cccacgaggc 240 ccacacgggg gagcagcctc cgcccaggac ggcagatgcc catgtggagc tcggagaccc 300 gattctaggc tgctgcagct gcatatcact atgcccttca gctcccctat ggaggctgaa 360 ctggtgaggc gcattctgtc ccgcgacgct gcacctctgc cacgaccagg ggccgtgctg 420 aaggatttca ccgtctcagg caatctgctg tttatgagcg tccgggacca ggatagagag 480 ggagcaggac gaatgcgagt ggtcggatgg ggactgggct ctgctagtcc tgaaggccag 540 aaagcacgcg atctgcgaac ccccaagcac aaagtgagcg agcagcgccc tggcacacca 600 gggccccctc cacccgaagg cgcccaggga gacggatgta gaggagtcgc cttcaatgtc 660 atgtttagtg caccccatat ttgataa 687 <210> 16 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Consensus NY-ESO-2 <400> 16 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Gln Ala Glu Gly Gln Gly Thr Gly Gly Ser Thr Gly Asp Ala 20 25 30 Asp Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala 35 40 45 Gly Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Arg Gly Pro Arg Gly 50 55 60 Ala Gly Ala Ala Arg Ala Ser Gly Pro Arg Gly Gly Ala Pro Arg Gly 65 70 75 80 Pro His Gly Gly Ala Ala Ser Ala Gln Asp Gly Arg Cys Pro Cys Gly 85 90 95 Ala Arg Arg Pro Asp Ser Arg Leu Leu Gln Leu His Ile Thr Met Pro 100 105 110 Phe Ser Ser Pro Met Glu Ala Glu Leu Val Arg Arg Ile Leu Ser Arg 115 120 125 Asp Ala Ala Pro Leu Pro Arg Pro Gly Ala Val Leu Lys Asp Phe Thr 130 135 140 Val Ser Gly Asn Leu Leu Phe Met Ser Val Arg Asp Gln Asp Arg Glu 145 150 155 160 Gly Ala Gly Arg Met Arg Val Val Gly Trp Gly Leu Gly Ser Ala Ser 165 170 175 Pro Glu Gly Gln Lys Ala Arg Asp Leu Arg Thr Pro Lys His Lys Val 180 185 190 Ser Glu Gln Arg Pro Gly Thr Pro Gly Pro Pro Pro Pro Glu Gly Ala 195 200 205 Gln Gly Asp Gly Cys Arg Gly Val Ala Phe Asn Val Met Phe Ser Ala 210 215 220 Pro His Ile 225 <210> 17 <211> 1584 <212> DNA <213> Artificial Sequence <220> <223> Shared PRAME <400> 17 atggactgga catggattct gttcctggtc gctgctgcta cacgggtgca ttcagagaga 60 cgaagactgc ggggctcaat tcagagtagg tacatcagta tgtcagtctg gacctcacca 120 cggagactgg tggaactggc cgggcagagc ctgctgaagg atgaggccct ggctattgcc 180 gctctggaac tgctgccccg agagctgttc cctcccctgt tcatggcagc cttcgacgga 240 cgccacagcc agactctgaa ggctatggtc caggcatggc cctttacctg cctgcctctg 300 ggcgtgctga tgaaggggca gcagctgcat ctggagactt tcaaagcagt gctggatggc 360 ctggacgtgc tgctggccca ggaagtgagg cctaggcgct ggaagctgga ggtcctggat 420 ctgcgcaaaa acagccacca ggacttttgg accgtgtggt ccgggaatcg ggccagtctg 480 tactcattcc cagaacccga ggctgcacag ccaatgcgga agaaaagaaa ggtggatgga 540 ctgtccaccg aagctgagca gccttttaca ccaatcgaag tgctggtcga tctgtccctg 600 aaagaaggcg catgcgacga gctgttctct tatctgatgg agaaggtcaa aagacagaag 660 aacgtgctgc acctgtgctg taagaaactg aaaatctttg ctatgcccat gcaggacatc 720 aagatgattc tgaaaatggt ccagctggat tccattgaag acctggaggt cacttgtacc 780 tggaagctgc caacactggc caaattctct ccctacctgg gacagatgat caatctgcga 840 cggctgctgc tgtctcacat ccatgctagc tcctctatta gtcctgagaa ggaggaagag 900 tacattgcac agtttacttc tcagttcctg agtctgcagt gcctgcaggc cctgtatgtg 960 gatagcctgt tctttctgag aggcaggctg gaccagctgc tgcgacacgt catgaacccc 1020 ctggaaacac tgagtgtgac taattgtaga ctgtcagagg gcgatgtgat gcatctgagc 1080 cagtccccta acgtgagcca gctgtccgtc ctgtctctga gtggcgtgat gctgacagac 1140 gtgagccctg aaccactgca ggccctgctg gagcgagcat ctgccactct gcaggacctg 1200 gattttgacg agtgtgggat catggacgat cagctgctgg tgctgctgcc ttcactgagc 1260 cactgctccc agctgaccac actgtctttc tgtgggaacc caatctccat ttctgtgctg 1320 cagaatctgc tgcaccatct gattggactg agcaacctga cccatgtgct gtaccccgtc 1380 cctctggaaa gctatgagga tgtgcacgga acactgcatc tgggcaggct ggcctatctg 1440 cacgctcgcc tgcgagaact gctgtgcgag ctgggcagac cctcaatggt gtggctgagc 1500 gccaatccat gtccccattg cggcgaccgg acattctacg accccgaacc tattctgtgc 1560 ccctgcttca tgcctaactg ataa 1584 <210> 18 <211> 526 <212> PRT <213> Artificial Sequence <220> <223> Shared PRAME <400> 18 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Glu Arg Arg Arg Leu Arg Gly Ser Ile Gln Ser Arg Tyr Ile 20 25 30 Ser Met Ser Val Trp Thr Ser Pro Arg Arg Leu Val Glu Leu Ala Gly 35 40 45 Gln Ser Leu Leu Lys Asp Glu Ala Leu Ala Ile Ala Ala Leu Glu Leu 50 55 60 Leu Pro Arg Glu Leu Phe Pro Pro Leu Phe Met Ala Ala Phe Asp Gly 65 70 75 80 Arg His Ser Gln Thr Leu Lys Ala Met Val Gln Ala Trp Pro Phe Thr 85 90 95 Cys Leu Pro Leu Gly Val Leu Met Lys Gly Gln Gln Leu His Leu Glu 100 105 110 Thr Phe Lys Ala Val Leu Asp Gly Leu Asp Val Leu Leu Ala Gln Glu 115 120 125 Val Arg Pro Arg Arg Trp Lys Leu Glu Val Leu Asp Leu Arg Lys Asn 130 135 140 Ser His Gln Asp Phe Trp Thr Val Trp Ser Gly Asn Arg Ala Ser Leu 145 150 155 160 Tyr Ser Phe Pro Glu Pro Glu Ala Ala Gln Pro Met Arg Lys Lys Arg 165 170 175 Lys Val Asp Gly Leu Ser Thr Glu Ala Glu Gln Pro Phe Thr Pro Ile 180 185 190 Glu Val Leu Val Asp Leu Ser Leu Lys Glu Gly Ala Cys Asp Glu Leu 195 200 205 Phe Ser Tyr Leu Met Glu Lys Val Lys Arg Gln Lys Asn Val Leu His 210 215 220 Leu Cys Cys Lys Lys Leu Lys Ile Phe Ala Met Pro Met Gln Asp Ile 225 230 235 240 Lys Met Ile Leu Lys Met Val Gln Leu Asp Ser Ile Glu Asp Leu Glu 245 250 255 Val Thr Cys Thr Trp Lys Leu Pro Thr Leu Ala Lys Phe Ser Pro Tyr 260 265 270 Leu Gly Gln Met Ile Asn Leu Arg Arg Leu Leu Leu Ser His Ile His 275 280 285 Ala Ser Ser Ser Ile Ser Pro Glu Lys Glu Glu Glu Tyr Ile Ala Gln 290 295 300 Phe Thr Ser Gln Phe Leu Ser Leu Gln Cys Leu Gln Ala Leu Tyr Val 305 310 315 320 Asp Ser Leu Phe Phe Leu Arg Gly Arg Leu Asp Gln Leu Leu Arg His 325 330 335 Val Met Asn Pro Leu Glu Thr Leu Ser Val Thr Asn Cys Arg Leu Ser 340 345 350 Glu Gly Asp Val Met His Leu Ser Gln Ser Pro Asn Val Ser Gln Leu 355 360 365 Ser Val Leu Ser Leu Ser Gly Val Met Leu Thr Asp Val Ser Pro Glu 370 375 380 Pro Leu Gln Ala Leu Leu Glu Arg Ala Ser Ala Thr Leu Gln Asp Leu 385 390 395 400 Asp Phe Asp Glu Cys Gly Ile Met Asp Asp Gln Leu Leu Val Leu Leu 405 410 415 Pro Ser Leu Ser His Cys Ser Gln Leu Thr Thr Leu Ser Phe Cys Gly 420 425 430 Asn Pro Ile Ser Ile Ser Val Leu Gln Asn Leu Leu His His Leu Ile 435 440 445 Gly Leu Ser Asn Leu Thr His Val Leu Tyr Pro Val Pro Leu Glu Ser 450 455 460 Tyr Glu Asp Val His Gly Thr Leu His Leu Gly Arg Leu Ala Tyr Leu 465 470 475 480 His Ala Arg Leu Arg Glu Leu Leu Cys Glu Leu Gly Arg Pro Ser Met 485 490 495 Val Trp Leu Ser Ala Asn Pro Cys Pro His Cys Gly Asp Arg Thr Phe 500 505 510 Tyr Asp Pro Glu Pro Ile Leu Cys Pro Cys Phe Met Pro Asn 515 520 525 <210> 19 <211> 1332 <212> Ms <213> Artificial Sequence <220> <223> Con WT1-L nucleic acid sequence with modified zinc fingers <400> 19 ggatccgcca ccatggactg gacctggatt ctgttcctgg tcgccgccgc aacacgggtg 60 catagtggga gtgatgtgag agacctgaac gccctgctgc cagcagtgcc atccctgcct 120 ggcgggggag gctgcgctct gccagtctct ggagcagctc agtgggctcc cgtgctggac 180 tttgcacccc ctgcagcccc ttacggaagt ctgggcggcc cacactcatt catcaaacag 240 gagccaagct ggggcggggc agatcctcat gaggaacagt gcctgtcagc cttcacagtc 300 cactttagcg ggcagttcac tggaaccgca ggagcttgta gatacggacc ctttggagca 360 ccaccccctt cccaggcacc ttctggacag gcacgcatgt tcccaaacgc tccctatctg 420 cctaattgtc tggaaagcca gcccgctatt aggaaccagg gctactccac agtggcattt 480 gacgggactc ctagctatgg acatacccca tcccaccatg ctgcacagtt tcctaatcac 540 tccttcaagc atgaggaccc catgggacag caggggtccc tgggagaaca gcagtactct 600 gtgccccctc ccgtgtacgg atgccacaca ccaactgaca gttgtacagg ctcacaggcc 660 ctgctgctgc gaactccata cacagtgat aatctgtac agatgaccctc acagctggag 720 tgcatgacat ggaaccagat gatctgggc agcacactga aaggccatgc cactgggtac 780 gatctgaca accaccac acctatgctg tacagttgtg gagcccagta tagaatccac 840 actcatggag tctcatggagg cattcaggag gtgcggag tccatggag ggcaccact 900 atcgtgcgga gcgcctccga gaccacgaa aagcgcccct ttagggcgc ctaccctgga 960 ggcaataagc ggtatttcaa actgtctcac ctgcagatgg ggagtagaa ggggaccgga 1020 gagaaacctt atcagggcga ctttaaagat ggggaaggc gctctctcg cagtgaccag 1080 ctgaagcgag ggagcgacg aggaccggg gtgaagccat ttcagtgca aacatgtcag 1140 agaaagttct cggcagaccga tcacctgaag acccataca gaaccacac cggcagacc 1200 agcgagaaac cattttcctg ccgatggccc tctgtcaga agaattcgc ccgctccgac 1260 gaactggtcc vakaccaca tatgcatcag agaaattga caaactgca gctggctctg 1320 tgataactcg ag 1332 <210> 20 <211> 436 <212> PRT <213> Artificial Sequence <220> <223> Con WT1-L protein sequence with modified zinc fingers <400> 20 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val 20 25 30 Pro Ser Leu Pro Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala 35 40 45 Ala Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Ala Ala Pro Tyr 50 55 60 Gly Ser Leu Gly Gly Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp 65 70 75 80 Gly Gly Ala Asp Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val 85 90 95 His Phe Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly 100 105 110 Pro Phe Gly Ala Pro Pro Pro Ser Gln Ala Pro Ser Gly Gln Ala Arg 115 120 125 Met Phe Pro Asn Ala Pro Tyr Leu Pro Asn Cys Leu Glu Ser Gln Pro 130 135 140 Ala Ile Arg Asn Gln Gly Tyr Ser Thr Val Ala Phe Asp Gly Thr Pro 145 150 155 160 Ser Tyr Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His 165 170 175 Ser Phe Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu 180 185 190 Gln Gln Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr 195 200 205 Asp Ser Cys Thr Gly Ser Gln Ala Leu Leu Leu Arg Thr Pro Tyr Asn 210 215 220 Ser Asp Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp 225 230 235 240 Asn Gln Met Asn Leu Gly Ser Thr Leu Lys Gly His Ala Thr Gly Tyr 245 250 255 Glu Ser Asp Asn His Thr Thr Pro Met Leu Tyr Ser Cys Gly Ala Gln 260 265 270 Tyr Arg Ile His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg 275 280 285 Arg Val Pro Gly Val Ala Pro Thr Ile Val Arg Ser Ala Ser Glu Thr 290 295 300 Asn Glu Lys Arg Pro Phe Met Gly Ala Tyr Pro Gly Gly Asn Lys Arg 305 310 315 320 Tyr Phe Lys Leu Ser His Leu Gln Met Gly Ser Arg Lys Gly Thr Gly 325 330 335 Glu Lys Pro Tyr Gln Gly Asp Phe Lys Asp Gly Glu Arg Arg Phe Ser 340 345 350 Arg Ser Asp Gln Leu Lys Arg Gly Gln Arg Arg Gly Thr Gly Val Lys 355 360 365 Pro Phe Gln Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Asp His 370 375 380 Leu Lys Thr His Thr Arg Thr His Thr Gly Lys Thr Ser Glu Lys Pro 385 390 395 400 Phe Ser Cys Arg Trp Pro Ser Cys Gln Lys Lys Phe Ala Arg Ser Asp 405 410 415 Glu Leu Val Arg His His Asn Met His Gln Arg Asn Met Thr Lys Leu 420 425 430 Gln Leu Ala Leu 435 <210> 21 <211> 954 <212> DNA <213> Artificial Sequence <220> <223> Con WT1-S nucleic acid sequence without zinc finger <400> 21 ggatccgcca ccatggactg gacctggatt ctgtttctgg tggctgctgc tacacgggtg 60 cattctggga gcgatgtgag agacctgaac gccctgctgc cagctgtgcc aagtctgcct 120 ggcgggggag gctgcgcact gccagtgagc ggagcagctc agtgggctcc cgtcctggac 180 tttgcacccc ctgcagcacc ttacggctca ctgggcggcc cacacagctt catcaagcag 240 gagccatctt ggggcggggc cgatcctcac gaggaacagt gcctgagtgc tttcacagtg 300 catttttcag gccagttcac tggaaccgca ggagcttgtc gatacggacc ctttggagcc 360 ccacccccta gccaggcacc ttccggacag gccagaatgt tcccaaacgc tccctatctg 420 cctaattgtc tggaatcaca gcctgcaatt cggaaccagg gctacagcac cgtcgccttt 480 gacgggacac catcctatgg acacactccc tctcaccatg ctgcacagtt tcctaatcac 540 agcttcaagc atgaggaccc catgggacag caggggagcc tgggagaaca gcagtactcc 600 gtgccacccc ctgtctatgg ctgccataca ccaactgact cttgtacagg gagtcaggcc 660 ctgctgctgc gaactccata caactctgat aatctgtatc agatgactag tcagctggag tgcatgacct ggaaccagat gaatctgggg tccaccctga aaggccacgc cacagggtat gaatccgaca accataccac acccatgctg tactcttgtg gcgcccagta tagatccac acccatggag tgttccgcgg cattcaggat gtgcggagag tcccaggagt cgctcccacc 900 atcgtgat ccgccagtga gaccatgaa aagagaccct tctgataact cgag <210> 22 <211> 310 <212> PRT <213> Artificial Sequence <220> <223> Like the Con WT1-S license plate <400> 22 Met Asp Trp Thr Trp Free Mp3 Download 1 5 10 15 His Ser Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val 20 25 30 Pro Ser Leu Pro Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala 35 40 45 Ala Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Ala Ala Pro Tyr 50 55 60 Gly Ser Leu Gly Gly Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp 65 70 75 80 Gly Gly Ala Asp Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val 85 90 95 His Phe Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly 100 105 110 Pro Phe Gly Ala Pro Pro Pro Ser Gln Ala Pro Ser Gly Gln Ala Arg 115 120 125 Met Phe Pro Asn Ala Pro Tyr Leu Pro Asn Cys Leu Glu Ser Gln Pro 130 135 140 Ala Ile Arg Asn Gln Gly Tyr Ser Thr Val Ala Phe Asp Gly Thr Pro 145 150 155 160 Ser Tyr Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His 165 170 175 Ser Phe Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu 180 185 190 Gln Gln Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr 195 200 205 Asp Ser Cys Thr Gly Ser Gln Ala Leu Leu Leu Arg Thr Pro Tyr Asn 210 215 220 Ser Asp Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp 225 230 235 240 Asn Gln Met Asn Leu Gly Ser Thr Leu Lys Gly His Ala Thr Gly Tyr 245 250 255 Glu Ser Asp Asn His Thr Thr Pro Met Leu Tyr Ser Cys Gly Ala Gln 260 265 270 Tyr Arg Ile His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg 275 280 285 Arg Val Pro Gly Val Ala Pro Thr Ile Val Arg Ser Ala Ser Glu Thr 290 295 300 Asn Glu Lys Arg Pro Phe 305 310 <210> 23 <211> 3447 <212> DNA <213> Artificial Sequence <220> <223> hTERT <400> 23 atggactgga cctggatcct gttcctggtg gccgctgcca caagagtgca cagccccagg 60 gcccccaggt gcagagccgt gcggagcctg ctgcggagcc actaccggga ggtgctgccc 120 ctggccacct tcgtgcggag gctggggccct caggggtggc ggctggtgca gagaggcgac 180 cctgccgcct tcagagccct ggtggcccag tgcctggtgt gcgtgccctg ggacgccaga 240 cctccccctg ccgcccctag cttccggcag gtgtcctgcc tgaaagaact ggtggcccgg 300 gtgctgcagc ggctgtgcga gaggggcgcc aagaacgtgc tggccttcgg cttcgccctg 360 ctggacggcg ccagaggcgg ccctcccgag gccttcacca cctccgtgag aagctacctg 420 cccaacaccg tgaccgacgc cctgagaggc agcggcgctt ggggcctgct gctgcgcaga 480 gtgggcgacg acgtgctggt gcacctgctg gccagatgcg ccctgttcgt gctggtcgcc 540 cccagctgcg cctaccaggt gtgcggccca cccctgtacc agctgggagc cgccacccag 600 gccagacccc ctcctcacgc ctccggcccc aggcggagac tgggctgcga gcgggcctgg 660 aaccacagcg tgcgggaggc cggcgtgccc ctgggcctgc cagcccctgg cgccaaga 720 aggggcggca gcgccagcag aagcctgccc ctgcccaagc ggcccagacg cggagccgcc 780 cctgagcccg agaacccc cgtgggccag ggctcttggg cccaccctgg ccggaccaga 840 ggccccagcg accggggctt ctgcgtggtg tcccccgcca gacccgccga ggaagccacc 900 tccctggaag gcgccctgag cggcaccagg cacagccacc ccagcgtggg ccgccagcac 960 cacgccggac cccccagcac ctccaggccc cccaggccct gggacacccc ttgcccccct 1020 gtgtacgccg agaccaagca cttcctgtac agcagcggcg acaaagagca gctgcggccc 1080 agcttcctgc tgtccagcct gaggccctcc ctgaccggcg ctaggcgcct ggtggagacc 1140 atctttctgg gcagccggcc ctggatgccc ggcaccccca ggcggctgcc caggctgccc 1200 cagcggtact ggcagatgag gcctctgttc ctggaactgc tgggcaacca cgcccagtgc 1260 ccctacggcg tgctgctgaa aacccactgc cccctgagag ccgccgtgac cccagccgcc 1320 ggagtgtgcg ccagagagaa gcctcagggc agcgtggccg ctcccgagga agaggacacc 1380 gaccccagac gcctggtgca gctgctgcgg cagcacagca gcccttggca ggtgtacggc 1440 ttcgtgcggg cctgcctgag aaggctggtg ccccctggcc tgtggggcag caggcacaac 1500 gagcggcggt ttctgcggaa caccaagaag ttcatcagcc tggggaagca cgccaagctg 1560 tccctgcagg aactgacctg gaagatgagc gtgcggggct gcgcctggct gagaagatcc 1620 cctggcgtgg gctgcgtgcc tgccgccgag caccggctgc gggaggaaat cctggccaag 1680 ttcctgcact ggctgatgag cgtgtacgtg gtggagctgc tgagatcctt cttctacgtg 1740 accgagacca ccttccagaa gaactacctg ttcttctacc ggaagagcgt gtggagcaag 1800 ctgcagagca tcggcatccg gcagcacctg aagcgggtgc agctgagaga gctgtccgag 1860 gccgaagtga ggcagcaccg ggaggccaga cctgccctgc tgaccagccg gctgcggttc 1920 atccccaagc ccgacggcct gcggcccatc gtgaacatgg actacgtggt gggcgccagg 1980 accttccggc gggagaagcg ggccgagcgg ctgacctcga gggtgaaggc cctgttcagc 2040 gtgctgaact acgagcgggc caggcggcca ggcctgctgg gcgccagcgt gctgggcctg 2100 gacgacatcc accgggcctg gcggaccttc gtgctgagag tgcgggccca ggacccccct 2160 cccgagctgt acttcgtgaa ggtggacgtg acaggcgcct acgacaccat cccccaggac 2220 cggctgaccg aggtgatcgc cagcatcatc aagccccaga acacctactg cgtgcggaga 2280 tacgccgtgg tgcagaaggc cgcccacggc cacgtgcgga aggccttcaa gagccacgtg 2340 agcaccctga ccgacctgca gccctacatg cggcagttcg tggcccacct gcaggaaacc 2400 agccccctgc gggatgccgt ggtgatcgag cagagcagca gcctgaacga ggccagcagc 2460 ggcctgttcg acgtgttcct gagattcatg tgccaccacg ccgtgcggat ccggggcaag 2520 agctacgtgc agtgccaggg catcccacag ggcagcatcc tgtccaccct gctgtgctcc 2580 ctgtgctacg gcgacatgga aaacaagctg ttcgccggca tcaggcggga cggactgctg 2640 ctgagactgg tggacgactt cctgctggtg accccccacc tgacccacgc caagaccttt 2700 ctgcggaccc tggtgcgcgg cgtgcccgag tacggctgcg tggtgaacct gagaaagacc 2760 gtggtgaact tccccgtgga ggacgaggcc ctgggcggca cagccttcgt gcagatgcct 2820 gcccatggac tgttcccttg gtgcgggctg ctgctggaca cccggaccct ggaagtgcag 2880 agcgactaca gcagctacgc ccggaccagc atccgggcct ccctgacctt caacaggggc 2940 ttcaaggccg gcaggaacat gcggcggaag ctgtttggcg tgctgcggct gaagtgccac 3000 agcctgtttc tgtacctgca ggtgaacagc ctgcagaccg tgtgcaccaa catctacaag 3060 atcctgctgc tgcaggccta ccggttccac gcctgcgtgc tgcagctgcc ctttcaccag 3120 caggtgtgga agaaccctac cttcttcctg cgggtgatca gcgacaccgc cagcctgtgc 3180 tacagcatcc tgaaggccaa gaacgccggc atgagcctgg gcgccaaggg agccgccgga 3240 cctctgccca gcgaggccgt gcagtggctg tgccaccagg cctttctgct gaagctgacc 3300 cggcaccggg tgacctacgt gcccctgctg ggcagcctgc ggaccgccca gacccagctg 3360 tcccggaagc tgcctggcac caccctgaca gccctggaag ccgccgccaa ccccgccctg 3420 ccctccgact tcaagaccat cctggac 3447 <210> 24 <211> 1149 <212> PRT <213> Artificial Sequence <220> <223> hTERT <400> 24 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg 20 25 30 Ser His Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu 35 40 45 Gly Pro Gln Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe 50 55 60 Arg Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg 65 70 75 80 Pro Pro Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu 85 90 95 Leu Val Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Lys Asn 100 105 110 Val Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro 115 120 125 Pro Glu Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val 130 135 140 Thr Asp Ala Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg 145 150 155 160 Val Gly Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Phe 165 170 175 Val Leu Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu 180 185 190 Tyr Gln Leu Gly Ala Ala Thr Gln Ala Arg Pro Pro Pro His Ala Ser 195 200 205 Gly Pro Arg Arg Arg Leu Gly Cys Glu Arg Ala Trp Asn His Ser Val 210 215 220 Arg Glu Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg 225 230 235 240 Arg Gly Gly Ser Ala Ser Arg Ser Leu Pro Leu Pro Lys Arg Pro Arg 245 250 255 Arg Gly Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser 260 265 270 Trp Ala His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys 275 280 285 Val Val Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly 290 295 300 Ala Leu Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His 305 310 315 320 His Ala Gly Pro Pro Ser Thr Ser Arg Pro Pro Arg Pro Trp Asp Thr 325 330 335 Pro Cys Pro Pro Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Ser Ser 340 345 350 Gly Asp Lys Glu Gln Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg 355 360 365 Pro Ser Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly 370 375 380 Ser Arg Pro Trp Met Pro Gly Thr Pro Arg Arg Leu Pro Arg Leu Pro 385 390 395 400 Gln Arg Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn 405 410 415 His Ala Gln Cys Pro Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu 420 425 430 Arg Ala Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro 435 440 445 Gln Gly Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg 450 455 460 Leu Val Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly 465 470 475 480 Phe Val Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly 485 490 495 Ser Arg His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile 500 505 510 Ser Leu Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys 515 520 525 Met Ser Val Arg Gly Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly 530 535 540 Cys Val Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys 545 550 555 560 Phe Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser 565 570 575 Phe Phe Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Tyr Leu Phe Phe 580 585 590 Tyr Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln 595 600 605 His Leu Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg 610 615 620 Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe 625 630 635 640 Ile Pro Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val 645 650 655 Val Gly Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr 660 665 670 Ser Arg Val Lys Ala Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg 675 680 685 Arg Pro Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His 690 695 700 Arg Ala Trp Arg Thr Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro 705 710 715 720 Pro Glu Leu Tyr Phe Val Lys Val Asp Val Thr Gly Ala Tyr Asp Thr 725 730 735 Ile Pro Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro 740 745 750 Gln Asn Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Gln Lys Ala Ala 755 760 765 His Gly His Val Arg Lys Ala Phe Lys Ser His Val Ser Thr Leu Thr 770 775 780 Asp Leu Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr 785 790 795 800 Ser Pro Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn 805 810 815 Glu Ala Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Met Cys His 820 825 830 His Ala Val Arg Ile Arg Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile 835 840 845 Pro Gln Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly 850 855 860 Asp Met Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp Gly Leu Leu 865 870 875 880 Leu Arg Leu Val Asp Asp Phe Leu Leu Val Thr Pro His Leu Thr His 885 890 895 Ala Lys Thr Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly 900 905 910 Cys Val Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp 915 920 925 Glu Ala Leu Gly Gly Thr Ala Phe Val Gln Met Pro Ala His Gly Leu 930 935 940 Phe Pro Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln 945 950 955 960 Ser Asp Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr 965 970 975 Phe Asn Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe 980 985 990 Gly Val Leu Arg Leu Lys Cys His Ser Leu Phe Leu Tyr Leu Gln Val 995 1000 1005 Asn Ser Leu Gln Thr Val Cys Thr Asn Ile Tyr Lys Ile Leu Leu 1010 1015 1020 Leu Gln Ala Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe 1025 1030 1035 His Gln Gln Val Trp Lys Asn Pro Thr Phe Phe Leu Arg Val Ile 1040 1045 1050 Ser Asp Thr Ala Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn 1055 1060 1065 Ala Gly Met Ser Leu Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro 1070 1075 1080 Ser Glu Ala Val Gln Trp Leu Cys His Gln Ala Phe Leu Leu Lys 1085 1090 1095 Leu Thr Arg His Arg Val Thr Tyr Val Pro Leu Leu Gly Ser Leu 1100 1105 1110 Arg Thr Ala Gln Thr Gln Leu Ser Arg Lys Leu Pro Gly Thr Thr 1115 1120 1125 Leu Thr Ala Leu Glu Ala Ala Ala Asn Pro Ala Leu Pro Ser Asp 1130 1135 1140 Phe Lys Thr Ile Leu Asp 1145 <210> 25 <211> 2724 <212> DNA <213> Artificial Sequence <220> <223> gB common nucleic acid sequence <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <400> 25 nnngagagca gaatctggtg cctggtcgtg tgcgtgaacc tgtgcatcgt gtgcctggga 60 gccgccgtgt ccagcagcag cacccggggc acaagcgcca cacacagcca ccacagcagc 120 cacaccacca gcgccgccca cagccggagc ggaagcgtga gcagccagcg ggtgaccagc 180 agcgaggccg tgtcccaccg ggccaacgag acaatctaca acaccaccct gaagtacggc 240 gacgtcgtgg gagtgaacac caccaagtac ccctacagag tgtgcagcat ggcccagggc 300 accgacctga tcagattcga gcggaacatc gtgtgtacca gcatgaagcc catcaacgag 360 gacctggacg agggcatcat ggtggtgtac aagagaaaca tcgtggccca caccttcaaa 420 gtgcgggtgt accagaaggt gctgaccttc cggcggagct acgcctacat ccacaccacc 480 tacctgctgg gcagcaacac cgagtacgtg gcccctccca tgtgggagat ccaccacatc 540 aacagccaca gccagtgcta cagcagctac agccgcgtga tcgccggcac cgtgttcgtg 600 gcctaccacc gggacagcta cgagaacaag accatgcagc tgatgcccga cgactacagc 660 aacacccaca gcaccagata cgtgaccgtg aaggaccagt ggcacagccg gggaagcacc 720 tggctgtaca gagagacatg caacctgaac tgcatggtca ccatcaccac cgccagaagc 780 aagtaccctt accacttctt cgccaccagc accggcgacg tggtggacat cagccccttc 840 tacaacggca ccaaccggaa cgccagctac ttcggcgaga acgccgacaa gttcttcatc 900 ttccccaact acaccatcgt gtccgacttc ggcagaccca acagcgcccc tgagacacac 960 cggctggtgg cctttctgga acgggccgac agcgtgatca gctgggacat ccaggacgag 1020 aagaacgtga cctgccagct gaccttctgg gaggctagcg agcggaccat cagaagcgag 1080 gccgaggaca gctaccactt cagcagcgcc aagatgaccg ccaccttcct gagcaagaaa 1140 caggaagtga acatgagcga cagcgccctg gactgcgtgc gggatgaggc catcaacaag 1200 ctgcagcaga tcttcaacac cagctacaac cagacctacg agaagtatgg caacgtgtcc 1260 gtgttcgaga caacaggcgg cctggtggtg ttctggcagg gcatcaagca gaagtccctg 1320 gtcgagctgg aacggctggc caacagaagc agcctgaacc tgacccaccg gaccaagcgg 1380 agcaccgacg gcaacaatac cacccacctg agcaacatgg aaagcgtcca caacctggtg 1440 tacgcccagc tgcagttcac ctacgacacc ctgcggggct acatcaaccg ggccctggcc 1500 cagatcgccg aggcttggtg tgtggaccag cggcggaccc tggaagtgtt caaagagctg 1560 agcaagatca accccagcgc catcctgagc gccatctaca acaagcctat cgccgccaga 1620 ttcatgggcg acgtgctggg cctggccagc tgcgtgacca tcaaccagac cagcgtgaag 1680 gtgctgcggg acatgaacgt gaaagaaagc cccggcagat gctactccag acccgtggtc 1740 atcttcaact tcgccaacag ctcctacgtg cagtacggcc agctgggcga ggacaacgag 1800 atcctgctgg gaaaccaccg gaccgaggaa tgccagctgc ccagcctgaa gatctttatc 1860 gccggcaaca gcgcctacga gtatgtggac tacctgttca agcggatgat cgacctgagc 1920 agcatcagca ccgtggacag catgatcgcc ctggacatcg accccctgga aaacaccgac 1980 ttccgggtgc tggaactgta cagccagaaa gagctgcgga gcagcaacgt gttcgacctg 2040 gaagagatca tgcgcgagtt caacagctac aagcagcgcg tgaaatacgt cgaggacaag 2100 gtggtggacc ccctgccccc ctacctgaag ggcctggacg acctgatgag cggcctggga 2160 gctgctggca aggccgtggg agtggccatt ggagctgtgg gcggagccgt ggccagcgtg 2220 gtggaaggcg tggccacctt tctgaagaac cccttcggcg ccttcaccat catcctggtg 2280 gctatcgccg tcgtgatcat cacctacctg atctacaccc ggcagcggcg gctgtgtacc 2340 cagcctctgc agaacctgtt cccctacctg gtgtccgccg acggcaccac cgtgacaagc 2400 ggctccacca aggacaccag cctgcaggcc ccacccagct acgaggaatc cgtgtacaac 2460 agcggccgga agggcccagg ccctcctagc tctgacgcct ctacagccgc cccaccctac 2520 accaacgagc aggcctacca gatgctgctg gccctggcta gactggacgc cgagcagaga 2580 gcccagcaga acggaaccga cagcctggat ggccagaccg gcacccagga caagggccag 2640 aagcccaacc tgctggaccg gctgcggcac agaaagaacg gctaccggca cctgaaggac 2700 agcgacgaag aggaaaacgt gtga 2724 <210> 26 <211> 907 <212> PRT <213> Artificial Sequence <220> <223> gB consensus amino acid sequence <220> <221> MISC_FEATURE <222> (1) <223> Xaa can be any naturally occurring amino acid <400> 26 Xaa Glu Ser Arg Ile Trp Cys Leu Val Val Cys Val Asn Leu Cys Ile 1 5 10 15 Val Cys Leu Gly Ala Ala Val Ser Ser Ser Ser Thr Arg Gly Thr Ser 20 25 30 Ala Thr His Ser His His Ser Ser His Thr Thr Ser Ala Ala His Ser 35 40 45 Arg Ser Gly Ser Val Ser Ser Gln Arg Val Thr Ser Ser Glu Ala Val 50 55 60 Ser His Arg Ala Asn Glu Thr Ile Tyr Asn Thr Thr Leu Lys Tyr Gly 65 70 75 80 Asp Val Val Gly Val Asn Thr Thr Lys Tyr Pro Tyr Arg Val Cys Ser 85 90 95 Met Ala Gln Gly Thr Asp Leu Ile Arg Phe Glu Arg Asn Ile Val Cys 100 105 110 Thr Ser Met Lys Pro Ile Asn Glu Asp Leu Asp Glu Gly Ile Met Val 115 120 125 Val Tyr Lys Arg Asn Ile Val Ala His Thr Phe Lys Val Arg Val Tyr 130 135 140 Gln Lys Val Leu Thr Phe Arg Arg Ser Tyr Ala Tyr Ile His Thr Thr 145 150 155 160 Tyr Leu Leu Gly Ser Asn Thr Glu Tyr Val Ala Pro Pro Met Trp Glu 165 170 175 Ile His His Ile Asn Ser His Ser Gln Cys Tyr Ser Ser Tyr Ser Arg 180 185 190 Val Ile Ala Gly Thr Val Phe Val Ala Tyr His Arg Asp Ser Tyr Glu 195 200 205 Asn Lys Thr Met Gln Leu Met Pro Asp Asp Tyr Ser Asn Thr His Ser 210 215 220 Thr Arg Tyr Val Thr Val Lys Asp Gln Trp His Ser Arg Gly Ser Thr 225 230 235 240 Trp Leu Tyr Arg Glu Thr Cys Asn Leu Asn Cys Met Val Thr Ile Thr 245 250 255 Thr Ala Arg Ser Lys Tyr Pro Tyr His Phe Phe Ala Thr Ser Thr Gly 260 265 270 Asp Val Val Asp Ile Ser Pro Phe Tyr Asn Gly Thr Asn Arg Asn Ala 275 280 285 Ser Tyr Phe Gly Glu Asn Ala Asp Lys Phe Phe Ile Phe Pro Asn Tyr 290 295 300 Thr Ile Val Ser Asp Phe Gly Arg Pro Asn Ser Ala Leu Glu Thr His 305 310 315 320 Arg Leu Val Ala Phe Leu Glu Arg Ala Asp Ser Val Ile Ser Trp Asp 325 330 335 Ile Gln Asp Glu Lys Asn Val Thr Cys Gln Leu Thr Phe Trp Glu Ala 340 345 350 Ser Glu Arg Thr Ile Arg Ser Glu Ala Glu Asp Ser Tyr His Phe Ser 355 360 365 Ser Ala Lys Met Thr Ala Thr Phe Leu Ser Lys Lys Gln Glu Val Asn 370 375 380 Met Ser Asp Ser Ala Leu Asp Cys Val Arg Asp Glu Ala Ile Asn Lys 385 390 395 400 Leu Gln Gln Ile Phe Asn Thr Ser Tyr Asn Gln Thr Tyr Glu Lys Tyr 405 410 415 Gly Asn Val Ser Val Phe Glu Thr Thr Gly Gly Leu Val Val Phe Trp 420 425 430 Gln Gly Ile Lys Gln Lys Ser Leu Val Glu Leu Glu Arg Leu Ala Asn 435 440 445 Arg Ser Ser Leu Asn Leu Thr His Arg Thr Lys Arg Ser Thr Asp Gly 450 455 460 Asn Asn Thr Thr His Leu Ser Asn Met Glu Ser Val His Asn Leu Val 465 470 475 480 Tyr Ala Gln Leu Gln Phe Thr Tyr Asp Thr Leu Arg Gly Tyr Ile Asn 485 490 495 Arg Ala Leu Ala Gln Ile Ala Glu Ala Trp Cys Val Asp Gln Arg Arg 500 505 510 Thr Leu Glu Val Phe Lys Glu Leu Ser Lys Ile Asn Pro Ser Ala Ile 515 520 525 Leu Ser Ala Ile Tyr Asn Lys Pro Ile Ala Ala Arg Phe Met Gly Asp 530 535 540 Val Leu Gly Leu Ala Ser Cys Val Thr Ile Asn Gln Thr Ser Val Lys 545 550 555 560 Val Leu Arg Asp Met Asn Val Lys Glu Ser Pro Gly Arg Cys Tyr Ser 565 570 575 Arg Pro Val Val Ile Phe Asn Phe Ala Asn Ser Ser Tyr Val Gln Tyr 580 585 590 Gly Gln Leu Gly Glu Asp Asn Glu Ile Leu Leu Gly Asn His Arg Thr 595 600 605 Glu Glu Cys Gln Leu Pro Ser Leu Lys Ile Phe Ile Ala Gly Asn Ser 610 615 620 Ala Tyr Glu Tyr Val Asp Tyr Leu Phe Lys Arg Met Ile Asp Leu Ser 625 630 635 640 Ser Ile Ser Thr Val Asp Ser Met Ile Ala Leu Asp Ile Asp Pro Leu 645 650 655 Glu Asn Thr Asp Phe Arg Val Leu Glu Leu Tyr Ser Gln Lys Glu Leu 660 665 670 Arg Ser Ser Asn Val Phe Asp Leu Glu Glu Ile Met Arg Glu Phe Asn 675 680 685 Ser Tyr Lys Gln Arg Val Lys Tyr Val Glu Asp Lys Val Val Asp Pro 690 695 700 Leu Pro Pro Tyr Leu Lys Gly Leu Asp Asp Leu Met Ser Gly Leu Gly 705 710 715 720 Ala Ala Gly Lys Ala Val Gly Val Ala Ile Gly Ala Val Gly Gly Ala 725 730 735 Val Ala Ser Val Val Glu Gly Val Ala Thr Phe Leu Lys Asn Pro Phe 740 745 750 Gly Ala Phe Thr Ile Ile Leu Val Ala Ile Ala Val Val Ile Ile Thr 755 760 765 Tyr Leu Ile Tyr Thr Arg Gln Arg Arg Leu Cys Thr Gln Pro Leu Gln 770 775 780 Asn Leu Phe Pro Tyr Leu Val Ser Ala Asp Gly Thr Thr Val Thr Ser 785 790 795 800 Gly Ser Thr Lys Asp Thr Ser Leu Gln Ala Pro Pro Ser Tyr Glu Glu 805 810 815 Ser Val Tyr Asn Ser Gly Arg Lys Gly Pro Gly Pro Pro Ser Ser Asp 820 825 830 Ala Ser Thr Ala Ala Pro Pro Tyr Thr Asn Glu Gln Ala Tyr Gln Met 835 840 845 Leu Leu Ala Leu Ala Arg Leu Asp Ala Glu Gln Arg Ala Gln Gln Asn 850 855 860 Gly Thr Asp Ser Leu Asp Gly Gln Thr Gly Thr Gln Asp Lys Gly Gln 865 870 875 880 Lys Pro Asn Leu Leu Asp Arg Leu Arg His Arg Lys Asn Gly Tyr Arg 885 890 895 His Leu Lys Asp Ser Asp Glu Glu Glu Asn Val 900 905 <210> 27 <211> 1119 <212> DNA <213> Artificial Sequence <220> <223> gM consensus nucleic acid sequence <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <400> 27 nnngcaccca gccacgtgga caaagtgaac acccggactt ggagcgccag catcgtgttc 60 atggtgctga ccttcgtgaa tgtgtccgtc cacctggtgc tgagcaactt cccccacctg 120 ggctacccct gcgtgtacta ccacgtggtg gacttcgagc ggctgaacat gagcgcctac 180 aacgtgatgc atctgcacac ccccatgctg tttctggaca gcgtgcagct cgtgtgctac 240 gccgtgttta tgcagctggt gttcctggcc gtgaccatct actacctcgt gtgctggatc 300 aagatttcta tgcggaagga caagggcatg agcctgaacc agagcacccg ggacatcagc 360 tacatgggcg acagcctgac cgccttcctg ttcatcctga gcatggacac cttccagctg 420 ttcaccctga ccatgagctt ccggctgccc agcatgatcg cctttatggc cgccgtccac 480 ttcttctgtc tgaccatctt caacgtgtcc atggtcaccc agtacagaag ctacaagcgg 540 agcctgttct tcttcagtcg gctgcacccc aagctgaagg gcaccgtcca gttccggacc 600 ctgatcgtga acctggtgga agtggccctg ggcttcaaca ccaccgtggt ggctatggct 660 ctgtgctacg gcttcggcaa caacttcttc gtgcggacag gccacatggt gctggccgtg 720 ttcgtggtgt acgccattat cagcatcatc tactttctgc tgatcgaggc cgtgttcttc 780 cagtacgtga aggtgcagtt cggctaccac ctgggcgcct ttttcggcct gtgcggcctg 840 atctacccca tcgtgcagta cgacaccttc ctgagcaacg agtaccggac cggcatcagc 900 tggtccttcg gcatgctgtt cttcatctgg gccatgttca ccacctgtcg ggccgtgcgg 960 tacttcagag gcagaggcag cggctccgtg aagtaccagg ccctggccac agccagcggc 1020 gaagaagtgg ccgccctgag ccaccacgac agcctggaaa gcagacggct gagagaggaa 1080 gaggacgacg acgacgatga ggacttcgag gacgcctga 1119 <210> 28 <211> 372 <212> PRT <213> Artificial Sequence <220> <223> gM consensus amino acid sequence <220> <221> MISC_FEATURE <222> (1) <223> Xaa can be any naturally occurring amino acid <400> 28 Xaa Ala Pro Ser His Val Asp Lys Val Asn Thr Arg Thr Trp Ser Ala 1 5 10 15 Ser Ile Val Phe Met Val Leu Thr Phe Val Asn Val Ser Val His Leu 20 25 30 Val Leu Ser Asn Phe Pro His Leu Gly Tyr Pro Cys Val Tyr Tyr His 35 40 45 Val Val Asp Phe Glu Arg Leu Asn Met Ser Ala Tyr Asn Val Met His 50 55 60 Leu His Thr Pro Met Leu Phe Leu Asp Ser Val Gln Leu Val Cys Tyr 65 70 75 80 Ala Val Phe Met Gln Leu Val Phe Leu Ala Val Thr Ile Tyr Tyr Leu 85 90 95 Val Cys Trp Ile Lys Ile Ser Met Arg Lys Asp Lys Gly Met Ser Leu 100 105 110 Asn Gln Ser Thr Arg Asp Ile Ser Tyr Met Gly Asp Ser Leu Thr Ala 115 120 125 Phe Leu Phe Ile Leu Ser Met Asp Thr Phe Gln Leu Phe Thr Leu Thr 130 135 140 Met Ser Phe Arg Leu Pro Ser Met Ile Ala Phe Met Ala Ala Val His 145 150 155 160 Phe Phe Cys Leu Thr Ile Phe Asn Val Ser Met Val Thr Gln Tyr Arg 165 170 175 Ser Tyr Lys Arg Ser Leu Phe Phe Phe Ser Arg Leu His Pro Lys Leu 180 185 190 Lys Gly Thr Val Gln Phe Arg Thr Leu Ile Val Asn Leu Val Glu Val 195 200 205 Ala Leu Gly Phe Asn Thr Thr Val Val Ala Met Ala Leu Cys Tyr Gly 210 215 220 Phe Gly Asn Asn Phe Phe Val Arg Thr Gly His Met Val Leu Ala Val 225 230 235 240 Phe Val Val Tyr Ala Ile Ile Ser Ile Ile Tyr Phe Leu Leu Ile Glu 245 250 255 Ala Val Phe Phe Gln Tyr Val Lys Val Gln Phe Gly Tyr His Leu Gly 260 265 270 Ala Phe Phe Gly Leu Cys Gly Leu Ile Tyr Pro Ile Val Gln Tyr Asp 275 280 285 Thr Phe Leu Ser Asn Glu Tyr Arg Thr Gly Ile Ser Trp Ser Phe Gly 290 295 300 Met Leu Phe Phe Ile Trp Ala Met Phe Thr Thr Cys Arg Ala Val Arg 305 310 315 320 Tyr Phe Arg Gly Arg Gly Ser Gly Ser Val Lys Tyr Gln Ala Leu Ala 325 330 335 Thr Ala Ser Gly Glu Glu Val Ala Ala Leu Ser His His Asp Ser Leu 340 345 350 Glu Ser Arg Arg Leu Arg Glu Glu Glu Asp Asp Asp Asp Asp Glu Asp 355 360 365 Phe Glu Asp Ala 370 <210> 29 <211> 411 <212> DNA <213> Artificial Sequence <220> <223> gN consensus nucleic acid sequence <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <400> 29 nnngagtgga acaccctggt gctgggtctg ctggtgctgt ctgtggccgc cagcagcaac 60 aacaccagca ctgccagcac ccccagccct agcagcagca cccacacctc caccaccgtg 120 aaggccacca ccaccgccac cacaagcacc acaacagcca ccagcaccac ctcttccacc 180 accagcacaa agcccggcag caccactcac gaccccaacg tgatgaggcc ccacgcccac 240 aacgacttct acaaggccca ctgcaccagc catatgtacg agctgagcct gagcagcttc 300 gccgcctggt ggaccatgct gaacgccctg atcctgatgg gcgccttctg catcgtgctg 360 cggcactgct gcttccagaa cttcaccgcc acaaccacca agggctactg a 411 <210> 30 <211> 136 <212> PRT <213> Artificial Sequence <220> <223> N consensus amino acid sequence <220> <221> MISC_FEATURE <222> (1) <223> Xaa can be any naturally occurring amino acid <400> 30 Xaa Glu Trp Asn Thr Leu Val Leu Gly Leu Leu Val Leu Ser Val Ala 1 5 10 15 Ala Ser Ser Asn Asn Thr Ser Thr Ala Ser Thr Pro Ser Pro Ser Ser 20 25 30 Ser Thr His Thr Ser Thr Thr Val Lys Ala Thr Thr Thr Ala Thr Thr 35 40 45 Ser Thr Thr Thr Ala Thr Ser Thr Thr Ser Ser Thr Thr Ser Thr Lys 50 55 60 Pro Gly Ser Thr Thr His Asp Pro Asn Val Met Arg Pro His Ala His 65 70 75 80 Asn Asp Phe Tyr Lys Ala His Cys Thr Ser His Met Tyr Glu Leu Ser 85 90 95 Leu Ser Ser Phe Ala Ala Trp Trp Thr Met Leu Asn Ala Leu Ile Leu 100 105 110 Met Gly Ala Phe Cys Ile Val Leu Arg His Cys Cys Phe Gln Asn Phe 115 120 125 Thr Ala Thr Thr Thr Lys Gly Tyr 130 135 <210> 31 <211> 2232 <212> DNA <213> Artificial Sequence <220> <223> gH consensus nucleic acid sequence <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <400> 31 nnncgacccg gcctgcccag ctacctgacc gtgttcgccg tgtacctgct gagccatctg 60 cccagccaga gatacggcgc cgatgccgcc tctgaggccc tggatcctca cgccttccat 120 ctgctgctga acacctacgg cagacctatc cggttcctgc gcgagaacac cacccagtgc 180 acctacaaca gcagcctgcg gaacagcacc gtcgtgcgcg agaatgctat cagcttcaac 240 ttcttccaga gctacaacca gtactacgtg ttccacatgc cccggtgcct gttcgccgga 300 cctctggccg agcagttcct gaaccaggtg gacctgaccg agacactgga aagataccag 360 cagcggctga atacctacgc cctggtgtcc aaggacctgg ccagctaccg gtccttcagc 420 cagcagctga aggctcagga cagcctgggc gagcagccta ccaccgtgcc ccctccaatc 480 gacctgagca tcccccacgt gtggatgccc ccccagacca cacctcacgg ctggaaagag 540 agccacacca ccagcggcct gcacagaccc cacttcaacc agacctgcat tctgttcgac 600 ggccacgacc tgctgttcag caccgtgacc ccctgcctgc accagggctt ctacctgatc 660 gacgagctga gatacgtgaa gatcaccctg accgaggatt tcttcgtggt caccgtgtcc 720 atcgacgacg acacccccat gctgctgatc ttcggccatc tgcctcgggt gctgttcaag 780 gccccctacc agcgggacaa cttcatcctg cggcagaccg agaagcacga gctgctggtg 840 ctggtcaaga aggaccagct gaaccggcac tcctacctga aggaccccga cttcctggac 900 gccgccctgg acttcaacta cctggacctg agcgccctgc tgagaaacag cttccacaga 960 tacgccgtgg acgtgctgaa gtccggccgg tgccagatgc tggacagacg gaccgtggaa 1020 atggccttcg cctatgccct ggccctgttt gccgccgctc ggcaggaaga ggctggcgct 1080 gaagtgtccg tgcccagagc cctggacaga caggccgctc tgctgcagat ccaggaattc 1140 atgatcacct gtctgagcca gaccccccct cggaccaccc tgctgctgta ccctaccgcc 1200 gtggatctgg ccaagcgggc cctgtggacc cccaaccaga tcaccgacat cacaagcctc 1260 gtgcggctgg tgtacatcct gagcaagcag aaccagcagc acctgatccc ccagtgggcc 1320 ctgagacaga tcgccgactt cgccctgaag ctgcacaaga cccacctggc tagctttctg 1380 agcgccttcg ctaggcagga actgtacctg atgggcagcc tggtgcactc catgctggtg 1440 cacaccaccg agaggcggga aatcttcatc gtggaaaccg gcctgtgcag cctggccgag 1500 ctgagccact tcacccagct gctggcccac ccccaccacg agtacctgag cgacctgtac 1560 accccctgca gctctagcgg cagacgggat cacagcctgg aacggctgac ccggctgttc 1620 cccgatgcca cagtgcctgc cactgtgcca gccgccctgt ccatcctgtc caccatgcag 1680 cccagcaccc tggaaacctt ccccgacctg ttctgcctgc ccctgggcga gagcttcagc 1740 gccctgacag tgtccgagca cgtgtcctac gtggtcacca accagtacct gatcaagggc 1800 atcagctacc ccgtgtccac caccgtcgtg ggccagagcc tgatcatcac ccagaccgac 1860 agccagacca agtgcgagct gacccggaac atgcacacca cacacagcat cactgccgcc 1920 ctgaacatca gcctggaaaa ctgcgccttc tgccagtctg ccctgctgga atacgacgat 1980 acccagggcg tgatcaacat catgtacatg cacgacagcg acgacgtgct gttcgccctg 2040 gacccctaca acgaggtggt ggtgtccagc ccccggaccc actacctgat gctgctgaag 2100 aacggcaccg tgctggaagt gaccgacgtg gtggtggacg ccaccgacag cagactgctg 2160 atgatgagcg tgtacgccct gagcgccatc atcggcatct acctgctgta ccggatgctg 2220 aaaacctgct ga 2232 <210> 32 <211> 743 <212> PRT <213> Artificial Sequence <220> <223> gH consensus amino acid sequence <220> <221> MISC_FEATURE <222> (1) <223> Xaa can be any naturally occurring amino acid <400> 32 Xaa Arg Pro Gly Leu Pro Ser Tyr Leu Thr Val Phe Ala Val Tyr Leu 1 5 10 15 Leu Ser His Leu Pro Ser Gln Arg Tyr Gly Ala Asp Ala Ala Ser Glu 20 25 30 Ala Leu Asp Pro His Ala Phe His Leu Leu Leu Asn Thr Tyr Gly Arg 35 40 45 Pro Ile Arg Phe Leu Arg Glu Asn Thr Thr Gln Cys Thr Tyr Asn Ser 50 55 60 Ser Leu Arg Asn Ser Thr Val Val Arg Glu Asn Ala Ile Ser Phe Asn 65 70 75 80 Phe Phe Gln Ser Tyr Asn Gln Tyr Tyr Val Phe His Met Pro Arg Cys 85 90 95 Leu Phe Ala Gly Pro Leu Ala Glu Gln Phe Leu Asn Gln Val Asp Leu 100 105 110 Thr Glu Thr Leu Glu Arg Tyr Gln Gln Arg Leu Asn Thr Tyr Ala Leu 115 120 125 Val Ser Lys Asp Leu Ala Ser Tyr Arg Ser Phe Ser Gln Gln Leu Lys 130 135 140 Ala Gln Asp Ser Leu Gly Glu Gln Pro Thr Thr Val Pro Pro Pro Ile 145 150 155 160 Asp Leu Ser Ile Pro His Val Trp Met Pro Pro Gln Thr Thr Pro His 165 170 175 Gly Trp Lys Glu Ser His Thr Thr Ser Gly Leu His Arg Pro His Phe 180 185 190 Asn Gln Thr Cys Ile Leu Phe Asp Gly His Asp Leu Leu Phe Ser Thr 195 200 205 Val Thr Pro Cys Leu His Gln Gly Phe Tyr Leu Ile Asp Glu Leu Arg 210 215 220 Tyr Val Lys Ile Thr Leu Thr Glu Asp Phe Phe Val Val Thr Val Ser 225 230 235 240 Ile Asp Asp Asp Thr Pro Met Leu Leu Ile Phe Gly His Leu Pro Arg 245 250 255 Val Leu Phe Lys Ala Pro Tyr Gln Arg Asp Asn Phe Ile Leu Arg Gln 260 265 270 Thr Glu Lys His Glu Leu Leu Val Leu Val Lys Lys Asp Gln Leu Asn 275 280 285 Arg His Ser Tyr Leu Lys Asp Pro Asp Phe Leu Asp Ala Ala Leu Asp 290 295 300 Phe Asn Tyr Leu Asp Leu Ser Ala Leu Leu Arg Asn Ser Phe His Arg 305 310 315 320 Tyr Ala Val Asp Val Leu Lys Ser Gly Arg Cys Gln Met Leu Asp Arg 325 330 335 Arg Thr Val Glu Met Ala Phe Ala Tyr Ala Leu Ala Leu Phe Ala Ala 340 345 350 Ala Arg Gln Glu Glu Ala Gly Ala Glu Val Ser Val Pro Arg Ala Leu 355 360 365 Asp Arg Gln Ala Ala Leu Leu Gln Ile Gln Glu Phe Met Ile Thr Cys 370 375 380 Leu Ser Gln Thr Pro Pro Arg Thr Thr Leu Leu Leu Tyr Pro Thr Ala 385 390 395 400 Val Asp Leu Ala Lys Arg Ala Leu Trp Thr Pro Asn Gln Ile Thr Asp 405 410 415 Ile Thr Ser Leu Val Arg Leu Val Tyr Ile Leu Ser Lys Gln Asn Gln 420 425 430 Gln His Leu Ile Pro Gln Trp Ala Leu Arg Gln Ile Ala Asp Phe Ala 435 440 445 Leu Lys Leu His Lys Thr His Leu Ala Ser Phe Leu Ser Ala Phe Ala 450 455 460 Arg Gln Glu Leu Tyr Leu Met Gly Ser Leu Val His Ser Met Leu Val 465 470 475 480 His Thr Thr Glu Arg Arg Glu Ile Phe Ile Val Glu Thr Gly Leu Cys 485 490 495 Ser Leu Ala Glu Leu Ser His Phe Thr Gln Leu Leu Ala His Pro His 500 505 510 His Glu Tyr Leu Ser Asp Leu Tyr Thr Pro Cys Ser Ser Ser Gly Arg 515 520 525 Arg Asp His Ser Leu Glu Arg Leu Thr Arg Leu Phe Pro Asp Ala Thr 530 535 540 Val Pro Ala Thr Val Pro Ala Ala Leu Ser Ile Leu Ser Thr Met Gln 545 550 555 560 Pro Ser Thr Leu Glu Thr Phe Pro Asp Leu Phe Cys Leu Pro Leu Gly 565 570 575 Glu Ser Phe Ser Ala Leu Thr Val Ser Glu His Val Ser Tyr Val Val 580 585 590 Thr Asn Gln Tyr Leu Ile Lys Gly Ile Ser Tyr Pro Val Ser Thr Thr 595 600 605 Val Val Gly Gln Ser Leu Ile Ile Thr Gln Thr Asp Ser Gln Thr Lys 610 615 620 Cys Glu Leu Thr Arg Asn Met His Thr Thr His Ser Ile Thr Ala Ala 625 630 635 640 Leu Asn Ile Ser Leu Glu Asn Cys Ala Phe Cys Gln Ser Ala Leu Leu 645 650 655 Glu Tyr Asp Asp Thr Gln Gly Val Ile Asn Ile Met Tyr Met His Asp 660 665 670 Ser Asp Asp Val Leu Phe Ala Leu Asp Pro Tyr Asn Glu Val Val Val 675 680 685 Ser Ser Pro Arg Thr His Tyr Leu Met Leu Leu Lys Asn Gly Thr Val 690 695 700 Leu Glu Val Thr Asp Val Val Val Asp Ala Thr Asp Ser Arg Leu Leu 705 710 715 720 Met Met Ser Val Tyr Ala Leu Ser Ala Ile Ile Gly Ile Tyr Leu Leu 725 730 735 Tyr Arg Met Leu Lys Thr Cys 740 <210> 33 <211> 837 <212> DNA <213> Artificial Sequence <220> <223> gL consensus nucleic acid sequence <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <400> 33 nnntgcaggc ggcccgactg cggcttcagc ttcagccctg gccccgtgat cctgctgtgg 60 tgctgcctgc tgctgcccat cgtgtcctct gccgccgtgt ctgtggcccc tacagccgcc 120 gagaaggtgc cagccgagtg ccctgagctg accagacggt gtctgctggg cgaggtgttc 180 cagggcgata agtacgagag ctggctgcgg cccctggtca acgtgaccgg cagagatggc 240 cccctgagcc agctgatccg gtacagaccc gtgacccctg aggccgccaa cagcgtgctg 300 ctggacgaag cctttctgga cacactggcc ctgctgtaca acaaccccga ccagctgcgg 360 gccctgctga cactgctgag cagcgatacc gcccccagat ggatgaccgt gatgcggggc 420 tacagcgagt gcggcgacgg atctcccgcc gtgtacacct gtgtggacga cctgtgccgg 480 ggctacgacc tgaccagact gagctacggc cggtccatct tcacagagca cgtgctgggc 540 ttcgagctgg tgccccccag cctgttcaat gtggtggtgg ccatccggaa cgaggccacc 600 cggaccaaca gagcagtgcg gctgcctgtg tccaccgctg ctgctccaga gggcatcacc 660 ctgttctacg gcctgtacaa cgccgtgaaa gagttctgcc tgagacacca gctggacccc 720 cccctgctgc ggcacctgga caagtactac gccggcctgc ctcccgagct gaagcagacc 780 agagtgaacc tgcccgccca cagcagatac ggccctcagg ccgtggacgc cagatga 837 <210> 34 <211> 278 <212> PRT <213> Artificial Sequence <220> <223> gL consensus amino acid sequence <220> <221> MISC_FEATURE <222> (1)..(1) <223> Xaa can be any naturally occurring amino acid <400> 34 Xaa Cys Arg Arg Pro Asp Cys Gly Phe Ser Phe Ser Pro Gly Pro Val 1 5 10 15 Ile Leu Leu Trp Cys Cys Leu Leu Leu Pro Ile Val Ser Ser Ala Ala 20 25 30 Val Ser Val Ala Pro Thr Ala Ala Glu Lys Val Pro Ala Glu Cys Pro 35 40 45 Glu Leu Thr Arg Arg Cys Leu Leu Gly Glu Val Phe Gln Gly Asp Lys 50 55 60 Tyr Glu Ser Trp Leu Arg Pro Leu Val Asn Val Thr Gly Arg Asp Gly 65 70 75 80 Pro Leu Ser Gln Leu Ile Arg Tyr Arg Pro Val Thr Pro Glu Ala Ala 85 90 95 Asn Ser Val Leu Leu Asp Glu Ala Phe Leu Asp Thr Leu Ala Leu Leu 100 105 110 Tyr Asn Asn Pro Asp Gln Leu Arg Ala Leu Leu Thr Leu Leu Ser Ser 115 120 125 Asp Thr Ala Pro Arg Trp Met Thr Val Met Arg Gly Tyr Ser Glu Cys 130 135 140 Gly Asp Gly Ser Pro Ala Val Tyr Thr Cys Val Asp Asp Leu Cys Arg 145 150 155 160 Gly Tyr Asp Leu Thr Arg Leu Ser Tyr Gly Arg Ser Ile Phe Thr Glu 165 170 175 His Val Leu Gly Phe Glu Leu Val Pro Pro Ser Leu Phe Asn Val Val 180 185 190 Val Ala Ile Arg Asn Glu Ala Thr Arg Thr Asn Arg Ala Val Arg Leu 195 200 205 Pro Val Ser Thr Ala Ala Ala Pro Glu Gly Ile Thr Leu Phe Tyr Gly 210 215 220 Leu Tyr Asn Ala Val Lys Glu Phe Cys Leu Arg His Gln Leu Asp Pro 225 230 235 240 Pro Leu Leu Arg His Leu Asp Lys Tyr Tyr Ala Gly Leu Pro Pro Glu 245 250 255 Leu Lys Gln Thr Arg Val Asn Leu Pro Ala His Ser Arg Tyr Gly Pro 260 265 270 Gln Ala Val Asp Ala Arg 275 <210> 35 <211> 1419 <212> Ms <213> Artificial Sequence <220> <223> gO shared nucleic acid sequence <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <400> 35 nnnggcaaga aagaaatgat catggtcaag ggcatcccca agatcatgct gctgatcagc 60 atcacctttc tgctgctgag cctgatcaac tgcaacgtgc tggtcaacag caagggcaca 120 cggcggagct ggccctacac cgtgctgagc taccggggca aagagatcct gaagaagcag 180 aaagaggaca tcctgaagcg gctgatgagc accagcagcg acggctaccg gttcctgatg 240 taccccagcc agcagaaatt ccacgccatc gtgatcagca tggacaagtt cccccaggac 300 tacatcctgg ccggacccat ccggaacgac agcatcaccc acatgtggtt cgacttctac 360 agcacccagc tgcggaagcc cgccaaatac gtgtacagcg agtacaacca caccgcccac 420 aagatcaccc tgcggcctcc cccttgcggc accgtgccca gcatgaactg cctgagcgag 480 atgctgaacg tgtccaagcg gaacgacacc ggcgagaagg gctgcggcaa cttcaccacc 540 ttcaacccca tgttcttcaa cgtgccccgg tggaacacca agctgtacat cggcagcaac 600 aaagtgaacg tggacagcca gaccatctac tttctgggcc tgaccgccct gctgctgcgc 660 tacgcccaga gaaactgcac ccggtccttc tacctggtca acgccatgag ccggaacctg 720 ttccgggtgc ccaagtacat caacggcacc aagctgaaga acaccatgcg gaagctgaag 780 cggaagcagg ccctggtcaa agagcagccc cagaagaaga acaagaagtc ccagagcacc 840 accaccccct acctgagcta caccaccagc accgccttca acgtgaccac caacgtgacc 900 tacagcgcca cagccgccgt gaccagagtg gccacctcca ccaccggcta ccggcccgac 960 agcaacttca tgaagtccat catggccacc cagctgaggg acctggccac ctgggtgtac 1020 accaccctgc ggtacagaaa cgagcccttc tgcaagcccg accggaacag aaccgccgtg 1080 tccgagttca tgaagaatac ccacgtgctg atccgcaacg agacacccta caccatctac 1140 ggcaccctgg acatgagcag cctgtactac aacgagacaa tgagcgtcga gaacgagaca 1200 gccagcgaca acaacgaaac cacccccacc agccccagca cccggttcca gcggaccttc 1260 atcgaccccc tgtgggacta cctggacagc ctgctgttcc tggacaagat ccggaacttc 1320 agcctgcagc tgcccgccta cggcaacctg accccccctg aacacagaag ggccgccaac 1380 ctgagcaccc tgaacagcct gtggtggtgg ctgcagtga 1419 <210> 36 <211> 472 <212> PRT <213> Artificial Sequence <220> <223> gO consensus amino acid sequence <220> <221> MISC_FEATURE <222> (1) <223> Xaa can be any naturally occurring amino acid <400> 36 Xaa Gly Lys Lys Glu Met Ile Met Val Lys Gly Ile Pro Lys Ile Met 1 5 10 15 Leu Leu Ile Ser Ile Thr Phe Leu Leu Leu Ser Leu Ile Asn Cys Asn 20 25 30 Val Leu Val Asn Ser Lys Gly Thr Arg Arg Ser Trp Pro Tyr Thr Val 35 40 45 Leu Ser Tyr Arg Gly Lys Glu Ile Leu Lys Lys Gln Lys Glu Asp Ile 50 55 60 Leu Lys Arg Leu Met Ser Thr Ser Ser Asp Gly Tyr Arg Phe Leu Met 65 70 75 80 Tyr Pro Ser Gln Gln Lys Phe His Ala Ile Val Ile Ser Met Asp Lys 85 90 95 Phe Pro Gln Asp Tyr Ile Leu Ala Gly Pro Ile Arg Asn Asp Ser Ile 100 105 110 Thr His Met Trp Phe Asp Phe Tyr Ser Thr Gln Leu Arg Lys Pro Ala 115 120 125 Lys Tyr Val Tyr Ser Glu Tyr Asn His Thr Ala His Lys Ile Thr Leu 130 135 140 Arg Pro Pro Pro Cys Gly Thr Val Pro Ser Met Asn Cys Leu Ser Glu 145 150 155 160 Met Leu Asn Val Ser Lys Arg Asn Asp Thr Gly Glu Lys Gly Cys Gly 165 170 175 Asn Phe Thr Thr Phe Asn Pro Met Phe Phe Asn Val Pro Arg Trp Asn 180 185 190 Thr Lys Leu Tyr Ile Gly Ser Asn Lys Val Asn Val Asp Ser Gln Thr 195 200 205 Ile Tyr Phe Leu Gly Leu Thr Ala Leu Leu Leu Arg Tyr Ala Gln Arg 210 215 220 Asn Cys Thr Arg Ser Phe Tyr Leu Val Asn Ala Met Ser Arg Asn Leu 225 230 235 240 Phe Arg Val Pro Lys Tyr Ile Asn Gly Thr Lys Leu Lys Asn Thr Met 245 250 255 Arg Lys Leu Lys Arg Lys Gln Ala Leu Val Lys Glu Gln Pro Gln Lys 260 265 270 Lys Asn Lys Lys Ser Gln Ser Thr Thr Thr Pro Tyr Leu Ser Tyr Thr 275 280 285 Thr Ser Thr Ala Phe Asn Val Thr Thr Asn Val Thr Tyr Ser Ala Thr 290 295 300 Ala Ala Val Thr Arg Val Ala Thr Ser Thr Thr Gly Tyr Arg Pro Asp 305 310 315 320 Ser Asn Phe Met Lys Ser Ile Met Ala Thr Gln Leu Arg Asp Leu Ala 325 330 335 Thr Trp Val Tyr Thr Thr Leu Arg Tyr Arg Asn Glu Pro Phe Cys Lys 340 345 350 Pro Asp Arg Asn Arg Thr Ala Val Ser Glu Phe Met Lys Asn Thr His 355 360 365 Val Leu Ile Arg Asn Glu Thr Pro Tyr Thr Ile Tyr Gly Thr Leu Asp 370 375 380 Met Ser Ser Leu Tyr Tyr Asn Glu Thr Met Ser Val Glu Asn Glu Thr 385 390 395 400 Ala Ser Asp Asn Asn Glu Thr Thr Pro Thr Ser Pro Ser Thr Arg Phe 405 410 415 Gln Arg Thr Phe Ile Asp Pro Leu Trp Asp Tyr Leu Asp Ser Leu Leu 420 425 430 Phe Leu Asp Lys Ile Arg Asn Phe Ser Leu Gln Leu Pro Ala Tyr Gly 435 440 445 Asn Leu Thr Pro Pro Glu His Arg Arg Ala Ala Asn Leu Ser Thr Leu 450 455 460 Asn Ser Leu Trp Trp Trp Leu Gln 465 470 <210> 37 <211> 516 <212> DNA <213> Artificial Sequence <220> <223> UL128 consensus nucleic acid sequence <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <400> 37 nnnagcccca aggatctgac ccctttcctg accgccctgt ggctgctcct gggccacagc 60 agagtgccta gagtgcgggc cgaggaatgc tgcgagttca tcaacgtgaa ccaccccccc 120 gagcggtgct acgacttcaa gatgtgcaac cggttcaccg tggctctgag atgccccgac 180 ggcgaagtgt gctacagccc cgagaaaacc gccgagatcc ggggcatcgt gaccaccatg 240 acccacagcc tgaccagaca ggtggtgcat aacaagctga ccagttgcaa ctacaacccc 300 ctgtacctgg aagccgacgg ccggatcaga tgcggcaaag tgaacgacaa ggcccagtac 360 ctgctgggcg ctgcaggcag tgtgccctac agatggatca acctggaata cgacaagatc 420 acccggatcg tgggcctgga ccagtacctg gaaagcgtga agaagcacaa gcggctggac 480 gtgtgccggg ccaagatggg ctacatgctg cagtga 516 <210> 38 <211> 171 <212> PRT <213> Artificial Sequence <220> <223> UL128 consensus amino acid sequence <220> <221> MISC_FEATURE <222> (1) <223> Xaa can be any naturally occurring amino acid <400> 38 Xaa Ser Pro Lys Asp Leu Thr Pro Phe Leu Thr Ala Leu Trp Leu Leu 1 5 10 15 Leu Gly His Ser Arg Val Pro Arg Val Arg Ala Glu Glu Cys Cys Glu 20 25 30 Phe Ile Asn Val Asn His Pro Pro Glu Arg Cys Tyr Asp Phe Lys Met 35 40 45 Cys Asn Arg Phe Thr Val Ala Leu Arg Cys Pro Asp Gly Glu Val Cys 50 55 60 Tyr Ser Pro Glu Lys Thr Ala Glu Ile Arg Gly Ile Val Thr Thr Met 65 70 75 80 Thr His Ser Leu Thr Arg Gln Val Val His Asn Lys Leu Thr Ser Cys 85 90 95 Asn Tyr Asn Pro Leu Tyr Leu Glu Ala Asp Gly Arg Ile Arg Cys Gly 100 105 110 Lys Val Asn Asp Lys Ala Gln Tyr Leu Leu Gly Ala Ala Gly Ser Val 115 120 125 Pro Tyr Arg Trp Ile Asn Leu Glu Tyr Asp Lys Ile Thr Arg Ile Val 130 135 140 Gly Leu Asp Gln Tyr Leu Glu Ser Val Lys Lys His Lys Arg Leu Asp 145 150 155 160 Val Cys Arg Ala Lys Met Gly Tyr Met Leu Gln 165 170 <210> 39 <211> 646 <212> DNA <213> Artificial Sequence <220> <223> UL130 Consensus Amino Acid Sequence <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <400> 39 nnngctgcgg ctgctgctgc ggcaccactt ccactgcctg ctgctgtgtg ccgtgtgggc 60 caccccttgt ctggccagcc cttggagcac cctgaccgcc aaccagaacc ctagcccccc 120 ctggtccaag ctgacctaca gcaagcccca cgacgccgct accttctact gcccattcct 180 gtaccccagc cctcccagaa gccccctgca gttcagcggc ttccagcggg tgtccaccgg 240 ccctgagtgc cggaacgaga cactgtacct gctgtacaac cgcgagggcc agaccctggt 300 ggaacggtct agcacctggg tcaagaaagt gatctggtat ctgagcggcc ggaaccagac 360 catcctgcag cggatgcctc ggaccgccag caagcctagc gacggcaacg tgcagatcag 420 cgtggaagat gccaaaatct tcggcgccca catggtgccc aagcagacca agctgctgag 480 attcgtggtc aacgacggca ccagatacca gatgtgcgtg atgaagctgg aaagctgggc 540 ccacgtgttc cgggactaca gcgtgtcatt ccaggtccga ctgaccttca ccgaggccaa 600 caaccagacc tacaccttct gcacccacccc caacctgatc gtctga 646 <210> 40 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> UL130 consensus amino acid sequence <220> <221> MISC_FEATURE <222> (1) <223> Xaa can be any naturally occurring amino acid <220> <221> MISC_FEATURE <222> (1) <223> Xaa can be any naturally occurring amino acid <400> 40 Xaa Leu Arg Leu Leu Leu Arg His His Phe His Cys Leu Leu Leu Cys 1 5 10 15 Ala Val Trp Ala Thr Pro Cys Leu Ala Ser Pro Trp Ser Thr Leu Thr 20 25 30 Ala Asn Gln Asn Pro Ser Pro Pro Trp Ser Lys Leu Thr Tyr Ser Lys 35 40 45 Pro His Asp Ala Ala Thr Phe Tyr Cys Pro Phe Leu Tyr Pro Ser Pro 50 55 60 Pro Arg Ser Pro Leu Gln Phe Ser Gly Phe Gln Arg Val Ser Thr Gly 65 70 75 80 Pro Glu Cys Arg Asn Glu Thr Leu Tyr Leu Leu Tyr Asn Arg Glu Gly 85 90 95 Gln Thr Leu Val Glu Arg Ser Ser Thr Trp Val Lys Lys Val Ile Trp 100 105 110 Tyr Leu Ser Gly Arg Asn Gln Thr Ile Leu Gln Arg Met Pro Arg Thr 115 120 125 Ala Ser Lys Pro Ser Asp Gly Asn Val Gln Ile Ser Val Glu Asp Ala 130 135 140 Lys Ile Phe Gly Ala His Met Val Pro Lys Gln Thr Lys Leu Leu Arg 145 150 155 160 Phe Val Val Asn Asp Gly Thr Arg Tyr Gln Met Cys Val Met Lys Leu 165 170 175 Glu Ser Trp Ala His Val Phe Arg Asp Tyr Ser Val Ser Phe Gln Val 180 185 190 Arg Leu Thr Phe Thr Glu Ala Asn Asn Gln Thr Tyr Thr Phe Cys Thr 195 200 205 His Pro Asn Leu Ile Val 210 <210> 41 <211> 390 <212> DNA <213> Artificial Sequence <220> <223> UL131a Consensus Nucleic Acid Sequence <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <400> 41 nnnagactgt gcagagtgtg gctgagcgtg tgcctgtgcg ccgtggtgct gggccagtgc 60 cagagagaga cagccgagaa gaacgactac taccgggtgc cccactactg ggacgcctgc 120 tctagagccc tgcccgacca gacccggtac aaatacgtgg aacagctggt ggacctgacc 180 ctgaactacc actacgacgc cagccacggc ctggacaact tcgacgtgct gaagcggatc 240 aacgtgaccg aggtgtccct gctgatcagc gacttccggc ggcagaacag aagaggcggc 300 accaacaagc ggactacctt caacgccgct ggcagcctgg cccctcacgc cagatccctg 360 gaattcagcg tgcggctgtt cgccaactga 390 <210> 42 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> UL131a consensus amino acid sequence <220> <221> MISC_FEATURE <222> (1) <223> Xaa can be any naturally occurring amino acid <400> 42 Xaa Arg Leu Cys Arg Val Trp Leu Ser Val Cys Leu Cys Ala Val Val 1 5 10 15 Leu Gly Gln Cys Gln Arg Glu Thr Ala Glu Lys Asn Asp Tyr Tyr Arg 20 25 30 Val Pro His Tyr Trp Asp Ala Cys Ser Arg Ala Leu Pro Asp Gln Thr 35 40 45 Arg Tyr Lys Tyr Val Glu Gln Leu Val Asp Leu Thr Leu Asn Tyr His 50 55 60 Tyr Asp Ala Ser His Gly Leu Asp Asn Phe Asp Val Leu Lys Arg Ile 65 70 75 80 Asn Val Thr Glu Val Ser Leu Leu Ile Ser Asp Phe Arg Arg Gln Asn 85 90 95 Arg Arg Gly Gly Thr Asn Lys Arg Thr Thr Phe Asn Ala Ala Gly Ser 100 105 110 Leu Ala Pro His Ala Arg Ser Leu Glu Phe Ser Val Arg Leu Phe Ala 115 120 125 Asn <210> 43 <211> 1687 <212> DNA <213> Artificial Sequence <220> <223> UL83 consensus nucleic acid sequence <220> <221> misc_feature <222> (1)..(3) <223> n is a, c, g or t <400> 43 nnntgagagt cgcgggcgga gatgccctga aatgatcagc gtgctgggcc caatttccgg 60 gcatgtgctg aaggccgtct tctcccgcgg agacaccccc gtgctgcctc acgagacaag 120 actgctgcag actggcatcc atgtgagggt ctcccagcca tctctgattc tggtgtctca 180 gtacacccca gatagtacac cctgccacag aggggacaac cagctgcagg tgcagcatac 240 ctacttcacc ggatcagagg tcgaaaatgt gagcgtcaac gtgcacaatc ccacaggcag 300 gagtatctgt ccttcacagg agccaatgag catctacgtg tacgccctgc ccctgaaaat 360 gctgaacatc cctagcatta atgtgcacca ttacccctcc gccgctgaac gaaagcaccg 420 gcatctgcct gtggcagatg ccgtcatcca tgcttcaggc aaacagatgt ggcaggcacg 480 actgaccgtg agcggactgg catggacacg acagcagaac cagtggaagg agccagacgt 540 gtactatact agcgccttcg tgttccccac caaagacgtg gccctgcgac acgtggtctg 600 cgcacatgag ctggtgtgct ctatggaaaa tactcgggcc accaagatgc aggtcattgg 660 cgatcagtac gtcaaagtgt atctggagtc cttttgtgaa gacgtgccct ctgggaagct 720 gttcatgcac gtgaccctgg gaagcgatgt cgaggaagac ctgactatga cccggaaccc 780 acagcccttt atgagacctc acgagaggaa cggcttcact gtgctgtgcc caaagaatat 840 gatcattaag cccgggaaaa tctctcatat tatgctggat gtggccttta caagtcacga 900 gcatttcgga ctgctgtgcc ccaaaagcat ccctgggctg tcaattagcg gaaacctgct 960 gatgaatggc cagcagatct ttctggaagt gcaggccatt cgagagaccg tcgaactgcg 1020 acagtacgac ccagtggcag ccctgttctt tttcgatatc gacctgctgc tgcagagagg 1080 ccctcagtat agtgagcacc caacattcac ttcacagtac aggattcagg ggaagctgga 1140 gtatcggcac acttgggata gacatgacga aggagctgca cagggcgacg atgacgtgtg 1200 gacctccggc tctgatagtg acgaggaact ggtgaccaca gagcgaaaaa ctccccgggt 1260 gaccggagga ggagctatgg caggagcatc aaccagcgcc ggacgaaaga gaaaaagcgc 1320 cagcagcgcc acagcatgca ctgcaggcgt gatgacaagg gggcgcctga aggcagaatc 1380 cacagtcgcc cctgaggaag atactgacga ggattctgac aacgaaatcc acaatccagc 1440 cgtgttcacc tggccacctt ggcaggcagg aattctggct cgcaatctgg tccctatggt 1500 ggccactgtc cagggacaga acctgaagta ccaggagttt ttctgggatg ctaatgacat 1560 ctatcggatt ttcgcagagc tggaaggcgt gtggcagcca gcagctcagc caaaaaggcg 1620 ccgacacaga caggacgcac tgcctggacc atgtatcgcc tccaccccaa agaaacatag 1680 gggctga 1687 <210> 44 <211> 561 <212> PRT <213> Artificial Sequence <220> <223> UL83 consensus amino acid sequence <220> <221> MISC_FEATURE <222> (1) <223> Xaa can be any naturally occurring amino acid <400> 44 Xaa Glu Ser Arg Gly Arg Arg Cys Pro Glu Met Ile Ser Val Leu Gly 1 5 10 15 Pro Ile Ser Gly His Val Leu Lys Ala Val Phe Ser Arg Gly Asp Thr 20 25 30 Pro Val Leu Pro His Glu Thr Arg Leu Leu Gln Thr Gly Ile His Val 35 40 45 Arg Val Ser Gln Pro Ser Leu Ile Leu Val Ser Gln Tyr Thr Pro Asp 50 55 60 Ser Thr Pro Cys His Arg Gly Asp Asn Gln Leu Gln Val Gln His Thr 65 70 75 80 Tyr Phe Thr Gly Ser Glu Val Glu Asn Val Ser Val Asn Val His Asn 85 90 95 Pro Thr Gly Arg Ser Ile Cys Pro Ser Gln Glu Pro Met Ser Ile Tyr 100 105 110 Val Tyr Ala Leu Pro Leu Lys Met Leu Asn Ile Pro Ser Ile Asn Val 115 120 125 His His Tyr Pro Ser Ala Ala Glu Arg Lys His Arg His Leu Pro Val 130 135 140 Ala Asp Ala Val Ile His Ala Ser Gly Lys Gln Met Trp Gln Ala Arg 145 150 155 160 Leu Thr Val Ser Gly Leu Ala Trp Thr Arg Gln Gln Asn Gln Trp Lys 165 170 175 Glu Pro Asp Val Tyr Tyr Thr Ser Ala Phe Val Phe Pro Thr Lys Asp 180 185 190 Val Ala Leu Arg His Val Val Cys Ala His Glu Leu Val Cys Ser Met 195 200 205 Glu Asn Thr Arg Ala Thr Lys Met Gln Val Ile Gly Asp Gln Tyr Val 210 215 220 Lys Val Tyr Leu Glu Ser Phe Cys Glu Asp Val Pro Ser Gly Lys Leu 225 230 235 240 Phe Met His Val Thr Leu Gly Ser Asp Val Glu Glu Asp Leu Thr Met 245 250 255 Thr Arg Asn Pro Gln Pro Phe Met Arg Pro His Glu Arg Asn Gly Phe 260 265 270 Thr Val Leu Cys Pro Lys Asn Met Ile Ile Lys Pro Gly Lys Ile Ser 275 280 285 His Ile Met Leu Asp Val Ala Phe Thr Ser His Glu His Phe Gly Leu 290 295 300 Leu Cys Pro Lys Ser Ile Pro Gly Leu Ser Ile Ser Gly Asn Leu Leu 305 310 315 320 Met Asn Gly Gln Gln Ile Phe Leu Glu Val Gln Ala Ile Arg Glu Thr 325 330 335 Val Glu Leu Arg Gln Tyr Asp Pro Val Ala Ala Leu Phe Phe Phe Asp 340 345 350 Ile Asp Leu Leu Leu Gln Arg Gly Pro Gln Tyr Ser Glu His Pro Thr 355 360 365 Phe Thr Ser Gln Tyr Arg Ile Gln Gly Lys Leu Glu Tyr Arg His Thr 370 375 380 Trp Asp Arg His Asp Glu Gly Ala Ala Gln Gly Asp Asp Asp Val Trp 385 390 395 400 Thr Ser Gly Ser Asp Ser Asp Glu Glu Leu Val Thr Thr Glu Arg Lys 405 410 415 Thr Pro Arg Val Thr Gly Gly Gly Ala Met Ala Gly Ala Ser Thr Ser 420 425 430 Ala Gly Arg Lys Arg Lys Ser Ala Ser Ser Ala Thr Ala Cys Thr Ala 435 440 445 Gly Val Met Thr Arg Gly Arg Leu Lys Ala Glu Ser Thr Val Ala Pro 450 455 460 Glu Glu Asp Thr Asp Glu Asp Ser Asp Asn Glu Ile His Asn Pro Ala 465 470 475 480 Val Phe Thr Trp Pro Pro Trp Gln Ala Gly Ile Leu Ala Arg Asn Leu 485 490 495 Val Pro Met Val Ala Thr Val Gln Gly Gln Asn Leu Lys Tyr Gln Glu 500 505 510 Phe Phe Trp Asp Ala Asn Asp Ile Tyr Arg Ile Phe Ala Glu Leu Glu 515 520 525 Gly Val Trp Gln Pro Ala Ala Gln Pro Lys Arg Arg Arg His Arg Gln 530 535 540 Asp Ala Leu Pro Gly Pro Cys Ile Ala Ser Thr Pro Lys Lys His Arg 545 550 555 560 Gly <210> 45 <211> 3447 <212> DNA <213> Artificial Sequence <220> <223> Nonspecific IgE antibodies to the hTERT complex(pgx1434) . <400> 45 atggattgga catggattct gttcctggtc gcagccgcca cacgagtgca tagccctaga gccccacggt gtagagcagt ccgcagcctg ctgcgcagcc gataccggga agtgctgcct 120 ctggccacct ttgtccggag actgggacca cagggcaggc gcctggtgca gcgcggcgac 180 cccgcagctt tccgagcact ggtggcacag tgcctggtgt gcgtgccatg ggatgcacgg 240 ccccctccag cagcccctag ctttagacag gtgtcctgcc tgaaagaact ggtcgcaagg gtggtccagc ggctgtgcga gagaggcgcc aggaacgtgc tggcattcgg ctttgcactg 360 ctggacggag ctaggggcgg gccccctgag gcattcacca caagcgtgcg ctcctacctg 420 ccaaatacag tcactgatac cctgcgaggc tccggagcat ggggactgct gctgcgacgg 480 gtgggggacg atgtgctggt ccacctgctg gctagatgcg cactgtatgt gctggtcgct 540 ccctcttgcg cataccaggt gtgcggacca cccctgtatg acctgggcgc tgcaacccag 600 gcaagacctc caccccacgc ctctggcact agaaggggac tgggcaccga acaggcatgg 660 aaccatagtg tcagggaggc aggagtgcca ctgggactgc cagcacctgg ggctcgccga 720 cggagaggga gtgccggacg gtcactgcca ctggctaaga gaccaaggcg cggagccgct 780 ccagaaccag agaggacacc tgtgggacag ggaagctggg cacaccctgg aagaactagg 840 gggccaagtg ataggggctt ctgcgtggtc tcaccagcac gaccagcaga ggaagctact 900 tctctggagg gagctctgag tggcacccgg cactctcatc ctagtgtggg aagacagcac 960 catgcaggcc ctccaagcac cagccggcct ccccggccat gggacactcc ttgtccaccc 1020 gtgtacgctg aaaccaaaca ctttctgtat agctccggag ataaggagca gctgcggccc 1080 tctttcctgc tgtctagtct gagacctagt ctgaccggag cacgacggct ggtggaaaca 1140 atctttctgg ggtcccgccc ttggatgcca ggaaccccca gaaggacacc tcgactgcca 1200 cagcggtact ggcagatgcg gccactgttc ctggagctgc tgggcaatca cgctcagtgc 1260 ccctatgggg cactgctgcg aacacattgt cctctgcggg cagccgtgac tccagctgca 1320 ggagtctgcg ccagggaaaa gccacagggc agcgtggcag ctcctgagga agaggacacc 1380 gatccacgcc gactggtgca gctgctgaga cagcactcaa gcccctggca ggtgtacgga 1440 tttctgaggg cctgtctgcg gagactggtg cctccaggac tgtgggggtc caggcacaac 1500 gaaaggcgct ttctgcgcaa tactaagaaa ttcatcagcc tgggcaagca tgctaaactg 1560 tccctgcagg agctgacctg gaaaatgagt gtgcgcgact gcgcatggct gcgacggtca 1620 ccaggagtcg ggtgcgtgcc tgcagccgag caccgcctgc gagaagagat tctggccaag 1680 tttctgcatt ggctgatgtc agtgtacgtg gtcgaactgc tgcggagctt cttttatgtg 1740 acagagacta ccttccagaa aaactacctg ttcttttatc gcaagtcagt gtggagcaaa 1800 ctgcagtcaa tcggcattcg gcagcacctg aagagagtgc agctgaggga actgagtgaa gccgaggtcc ggcagcatag agaggcaagg cctgccctgc tgacctcccg gctgagattc 1920 ctgcctaagc cagacgggct gagaccaatc gtgaacatgg attacgtggt cggagcacgg accttccgga gggaaaaacg cgctgagcga ctgacatccc gcgtgaagac tctgttctct gtcctgaatt atgagcgagc tcgccgaccc ggactgctgg gagcatctgt gctgggactg 2100. gacgatattc accgggcttg gagagcattt gtcctgaggg tgcgcgcaca ggaccctccc 2160. ccagaactgt acttcgtgaa agtcgccgtg accggggctt atgacacaat ccctcaggat cggctgactg aagtgatcgc ctccatcatt aagccacaga atacctactg cgtgcggaga 2280 tatgctgtgg tcaggcgcgc tgcacacggc catgtgagga agagcttcaa gcgccacgtc agcacactga ctgatctgca gccctacatg agcacttcg tggctcatct gcaggagacc agccctctga gggacgcagt ggtcatcgaa cagtcctcta gtctgaacga ggcatcaagc gggctgttcg atgtctttct gcggttcgtg tgccaccatg ccgtcagaat tggaggcaaa 2520 tcttacgtgc agtgtcaggg catcccccag ggcagcattc tgtctaccct gctgtgcagc 2580 ctgtgctatg gcgacatgga aaataagctg tttgccggaa tccgacggga tggcctgctg 2640 ctgagactgg tggccgcttt tctgctggtc actccacacc tgacccatgc caaagctttc 2700 ctgcgcacac tggtccgagg ggtgccagag tacggatgcg tggtcaacct gaggaagacc 2760 gtggtcaatt tcccagtgga agacgaggcc ctgggcggca cagcatttgt ccagctgcca 2820 gcacacggac tgttcccatg gtgtggactg ctgctggaca cccgcacact ggaggtgcag 2880 tccgattact cctcttatgc ccggacaagc atcagagctt ccctgacttt taacagaggc 2940 ttcaaggccg ggaggaatat gagaaggaaa ctgtttggcg tgctgcgcct gaagtgccat 3000 tccctgttcc tgtatctgca ggtgaactct ctgcagactg tctgtaccaa cgtgtacaaa 3060 atttttctgc tgcaggccta tcggttccac gcttgcgtgc tgcagctgcc attccatcag 3120 caggtcagga agaaccccac cttctttctg cgcgtgatct ctgatacagc tagtctgtgc 3180 tactcaattc tgaaggccaa aaatgctggc atgagcctgg gagcaaaagg agcagcagga 3240 ccatttcctt ccgaggctgc acagtggctg tgccaccagg cattcctgct gaagctggcc 3300 cgacatcggg tgacatatag gtgcctgctg ggcgcactgc gaacagcaca gactcagctg 3360 tgcagaaagc tgcccggggc cactctggct gccctggaag ccgctgccga ccctgccctg 3420 acctccgatt tcaagactat tctggac 3447 <210> 46 <211> 1149 <212> PRT <213> Artificial Sequence <220> <223> Synthetic consensus hTERT amino acid sequence operatively linked to IgE (pgx 1434) <400> 46 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg 20 25 30 Ser Arg Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu 35 40 45 Gly Pro Gln Gly Arg Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe 50 55 60 Arg Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg 65 70 75 80 Pro Pro Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu 85 90 95 Leu Val Ala Arg Val Val Gln Arg Leu Cys Glu Arg Gly Ala Arg Asn 100 105 110 Val Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro 115 120 125 Pro Glu Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val 130 135 140 Thr Asp Thr Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg 145 150 155 160 Val Gly Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Tyr 165 170 175 Val Leu Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu 180 185 190 Tyr Asp Leu Gly Ala Ala Thr Gln Ala Arg Pro Pro Pro His Ala Ser 195 200 205 Gly Thr Arg Arg Gly Leu Gly Thr Glu Gln Ala Trp Asn His Ser Val 210 215 220 Arg Glu Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg 225 230 235 240 Arg Arg Gly Ser Ala Gly Arg Ser Leu Pro Leu Ala Lys Arg Pro Arg 245 250 255 Arg Gly Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser 260 265 270 Trp Ala His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys 275 280 285 Val Val Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly 290 295 300 Ala Leu Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His 305 310 315 320 His Ala Gly Pro Pro Ser Thr Ser Arg Pro Pro Arg Pro Trp Asp Thr 325 330 335 Pro Cys Pro Pro Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Ser Ser 340 345 350 Gly Asp Lys Glu Gln Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg 355 360 365 Pro Ser Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly 370 375 380 Ser Arg Pro Trp Met Pro Gly Thr Pro Arg Arg Thr Pro Arg Leu Pro 385 390 395 400 Gln Arg Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn 405 410 415 His Ala Gln Cys Pro Tyr Gly Ala Leu Leu Arg Thr His Cys Pro Leu 420 425 430 Arg Ala Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro 435 440 445 Gln Gly Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg 450 455 460 Leu Val Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly 465 470 475 480 Phe Leu Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly 485 490 495 Ser Arg His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile 500 505 510 Ser Leu Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys 515 520 525 Met Ser Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly 530 535 540 Cys Val Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys 545 550 555 560 Phe Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser 565 570 575 Phe Phe Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Tyr Leu Phe Phe 580 585 590 Tyr Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln 595 600 605 His Leu Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg 610 615 620 Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe 625 630 635 640 Leu Pro Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val 645 650 655 Val Gly Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr 660 665 670 Ser Arg Val Lys Thr Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg 675 680 685 Arg Pro Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His 690 695 700 Arg Ala Trp Arg Ala Phe Val Leu Arg Val Arg Ala Gln Asp Pro 705 710 715 720 Pro Glu Leu Tyr Phe Val Lys Val Ala Val Thr Gly Ala Tyr Asp Thr 725 730 735 Ile Pro Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro 740 745 750 Gln Asn Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Arg Arg Ala Ala 755 760 765 His Gly His Val Arg Lys Ser Phe Lys Arg His Val Ser Thr Leu Thr 770 775 780 Asp Leu Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr 785 790 795 800 Ser Pro Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn 805 810 815 Glu Ala Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Val Cys His 820 825 830 His Ala Val Arg Ile Gly Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile 835 840 845 Pro Gln Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly 850 855 860 Asp Met Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp Gly Leu Leu 865 870 875 880 Leu Arg Leu Val Ala Ala Phe Leu Leu Val Thr Pro His Leu Thr His 885 890 895 Ala Lys Ala Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly 900 905 910 Cys Val Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp 915 920 925 Glu Ala Leu Gly Gly Thr Ala Phe Val Gln Leu Pro Ala His Gly Leu 930 935 940 Phe Pro Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln 945 950 955 960 Ser Asp Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr 965 970 975 Phe Asn Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe 980 985 990 Gly Val Leu Arg Leu Lys Cys His Ser Leu Phe Leu Tyr Leu Gln Val 995 1000 1005 Asn Ser Leu Gln Thr Val Cys Thr Asn Val Tyr Lys Ile Phe Leu 1010 1015 1020 Leu Gln Ala Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe 1025 1030 1035 His Gln Gln Val Arg Lys Asn Pro Thr Phe Phe Leu Arg Val Ile 1040 1045 1050 Ser Asp Thr Ala Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn 1055 1060 1065 Ala Gly Met Ser Leu Gly Ala Lys Gly Ala Ala Gly Pro Phe Pro 1070 1075 1080 Ser Glu Ala Ala Gln Trp Leu Cys His Gln Ala Phe Leu Leu Lys 1085 1090 1095 Leu Ala Arg His Arg Val Thr Tyr Arg Cys Leu Leu Gly Ala Leu 1100 1105 1110 Arg Thr Ala Gln Thr Gln Leu Cys Arg Lys Leu Pro Gly Ala Thr 1115 1120 1125 Leu Ala Ala Leu Glu Ala Ala Ala Asp Pro Ala Leu Thr Ser Asp 1130 1135 1140 Phe Lys Thr Ile Leu Asp 1145 <210> 47 <211> 3393 <212> Ms <213> Artificial Sequence <220> <223> Synthesis of the total hTERT nucleic acid sequence (pgx1434) <400> 47 cctagagccc cacggtgtag agcagtccgc agcctgctgc gcagccgata ccgggaagtg 60 ctgcctctgg ccacctttgt ccggagactg ggaccacagg gcaggcgcct ggtgcagcgc 120 ggcgaccccg cagctttccg agcactggtg gcacagtgcc tggtgtgcgt gccatgggat 180 gcacggcccc ctccagcagc ccctagcttt agacaggtgt cctgcctgaa agaactggtc 240 gcaagggtgg tccagcggct gtgcgagaga ggcgccagga acgtgctggc attcggcttt 300 gcactgctgg acggagctag gggcgggccc cctgaggcat tcaccacaag cgtgcgctcc 360 tacctgccaa atacagtcac tgataccctg cgaggctccg gagcatgggg actgctgctg 420 cgacgggtgg gggacgatgt gctggtccac ctgctggcta gatgcgcact gtatgtgctg 480 gtcgctccct cttgcgcata ccaggtgtgc ggaccacccc tgtatgacct gggcgctgca 540 acccaggcaa gacctccacc ccacgcctct ggcactagaa ggggactggg caccgaacag 600 gcatggaacc atagtgtcag ggaggcagga gtgccactgg gactgccagc acctggggct 660 cgccgacgga gagggagtgc cggacggtca ctgccactgg ctaagagacc aaggcgcgga 720 gccgctccag aaccagagag gacacctgtg ggacagggaa gctgggcaca ccctggaaga 780 actagggggc caagtgatag gggcttctgc gtggtctcac cagcacgacc agcagaggaa 840 gctacttctc tggagggagc tctgagtggc acccggcact ctcatcctag tgtgggaaga 900 cagcaccatg caggccctcc aagcaccagc cggcctcccc ggccatggga cactccttgt 960 ccacccgtgt acgctgaaac caaacacttt ctgtatagct ccggagataa ggagcagctg 1020 cggccctctt tcctgctgtc tagtctgaga cctagtctga ccggagcacg acggctggtg 1080 gaaacaatct ttctggggtc ccgcccttgg atgccaggaa cccccagaag gacacctcga 1140 ctgccacagc ggtactggca gatgcggcca ctgttcctgg agctgctggg caatcacgct 1200 cagtgcccct atggggcact gctgcgaaca cattgtcctc tgcgggcagc cgtgactcca 1260 gctgcaggag tctgcgccag ggaaaagcca cagggcagcg tggcagctcc tgaggaagag 1320 gacaccgatc cacgccgact ggtgcagctg ctgagacagc actcaagccc ctggcaggtg 1380 tacggatttc tgagggcctg tctgcggaga ctggtgcctc caggactgtg ggggtccagg 1440 cacaacgaaa ggcgctttct gcgcaatact aagaaattca tcagcctggg caagcatgct 1500 aaactgtccc tgcaggagct gacctggaaa atgagtgtgc gcgactgcgc atggctgcga 1560 cggtcaccag gagtcgggtg cgtgcctgca gccgagcacc gcctgcgaga agagattctg 1620 gccaagtttc tgcattggct gatgtcagtg tacgtggtcg aactgctcg gagcttcttt 1680 tatgtgacag agactacctt ccagaaaaac tacctgttct tttatcgcaa gtcagtgtgg 1740 agcaaactgc agtcaatcgg cattcggcag cacctgaaga gagtgcagct gagggaactg 1800 agtgaagccg aggtccggca catagagag ccaaggcctg ccctgctgac ctcccggctg 1860 agattcctgc ctaagccaga cgggctgaga ccaatcgtga acatggatta cgtggtcgga 1920 gcacggacct tccggaggga aaaacgcgct gagcgactga catcccgcgt gaagactctg 1980 ttctctgtcc tgaattatga gcgagctcgc cgacccggac tgctgggagc atctgtgctg 2040 ggactggacg atattcaccg ggcttggaga gcatttgtcc tgagggtgcg cgcacaggac 2100 cctcccccag aactgtactt cgtgaaagtc gccgtgaccg gggcttatga cacaatccct 2160 caggatcggc tgactgaagt gatcgcctcc atcattaagc cacagaatac ctactgcgtg 2220 cggagatatg ctgtggtcag gcgcgctgca cacggccatg tgaggaagag cttcaagcgc 2280 cacgtcagca cactgactga tctgcagccc tacatgagac agttcgtggc tcatctgcag 2340 gagaccagcc ctctgaggga cgcagtggtc atcgaacagt cctctagtct gaacgaggca 2400 tcaagcgggc tgttcgatgt ctttctgcgg ttcgtgtgcc accatgccgt cagaattgga 2460 ggcaaatctt acgtgcagtg tcagggcatc ccccagggca gcattctgtc taccctgctg 2520 tgcagcctgt gctatggcga catggaaaat aagctgtttg ccggaatccg acgggatggc 2580 ctgctgctga gactggtggc cgcttttctg ctggtcactc cacacctgac ccatgccaaa 2640 gctttcctgc gcacactggt ccgaggggtg ccagagtacg gatgcgtggt caacctgagg 2700 aagaccgtgg tcaatttccc agtggaagac gaggccctgg gcggcacagc atttgtccag 2760 ctgccagcac acggactgtt cccatggtgt ggactgctgc tggacacccg cacactggag 2820 gtgcagtccg attactcctc ttatgcccgg acaagcatca gagcttccct gacttttaac agaggcttca aggccgggag gaatatgaga aggaaactgt ttggcgtgct gcgcctgaag tgccattccc tgttcctgta tctgcaggtg aactctctgc agactgtctg taccaacgtg tacaaaattt ttctgctgca ggcctatcgg ttccacgctt gcgtgctgca gctgccattc 3060 catcagcagg tcaggaga ccccaccttc tttctgcgcg tgatctctga tacagctagt ctgtgctact caattctga ggccaaaaat gctggcatga gcctgggagc aaaaggagca gcaggaccat ttccttccga ggctgcacag tggctgtgcc accaggcatt cctgctgaag ctgcccgac atcgggtgac fatherggtgc ctgctgggcg cactgcgac agcacagact 3360. cagctgtgca gaaagctgcc cggggccact ctggctgccc tggaagccgc tgccgaccct 3393. gccctgacct ccgatttcaa gactattctg gac <210> 48 <211> 1131 <212> PRT <213> Artificial Sequence <220> <223> Equivalent of hTERT sludge (pgx1434) <400> 48 Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser Arg 1 5 10 15 Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly Pro 20 25 30 Gln Gly Arg Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg Ala 35 40 45 Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro Pro 50 55 60 Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu Val 65 70 75 80 Ala Arg Val Val Gln Arg Leu Cys Glu Arg Gly Ala Arg Asn Val Leu 85 90 95 Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro Glu 100 105 110 Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr Asp 115 120 125 Thr Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val Gly 130 135 140 Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Tyr Val Leu 145 150 155 160 Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr Asp 165 170 175 Leu Gly Ala Ala Thr Gln Ala Arg Pro Pro Pro His Ala Ser Gly Thr 180 185 190 Arg Arg Gly Leu Gly Thr Glu Gln Ala Trp Asn His Ser Val Arg Glu 195 200 205 Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg Arg Arg 210 215 220 Gly Ser Ala Gly Arg Ser Leu Pro Leu Ala Lys Arg Pro Arg Arg Gly 225 230 235 240 Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser Trp Ala 245 250 255 His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys Val Val 260 265 270 Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly Ala Leu 275 280 285 Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His His Ala 290 295 300 Gly Pro Pro Ser Thr Ser Arg Pro Pro Arg Pro Trp Asp Thr Pro Cys 305 310 315 320 Pro Pro Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Ser Ser Gly Asp 325 330 335 Lys Glu Gln Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg Pro Ser 340 345 350 Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly Ser Arg 355 360 365 Pro Trp Met Pro Gly Thr Pro Arg Arg Thr Pro Arg Leu Pro Gln Arg 370 375 380 Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His Ala 385 390 395 400 Gln Cys Pro Tyr Gly Ala Leu Leu Arg Thr His Cys Pro Leu Arg Ala 405 410 415 Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln Gly 420 425 430 Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg Leu Val 435 440 445 Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe Leu 450 455 460 Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser Arg 465 470 475 480 His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser Leu 485 490 495 Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met Ser 500 505 510 Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly Cys Val 515 520 525 Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe Leu 530 535 540 His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe Phe 545 550 555 560 Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Tyr Leu Phe Phe Tyr Arg 565 570 575 Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His Leu 580 585 590 Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Gln His 595 600 605 Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Leu Pro 610 615 620 Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val Gly 625 630 635 640 Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr Ser Arg 645 650 655 Val Lys Thr Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg Arg Pro 660 665 670 Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His Arg Ala 675 680 685 Trp Arg Ala Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro Pro Glu 690 695 700 Leu Tyr Phe Val Lys Val Ala Val Thr Gly Ala Tyr Asp Thr Ile Pro 705 710 715 720 Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro Gln Asn 725 730 735 Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Arg Arg Ala Ala His Gly 740 745 750 His Val Arg Lys Ser Phe Lys Arg His Val Ser Thr Leu Thr Asp Leu 755 760 765 Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr Ser Pro 770 775 780 Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn Glu Ala 785 790 795 800 Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Val Cys His His Ala 805 810 815 Val Arg Ile Gly Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile Pro Gln 820 825 830 Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly Asp Met 835 840 845 Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp Gly Leu Leu Leu Arg 850 855 860 Leu Val Ala Ala Phe Leu Leu Val Thr Pro His Leu Thr His Ala Lys 865 870 875 880 Ala Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly Cys Val 885 890 895 Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp Glu Ala 900 905 910 Leu Gly Gly Thr Ala Phe Val Gln Leu Pro Ala His Gly Leu Phe Pro 915 920 925 Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln Ser Asp 930 935 940 Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr Phe Asn 945 950 955 960 Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe Gly Val 965 970 975 Leu Arg Leu Lys Cys His Ser Leu Phe Leu Tyr Leu Gln Val Asn Ser 980 985 990 Leu Gln Thr Val Cys Thr Asn Val Tyr Lys Ile Phe Leu Leu Gln Ala 995 1000 1005 Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe His Gln Gln 1010 1015 1020 Val Arg Lys Asn Pro Thr Phe Phe Leu Arg Val Ile Ser Asp Thr 1025 1030 1035 Ala Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala Gly Met 1040 1045 1050 Ser Leu Gly Ala Lys Gly Ala Ala Gly Pro Phe Pro Ser Glu Ala 1055 1060 1065 Ala Gln Trp Leu Cys His Gln Ala Phe Leu Leu Lys Leu Ala Arg 1070 1075 1080 His Arg Val Thr Tyr Arg Cys Leu Leu Gly Ala Leu Arg Thr Ala 1085 1090 1095 Gln Thr Gln Leu Cys Arg Lys Leu Pro Gly Ala Thr Leu Ala Ala 1100 1105 1110 Leu Glu Ala Ala Ala Asp Pro Ala Leu Thr Ser Asp Phe Lys Thr 1115 1120 1125 Ile Leu Asp 1130 <210> 49 <211> 3417 <212> DNA <213> Artificial Sequence <220> <223> Synthetic consensus mTERT nucleic acid sequence (pgx1418) effectively linked to IgE <400> 49 atggactgga catggattct gtttctcgtc gccgccgcta caagagtgca ttccccaaga 60 gcccccaggt gccctgctgt gaggtcactg ctccgaagca ggtacagaga agtgtggccc 120 ctggccacat tcgtcaggag actgggacct gaagggcggc gcctggtgca gccaggtgac 180 cccaaggtgt ttagaactct ggtcgctcag tgcctggtgt gcgtgccatg ggggtctcag 240 ccccctccag cagatctgag tttccaccag gtgagctccc tgaaggagct cgtcgcccga 300 gtggtccaga ggctgtgcga gagaggcgaa cggaacgtgc tggctttcgg ttttgcactg 360 ctcaatggag cccgcggcgg accccctatg gctttcacca catctgtgag gagttacctg 420 cccaactctg tgaccgagag tctgagagtc tcaggagctt ggatgctgct cctgagccgg 480 gtgggggacg atctcctggt ctacctcctg gctcattgcg cactgtatct cctggtgcca 540 ccctcatgcg cctaccaggt ctgtggaagc ccactgtatc agatctgtgc cactaccgac 600 acctggccaa gcgtgagcgc cagctaccga cctacccgac cagtcggacg gaacttcaca 660 aatctggggt ccctccacca gattaagaat tctagtcatc aggaggcccc taaaccactc 720 gctctgccct ccagagggac aaagcggcac ctctctctga cctccacatc tgtgcctagt 780 gccaagaaag ctcgatgcta tcccgcccct agggtcgaaa agggtcctca tcgccaggtg 840 gtcccaacac cctctggcaa aacttgggtg cctagcccag caaggtcccc agaggtccct 900 actgccgaaa aggacctgtc aagcaagggt aaagctagcg atctcagtct gtcaggcagc 960 gtgtgctgta agcacaaacc atcctctacc tcactcctga gccctccaag gcagaacgcc 1020 ttccagctga gaccctttac tgagacccgg catttcctgt acagccgcgg gggtggccag 1080 gaacgactga atccttcctt tctctgaac aatctgcagc catctctcac cggcgctcga 1140 aggctggtgg agatcattt cctcggttcc cggccacgca catctggacc tctgtgcaga 1200 actagacggc tctcccgccg atactggcag atgcggccac tgttccagca gctcctggtg 1260 aaccacgccg aatgccagta tgtcaggctc ctgagatctc attgtaggtt caggactgca 1320 aaccagcagg tgaccgacgc cctgaataca agccctcccc acctgatgga tctcctgcgc 1380 ctccatagtt caccatggca ggtgtacgga ttcctgcgag cttgcctgcg aaagctcgtc 1440 ccagcaggtc tgtggggcac aaggcacaac gagaggagat tctttaaaaa cgtgaagaag 1500 ttcatctcac tgggaaagta tgggaaactc agcctgcagg agctgatgtg gaagatgaaa 1560 gtggaagact gtcactggct gaggagctcc ccaggcaagg atagagtgcc cgccgctgag 1620 catagactgc gggaacgcat cctcgccatg ttcctgtttt ggctcatgga cacatacgtg 1680 gtccagctcc tgcgcagctt cttttatatt actgagacaa cttccagaa gaacaggctg 1740 ttctttaca gaaagtccgt gtggtctaaa ctgcagtcta tcggggtgag acagcacctg 1800 gagcgagtca ggctgagaga actcagtcag gaggaagtgc ggcaccatca ggatacatgg 1860 ctggccatgc ctatctgccg gctgcgcttc attcccaagc ctaacggcct gaggccaatt 1920 gtgaatatgt cctattctat gggaactcgg gcttttggga agcgcaaaca ggcacagcac 1980 ttcactcagc gcctgaagac cctctttagc gtgctgaact acgagaggac taaacatccc 2040 aatctgatgg gtgcttccgt gctcggcatg aacgacatct atcgaacctg gcgagccttc 2100 gtgctgcgag tcagggctct cgaccagacc cctagaatgt actttgtgaa ggccgatgtc 2160 acaggagcat atgacgccat tccacaggat aaactggtgg aggtggtcgc tatatgatc 2220 cggcacagtg aatcaaccta ctgtattcgg cagtatgcag tggtccagcg agacagccag 2280 ggacaggtgc ataagtcctt ccggcgccag gtcagtacac tgtcagatct ccagccctac 2340 atgggacagt ttctgaaaca cctccaggac agcgatgcct ccgctctgag aaacagcgtg 2400 gtcatcgagc agagcatttc catgaatgaa tctagttcaa gcctgttcga cttctttctc 2460 cactttgtgc gccattccgt ggtcaagatc ggagggcgat gctatgtcca gtgtcagggt 2520 attcctcagg gctcctctct gagtaccctc ctgtgctcac tgtgcttcgg agacatggag 2580 aacaagctgt ttgctgaagt gcagcaggat gggctcctgc tccggttcgt ggcagccttt 2640 ctgctcgtca ctccccacct ggatcaggca aaggccttcc tgtccaccct cgtgcatgga 2700 gtccctgagt acgggtgcat gatcaacctg cagaaaactg tggtcaattt tccagtggaa 2760 ccaggcaccc tgggtggcgc tgcacctcac cagctgccag cccattgcct cttcccttgg 2820 tgtggtctgc tcctggacac acagactctg gaggtgtttt gtgattactc cggctatgcc 2880 aggacctcta tcaagactag tctgaccttc cagagcgtgt tcaaggctgg aaaaacaatg 2940 cgatacaagc tcctgtcagt gctcaggctg aaatgccacg ggctcttcct ggacctccag 3000 gtgaactctc tgcagaccgt ctgtatcaat atctacaaga tcttcctcct gcaggcatat 3060 agatttcacg cctgcgtgat tcagctgcct ttcgatcagc atgtccggaa aaacctggcc 3120 ttctttctcg gaatcatttc aaatcaggct agctgctgtt atgcaatcct gaaggtgaaa 3180 aacccaggaa tgacactgaa ggcaaaaggg tccttcccac ccgaggccgc tagatggctg 3240 tgctaccagg cctttctcct gaagctggca gcccactctg tgacatataa atgcctcctg 3300 ggccctctga gaactgcaca gaagcagctg tgccggaaac tcccagaagc caccatgaca 3360 atcctgaaga ccgctgcaga ccccgctctc tccactgatt tccagaccat tctcgac 3417 <210> 50 <211> 1139 <212> PRT <213> Artificial Sequence <220> <223> Synthetic consensus mTERT amino acid sequence operatively linked to IgE (pgx1418) <400> 50 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Pro Arg Ala Pro Arg Cys Pro Ala Val Arg Ser Leu Leu Arg 20 25 30 Ser Arg Tyr Arg Glu Val Trp Pro Leu Ala Thr Phe Val Arg Arg Leu 35 40 45 Gly Pro Glu Gly Arg Arg Leu Val Gln Pro Gly Asp Pro Lys Val Phe 50 55 60 Arg Thr Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Gly Ser Gln 65 70 75 80 Pro Pro Pro Ala Asp Leu Ser Phe His Gln Val Ser Ser Leu Lys Glu 85 90 95 Leu Val Ala Arg Val Val Gln Arg Leu Cys Glu Arg Gly Glu Arg Asn 100 105 110 Val Leu Ala Phe Gly Phe Ala Leu Leu Asn Gly Ala Arg Gly Gly Pro 115 120 125 Pro Met Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Ser Val 130 135 140 Thr Glu Ser Leu Arg Val Ser Gly Ala Trp Met Leu Leu Leu Ser Arg 145 150 155 160 Val Gly Asp Asp Leu Leu Val Tyr Leu Leu Ala His Cys Ala Leu Tyr 165 170 175 Leu Leu Val Pro Pro Ser Cys Ala Tyr Gln Val Cys Gly Ser Pro Leu 180 185 190 Tyr Gln Ile Cys Ala Thr Thr Asp Thr Trp Pro Ser Val Ser Ala Ser 195 200 205 Tyr Arg Pro Thr Arg Pro Val Gly Arg Asn Phe Thr Asn Leu Gly Ser 210 215 220 Leu His Gln Ile Lys Asn Ser Ser His Gln Glu Ala Pro Lys Pro Leu 225 230 235 240 Ala Leu Pro Ser Arg Gly Thr Lys Arg His Leu Ser Leu Thr Ser Thr 245 250 255 Ser Val Pro Ser Ala Lys Lys Ala Arg Cys Tyr Pro Ala Pro Arg Val 260 265 270 Glu Lys Gly Pro His Arg Gln Val Val Pro Thr Pro Ser Gly Lys Thr 275 280 285 Trp Val Pro Ser Pro Ala Arg Ser Pro Glu Val Pro Thr Ala Glu Lys 290 295 300 Asp Leu Ser Ser Lys Gly Lys Ala Ser Asp Leu Ser Leu Ser Gly Ser 305 310 315 320 Val Cys Cys Lys His Lys Pro Ser Ser Thr Ser Leu Leu Ser Pro Pro 325 330 335 Arg Gln Asn Ala Phe Gln Leu Arg Pro Phe Thr Glu Thr Arg His Phe 340 345 350 Leu Tyr Ser Arg Gly Gly Gly Gln Glu Arg Leu Asn Pro Ser Phe Leu 355 360 365 Leu Asn Asn Leu Gln Pro Ser Leu Thr Gly Ala Arg Arg Leu Val Glu 370 375 380 Ile Ile Phe Leu Gly Ser Arg Pro Arg Thr Ser Gly Pro Leu Cys Arg 385 390 395 400 Thr Arg Arg Leu Ser Arg Arg Tyr Trp Gln Met Arg Pro Leu Phe Gln 405 410 415 Gln Leu Leu Val Asn His Ala Glu Cys Gln Tyr Val Arg Leu Leu Arg 420 425 430 Ser His Cys Arg Phe Arg Thr Ala Asn Gln Gln Val Thr Asp Ala Leu 435 440 445 Asn Thr Ser Pro Pro His Leu Met Asp Leu Leu Arg Leu His Ser Ser 450 455 460 Pro Trp Gln Val Tyr Gly Phe Leu Arg Ala Cys Leu Arg Lys Leu Val 465 470 475 480 Pro Ala Gly Leu Trp Gly Thr Arg His Asn Glu Arg Arg Phe Phe Lys 485 490 495 Asn Val Lys Lys Phe Ile Ser Leu Gly Lys Tyr Gly Lys Leu Ser Leu 500 505 510 Gln Glu Leu Met Trp Lys Met Lys Val Glu Asp Cys His Trp Leu Arg 515 520 525 Ser Ser Pro Gly Lys Asp Arg Val Pro Ala Ala Glu His Arg Leu Arg 530 535 540 Glu Arg Ile Leu Ala Met Phe Leu Phe Trp Leu Met Asp Thr Tyr Val 545 550 555 560 Val Gln Leu Leu Arg Ser Phe Phe Tyr Ile Thr Glu Thr Thr Phe Gln 565 570 575 Lys Asn Arg Leu Phe Phe Tyr Arg Lys Ser Val Trp Ser Lys Leu Gln 580 585 590 Ser Ile Gly Val Arg Gln His Leu Glu Arg Val Arg Leu Arg Glu Leu 595 600 605 Ser Gln Glu Glu Val Arg His His Gln Asp Thr Trp Leu Ala Met Pro 610 615 620 Ile Cys Arg Leu Arg Phe Ile Pro Lys Pro Asn Gly Leu Arg Pro Ile 625 630 635 640 Val Asn Met Ser Tyr Ser Met Gly Thr Arg Ala Phe Gly Lys Arg Lys 645 650 655 Gln Ala Gln His Phe Thr Gln Arg Leu Lys Thr Leu Phe Ser Val Leu 660 665 670 Asn Tyr Glu Arg Thr Lys His Pro Asn Leu Met Gly Ala Ser Val Leu 675 680 685 Gly Met Asn Asp Ile Tyr Arg Thr Trp Arg Ala Phe Val Leu Arg Val 690 695 700 Arg Ala Leu Asp Gln Thr Pro Arg Met Tyr Phe Val Lys Ala Asp Val 705 710 715 720 Thr Gly Ala Tyr Asp Ala Ile Pro Gln Asp Lys Leu Val Glu Val Val 725 730 735 Ala Asn Met Ile Arg His Ser Glu Ser Thr Tyr Cys Ile Arg Gln Tyr 740 745 750 Ala Val Val Gln Arg Asp Ser Gln Gly Gln Val His Lys Ser Phe Arg 755 760 765 Arg Gln Val Ser Thr Leu Ser Asp Leu Gln Pro Tyr Met Gly Gln Phe 770 775 780 Leu Lys His Leu Gln Asp Ser Asp Ala Ser Ala Leu Arg Asn Ser Val 785 790 795 800 Val Ile Glu Gln Ser Ile Ser Met Asn Glu Ser Ser Ser Ser Leu Phe 805 810 815 Asp Phe Phe Leu His Phe Val Arg His Ser Val Val Lys Ile Gly Gly 820 825 830 Arg Cys Tyr Val Gln Cys Gln Gly Ile Pro Gln Gly Ser Ser Leu Ser 835 840 845 Thr Leu Leu Cys Ser Leu Cys Phe Gly Asp Met Glu Asn Lys Leu Phe 850 855 860 Ala Glu Val Gln Gln Asp Gly Leu Leu Leu Arg Phe Val Ala Ala Phe 865 870 875 880 Leu Leu Val Thr Pro His Leu Asp Gln Ala Lys Ala Phe Leu Ser Thr 885 890 895 Leu Val His Gly Val Pro Glu Tyr Gly Cys Met Ile Asn Leu Gln Lys 900 905 910 Thr Val Val Asn Phe Pro Val Glu Pro Gly Thr Leu Gly Gly Ala Ala 915 920 925 Pro His Gln Leu Pro Ala His Cys Leu Phe Pro Trp Cys Gly Leu Leu 930 935 940 Leu Asp Thr Gln Thr Leu Glu Val Phe Cys Asp Tyr Ser Gly Tyr Ala 945 950 955 960 Arg Thr Ser Ile Lys Thr Ser Leu Thr Phe Gln Ser Val Phe Lys Ala 965 970 975 Gly Lys Thr Met Arg Tyr Lys Leu Leu Ser Val Leu Arg Leu Lys Cys 980 985 990 His Gly Leu Phe Leu Asp Leu Gln Val Asn Ser Leu Gln Thr Val Cys 995 1000 1005 Ile Asn Ile Tyr Lys Ile Phe Leu Leu Gln Ala Tyr Arg Phe His 1010 1015 1020 Ala Cys Val Ile Gln Leu Pro Phe Asp Gln His Val Arg Lys Asn 1025 1030 1035 Leu Ala Phe Phe Leu Gly Ile Ile Ser Asn Gln Ala Ser Cys Cys 1040 1045 1050 Tyr Ala Ile Leu Lys Val Lys Asn Pro Gly Met Thr Leu Lys Ala 1055 1060 1065 Lys Gly Ser Phe Pro Pro Glu Ala Ala Arg Trp Leu Cys Tyr Gln 1070 1075 1080 Ala Phe Leu Leu Lys Leu Ala Ala His Ser Val Thr Tyr Lys Cys 1085 1090 1095 Leu Leu Gly Pro Leu Arg Thr Ala Gln Lys Gln Leu Cys Arg Lys 1100 1105 1110 Leu Pro Glu Ala Thr Met Thr Ile Leu Lys Thr Ala Ala Asp Pro 1115 1120 1125 Ala Leu Ser Thr Asp Phe Gln Thr Ile Leu Asp 1130 1135 <210> 51 <211> 3363 <212> Ms <213> Artificial Sequence <220> <223> Synthesis of TERT nucleic acid sequence (pgx1418) <400> 51 ccaagagcc ccaggtgcc tgctgtgagg tcactgctcc gaagcaggta cagagaagtg 60 tggcccctgg ccacattcgt caggagactg ggacctgaag ggcggcgcct ggtgcagcca 120 ggtgacccca aggtgtttag aactctggtc gctcagtgcc tggtgtgcgt gccatgggg 180 tctcagcccc ctccagcaga tctgagtttc caccaggtga gctccctgaa ggagctcgtc 240 gcccgagtgg tccagaggct gtgcgagaga ggcgaacgga acgtgctggc tttcggtttt 300 gcactgctca atggagcccg cggcggaccc cctatggctt tcaccacatc tgtgaggagt 360 tacctgccca actctgtgac cgagagtctg agagtctcag gagcttggat gctgctcctg 420 agccgggtgg gggacgatct cctggtctac ctcctggctc attgcgcact gtatctcctg 480 gtgccaccct catgcgccta ccaggtctgt ggaagcccac tgtatcagat ctgtgccact 540 accgacacct ggccaagcgt gagcgccagc taccgaccta cccgaccagt cggacggaac 600 ttcacaaatc tggggtccct ccaccagatt aagaattcta gtcatcagga ggcccctaaa 660 ccactcgctc tgccctccag agggacaaag cggcacctct ctctgacctc cacatctgtg 720 cctagtgcca agaaagctcg atgctatccc gcccctaggg tcgaaaaggg tcctcatcgc 780 caggtggtcc caacaccctc tggcaaaact tgggtgccta gcccagcaag gtccccagag 840 gtccctactg ccgaaaagga cctgtcaagc aagggtaaag ctagcgatct cagtctgtca 900 ggcagcgtgt gctgtaagca caaaccatcc tctacctcac tcctgagccc tccaaggcag 960 aacgccttcc agctgagacc ctttactgag acccggcatt tcctgtacag ccgcgggggt 1020 ggccaggaac gactgaatcc ttcctttctc ctgaacaatc tgcagccatc tctcaccggc 1080 gctcgaaggc tggtggagat catttcctc ggttcccggc cacgcacatc tggacctctg 1140 tgcagaacta gacggctctc ccgccgatac tggcagatgc ggccactgtt ccagcagctc 1200 ctggtgaacc acgccgaatg ccagtatgtc aggctcctga gatctcattg taggttcagg 1260 actgcaaacc agcaggtgac cgacgccctg aatacaagcc ctccccacct gatggatctc 1320 ctgcgctcc atagttcacc atggcaggtg tacggattcc tgcgagcttg cctgcgaaag 1380 ctcgtcccag caggtctgtg gggcacaagg cacaacgaga ggagattctt taaaaacgtg 1440 aagaagttca tctcactggg aaagtatggg aaactcagcc tgcaggagct gatgtggaag 1500 atgaaagtgg aagactgtca ctggctgagg agctccccag gcaaggatag agtgcccgcc 1560 gctgagcata gactgcgggga acgcatcctc gccatgttcc tgttttggct catggacaca 1620 tacgtggtcc agctcctgcg cagcttcttt tatattactg agacaacttt ccagaagaac 1680 aggctgttct tttacagaaa gtccgtgtgg tctaaactgc agtctatcgg ggtgagacag 1740 cacctggagc gagtcaggct gagagaactc agtcaggagg aagtgcggca ccatcaggat 1800 acatggctgg ccatgcctat ctgccggctg cgcttcattc ccaagcctaa cggcctgagg 1860 ccaattgtga atatgccta ttctatggga actcgggctt ttgggaagcg caaacaggca 1920 cagcacttca ctcagcgcct gaagaccctc tttagcgtgc tgaactacga gaggactaaa 1980 catcccaatc tgatgggtgc ttccgtgctc ggcatgaacg acatctatcg aacctggcga 2040 gccttcgtgc tgcgagtcag ggctctcgac cagaccccta gaatgtactt tgtgaaggcc 2100 gatgtcacag gagcatatga cgccattcca caggataaac tggtggaggt ggtcgctaat 2160 atgatccggc acagtgaatc aacctactgt attcggcagt atgcagtggt ccagcgagac 2220 agccagggac aggtgcataa gtccttccgg cgccaggtca gtacactgtc agatctccag 2280 ccctacatgg gacagtttct gaaacacctc caggacagcg atgcctccgc tctgagaaac 2340 agcgtggtca tcgagcagag catttccatg aatgaatcta gttcaagcct gttcgacttc 2400 tttctccact ttgtgcgcca ttccgtggtc aagatcggag ggcgatgcta tgtccagtgt 2460 cagggtattc ctcagggctc ctctctgagt accctcctgt gctcactgtg cttcggagac 2520 atggagaaca agctgtttgc tgaagtgcag caggatgggc tcctgctccg gttcgtggca 2580 gcctttctgc tcgtcactcc ccacctggat caggcaaagg ccttcctgtc caccctcgtg 2640 catggagtcc ctgagtacgg gtgcatgatc aacctgcaga aaactgtggt caattttcca 2700 gtggaaccag gcaccctggg tggcgctgca cctcaccagc tgccagccca ttgcctcttc 2760 ccttggtgtg gtctgctcct ggacacacag actctggagg tgttttgtga ttactccggc 2820 tatgccagga cctctatcaa gactagtctg accttccaga gcgtgttcaa ggctggaaaa 2880 acaatgcgat acaagctcct gtcagtgctc aggctgaaat gccacgggct cttcctggac 2940 ctccaggtga actctctgca gaccgtctgt atcaatatct acaagatctt cctcctgcag 3000 gcatatagat ttcacgcctg cgtgattcag ctgcctttcg atcagcatgt ccggaaaaac 3060 ctggccttct ttctcggaat catttcaaat caggctagct gctgttatgc aatcctgaag 3120 gtgaaaaacc caggaatgac actgaaggca aaagggtcct tcccacccga ggccgctaga 3180 tggctgtgct accaggcctt tctcctgaag ctggcagccc actctgtgac atataaatgc 3240 ctcctgggcc ctctgagaac tgcacagaag cagctgtgcc ggaaactccc agaagccacc 3300 atgacaatcc tgaagaccgc tgcagacccc gctctctcca ctgatttcca gaccattctc 3360 gac 3363 <210> 52 <211> 1121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic consensus mTERT amino acid sequence (pgx1418) <400> 52 Pro Arg Ala Pro Arg Cys Pro Ala Val Arg Ser Leu Leu Arg Ser Arg 1 5 10 15 Tyr Arg Glu Val Trp Pro Leu Ala Thr Phe Val Arg Arg Leu Gly Pro 20 25 30 Glu Gly Arg Arg Leu Val Gln Pro Gly Asp Pro Lys Val Phe Arg Thr 35 40 45 Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Gly Ser Gln Pro Pro 50 55 60 Pro Ala Asp Leu Ser Phe His Gln Val Ser Ser Leu Lys Glu Leu Val 65 70 75 80 Ala Arg Val Val Gln Arg Leu Cys Glu Arg Gly Glu Arg Asn Val Leu 85 90 95 Ala Phe Gly Phe Ala Leu Leu Asn Gly Ala Arg Gly Gly Pro Pro Met 100 105 110 Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Ser Val Thr Glu 115 120 125 Ser Leu Arg Val Ser Gly Ala Trp Met Leu Leu Leu Ser Arg Val Gly 130 135 140 Asp Asp Leu Leu Val Tyr Leu Leu Ala His Cys Ala Leu Tyr Leu Leu 145 150 155 160 Val Pro Pro Ser Cys Ala Tyr Gln Val Cys Gly Ser Pro Leu Tyr Gln 165 170 175 Ile Cys Ala Thr Thr Asp Thr Trp Pro Ser Val Ser Ala Ser Tyr Arg 180 185 190 Pro Thr Arg Pro Val Gly Arg Asn Phe Thr Asn Leu Gly Ser Leu His 195 200 205 Gln Ile Lys Asn Ser Ser His Gln Glu Ala Pro Lys Pro Leu Ala Leu 210 215 220 Pro Ser Arg Gly Thr Lys Arg His Leu Ser Leu Thr Ser Thr Ser Val 225 230 235 240 Pro Ser Ala Lys Lys Ala Arg Cys Tyr Pro Ala Pro Arg Val Glu Lys 245 250 255 Gly Pro His Arg Gln Val Val Pro Thr Pro Ser Gly Lys Thr Trp Val 260 265 270 Pro Ser Pro Ala Arg Ser Pro Glu Val Pro Thr Ala Glu Lys Asp Leu 275 280 285 Ser Ser Lys Gly Lys Ala Ser Asp Leu Ser Leu Ser Gly Ser Val Cys 290 295 300 Cys Lys His Lys Pro Ser Ser Thr Ser Leu Leu Ser Pro Pro Arg Gln 305 310 315 320 Asn Ala Phe Gln Leu Arg Pro Phe Thr Glu Thr Arg His Phe Leu Tyr 325 330 335 Ser Arg Gly Gly Gly Gln Glu Arg Leu Asn Pro Ser Phe Leu Leu Asn 340 345 350 Asn Leu Gln Pro Ser Leu Thr Gly Ala Arg Arg Leu Val Glu Ile Ile 355 360 365 Phe Leu Gly Ser Arg Pro Arg Thr Ser Gly Pro Leu Cys Arg Thr Arg 370 375 380 Arg Leu Ser Arg Arg Tyr Trp Gln Met Arg Pro Leu Phe Gln Gln Leu 385 390 395 400 Leu Val Asn His Ala Glu Cys Gln Tyr Val Arg Leu Leu Arg Ser His 405 410 415 Cys Arg Phe Arg Thr Ala Asn Gln Gln Val Thr Asp Ala Leu Asn Thr 420 425 430 Ser Pro Pro His Leu Met Asp Leu Leu Arg Leu His Ser Ser Pro Trp 435 440 445 Gln Val Tyr Gly Phe Leu Arg Ala Cys Leu Arg Lys Leu Val Pro Ala 450 455 460 Gly Leu Trp Gly Thr Arg His Asn Glu Arg Arg Phe Phe Lys Asn Val 465 470 475 480 Lys Lys Phe Ile Ser Leu Gly Lys Tyr Gly Lys Leu Ser Leu Gln Glu 485 490 495 Leu Met Trp Lys Met Lys Val Glu Asp Cys His Trp Leu Arg Ser Ser 500 505 510 Pro Gly Lys Asp Arg Val Pro Ala Ala Glu His Arg Leu Arg Glu Arg 515 520 525 Ile Leu Ala Met Phe Leu Phe Trp Leu Met Asp Thr Tyr Val Val Gln 530 535 540 Leu Leu Arg Ser Phe Phe Tyr Ile Thr Glu Thr Thr Phe Gln Lys Asn 545 550 555 560 Arg Leu Phe Phe Tyr Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile 565 570 575 Gly Val Arg Gln His Leu Glu Arg Val Arg Leu Arg Glu Leu Ser Gln 580 585 590 Glu Glu Val Arg His His Gln Asp Thr Trp Leu Ala Met Pro Ile Cys 595 600 605 Arg Leu Arg Phe Ile Pro Lys Pro Asn Gly Leu Arg Pro Ile Val Asn 610 615 620 Met Ser Tyr Ser Met Gly Thr Arg Ala Phe Gly Lys Arg Lys Gln Ala 625 630 635 640 Gln His Phe Thr Gln Arg Leu Lys Thr Leu Phe Ser Val Leu Asn Tyr 645 650 655 Glu Arg Thr Lys His Pro Asn Leu Met Gly Ala Ser Val Leu Gly Met 660 665 670 Asn Asp Ile Tyr Arg Thr Trp Arg Ala Phe Val Leu Arg Val Arg Ala 675 680 685 Leu Asp Gln Thr Pro Arg Met Tyr Phe Val Lys Ala Asp Val Thr Gly 690 695 700 Ala Tyr Asp Ala Ile Pro Gln Asp Lys Leu Val Glu Val Val Ala Asn 705 710 715 720 Met Ile Arg His Ser Glu Ser Thr Tyr Cys Ile Arg Gln Tyr Ala Val 725 730 735 Val Gln Arg Asp Ser Gln Gly Gln Val His Lys Ser Phe Arg Arg Gln 740 745 750 Val Ser Thr Leu Ser Asp Leu Gln Pro Tyr Met Gly Gln Phe Leu Lys 755 760 765 His Leu Gln Asp Ser Asp Ala Ser Ala Leu Arg Asn Ser Val Val Ile 770 775 780 Glu Gln Ser Ile Ser Met Asn Glu Ser Ser Ser Ser Leu Phe Asp Phe 785 790 795 800 Phe Leu His Phe Val Arg His Ser Val Val Lys Ile Gly Gly Arg Cys 805 810 815 Tyr Val Gln Cys Gln Gly Ile Pro Gln Gly Ser Ser Leu Ser Thr Leu 820 825 830 Leu Cys Ser Leu Cys Phe Gly Asp Met Glu Asn Lys Leu Phe Ala Glu 835 840 845 Val Gln Gln Asp Gly Leu Leu Leu Arg Phe Val Ala Ala Phe Leu Leu 850 855 860 Val Thr Pro His Leu Asp Gln Ala Lys Ala Phe Leu Ser Thr Leu Val 865 870 875 880 His Gly Val Pro Glu Tyr Gly Cys Met Ile Asn Leu Gln Lys Thr Val 885 890 895 Val Asn Phe Pro Val Glu Pro Gly Thr Leu Gly Gly Ala Ala Pro His 900 905 910 Gln Leu Pro Ala His Cys Leu Phe Pro Trp Cys Gly Leu Leu Leu Asp 915 920 925 Thr Gln Thr Leu Glu Val Phe Cys Asp Tyr Ser Gly Tyr Ala Arg Thr 930 935 940 Ser Ile Lys Thr Ser Leu Thr Phe Gln Ser Val Phe Lys Ala Gly Lys 945 950 955 960 Thr Met Arg Tyr Lys Leu Leu Ser Val Leu Arg Leu Lys Cys His Gly 965 970 975 Leu Phe Leu Asp Leu Gln Val Asn Ser Leu Gln Thr Val Cys Ile Asn 980 985 990 Ile Tyr Lys Ile Phe Leu Leu Gln Ala Tyr Arg Phe His Ala Cys Val 995 1000 1005 Ile Gln Leu Pro Phe Asp Gln His Val Arg Lys Asn Leu Ala Phe 1010 1015 1020 Phe Leu Gly Ile Ile Ser Asn Gln Ala Ser Cys Cys Tyr Ala Ile 1025 1030 1035 Leu Lys Val Lys Asn Pro Gly Met Thr Leu Lys Ala Lys Gly Ser 1040 1045 1050 Phe Pro Pro Glu Ala Ala Arg Trp Leu Cys Tyr Gln Ala Phe Leu 1055 1060 1065 Leu Lys Leu Ala Ala His Ser Val Thr Tyr Lys Cys Leu Leu Gly 1070 1075 1080 Pro Leu Arg Thr Ala Gln Lys Gln Leu Cys Arg Lys Leu Pro Glu 1085 1090 1095 Ala Thr Met Thr Ile Leu Lys Thr Ala Ala Asp Pro Ala Leu Ser 1100 1105 1110 Thr Asp Phe Gln Thr Ile Leu Asp 1115 1120 <210> 53 <211> 3447 <212> DNA <213> Artificial Sequence <220> <223> Synthetic consensus rhTERT nucleic acid sequence (pGX1473) effectively linked to IgE <400> 53 atggactgga cctggattct gttcctcgtc gccgccgcaa ctagagtgca tagcccaaga 60 gccccacgct gtagagctgt gagagccctg ctgaggtcca gatacaggga ggtgctgcca 120 ctggccacct tcgtgaggag actgggacct gagggccggc gcctggtgca gaggggcgac 180 cccgcagcct tccgcgccct ggtggcccag tgcctggtgt gcgtgccatg ggacgccagg 240 ccccctccag cagcaccatc cttcagacag gtgagctgcc tgaaggagct ggtggccagg 300 gtggtgcaga gactgtgcga gaggggcgcc aggaacgtgc tggccttcgg cttcgcactg 360 ctggacggag ccaggggcgg gccccctgag gccttcacca cctccgtgag aagctacctg 420 cctaacaccg tgaccgacac cctgaggggc tccggagcat ggggcctgct gctgaggaga 480 gtgggggacg acgtgctggt gcacctgctg gcaaggtgcg ccctgtacgt gctggtggca 540 ccaagctgcg cataccaggt gtgcggccca cccctgtacg agctgtgcgc agcaacccag 600 gccagaccag cccctcacgc atccggaacc aggaggggac tgggctgcga gagggcctgg 660 aacggaagcg tgagagaggc aggagtgcca ctgggactgc ctgcaccagg ggccaggaga 720 cggcgcgggt ctgccggacg gtcccctcca ctggcaaagc gccctaggag aggagccgca 780 ccagagcctg agaggacccc agtggggcag ggaagctggg cacaccctgg aaggaccagg 840 gggccatccg acaggggatt ctgcgtggtg agcccagcca ggcccgcaga ggaggccacc 900 tctctggagg gagccctgtc cggaaccagg cactctcacc catccgtggg aagacagcac 960 cacgcaggcc ctcccagcac ctctaggcca ccctccccat gggacacccc atgcccactg 1020 gtgtacgcag agacaaagca cttcctgtac tgcagcggag acaaggagag actgcggcca 1080 tctttcctgc tgtccagcct gcgcccctcc ctgaccggag cacggcgcct ggtggagaca 1140 atcttcctgg gaagcaggcc ttggatgcca ggaaccccca ggaggcctcc caggctgcca 1200 cagaggtact ggcagatgcg ccctctgttc ctggagctgc tgggaaacca cgcaaggtgc 1260 ccatacggag ccctgctgcg gacccactgc cctctgaggg cagcagcaac cccagcagca 1320 ggcgtgtgcg ccagggagaa gccccagggg agcgtggccg cccctgagga ggaggacacc 1380 gacccacggc gcctggtgca gctgctgaga cagcactctt ccccctggca ggtgtacgga 1440 ttcctgaggg catgcctgag gagactggtg ccccctggcc tgtggggctc caggcacaac 1500 gagcggcgct tcctgcgcaa caccaagaag ttcatctctc tgggcaagca cgccaagctg 1560 tccctgcagg agctgacctg gaagatgtct gtgagggact gcgcctggct gaggagatcc 1620 cccggagtgg gatgcgtgcc tgcagcagag cacaggctga gggaggagat cctggccaag 1680 ttcctgcact ggctgatggg ggtgtacgtg gtggagctgc tgaggtcttt cttctacgtg 1740 accgagacaa ccttccagaa gaactacctg ttcttctacc gcaagagcgt gtggtctaag 1800 ctgcagtcta tcggaatcag gcagcacctg aagagggtgc agctgagaga gctgtccgag 1860 gccgaggtga gacagcacag ggaggcccgc cccgccctgc tgacctccag actgcggttc 1920 ctgcctaagc cagacggcct gaggcccatc gtgaacatgg actacgtggt gggagcacgg 1980 accttccgga gggagaagag ggccgagaga ctgaccagcc gcgtgaagac cctgttctct 2040 gtgctgaact acgagagggc aaggaggccc ggactgctgg gagccagcgt gctgggcctg 2100 gacgacatcc acagggcatg gagggccttc gtgctgcgcg tgagggcaca ggacccaccc 2160 cctgagctgt acttcgtgaa ggtggcagtg accggagcat acgacaccat cccacaggac 2220 aggctgaccg aggtcatcgc ctctatcatc aagcctcaga acacctactg cgtgcggcgc 2280 tacgcagtgg tgcagaaggc agcacacgga cacgtgagga agaccttcaa gaagcacgtg 2340 tccaccctga ccgacctgca gccctacatg agacagttcg tggcccacct gcaggagaca 2400 tcctccctga gggacgcagt ggtcatcgag cagtccagct ctctgaacga ggcctccagc 2460 ggcctgttcg acgtgttcct gaggttcgtg tgcaaccacg tggtgagaat cggaggcaag 2520 agctacgtgc agtgccaggg catcccccag ggctccatcc tgagcaccct gctgtgctct 2580 ctgtgctacg gggacatgga gaacaagctg ttcgccggaa tcaggagaga cggcctgctg 2640 ctgagactgg tggcagcctt cctgctggtg acccctcacc tgacccacgc aaaggccttc 2700 ctgcggaccc tggtgcgcgg ggtgccagag tacggatgcg tggtgaacct gcggaagacc 2760 gtggtgaact tcccagtgga ggacgaggcc ctgggcggcg ccgccttcgt gcagctgcca 2820 gcacacgggc tgttcccatg gtgcggactg ctgctggaca ccagaaccct ggaggtgcag 2880 tccgactact cttcctacgc caggaccagc atcagagcct ctctgacctt caacaggggc 2940 ttcaaggccg ggagaaacat gcggcgcaag ctgttcgggg tgctgaggct gaagtgccac 3000 agcctgttcc tgtacctgca ggtgaactct ctgcagaccg tgtgcactaa cgtgtacaag 3060 atcttcctgc tgcaggccta cagattccac gcctgcgtgc tgcagctgcc tttcaaccag 3120 caagtgtgga agaacccagc cttcttcctg agagtgatct ccgacaccgc cagcctgtgc 3180 tactctatcc tgaaggcaaa gaacgcagga atgagcctgg gagcaaaggg agcagcagga 3240 ccactgcctt ctgaggcagt gcagtggctg tgccaccagg ccttcctgct gaagctgacc 3300 agacaccggg tgacctacgt gcctctgctg ggctccctga ggaccgcaca gacccagctg 3360 agccgcaagc tgccagggac caccctggcc gctctggaag ccgccgccaa ccccgccctc 3420 ccatccgatt tcaaaaccat tctggac 3447 <210> 54 <211> 1149 <212> PRT <213> Artificial Sequence <220> <223> Synthetic consensus rhTERT amino acid sequence operatively linked to IgE (pGX1473) <400> 54 Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15 His Ser Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ala Leu Leu Arg 20 25 30 Ser Arg Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu 35 40 45 Gly Pro Glu Gly Arg Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe 50 55 60 Arg Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg 65 70 75 80 Pro Pro Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu 85 90 95 Leu Val Ala Arg Val Val Gln Arg Leu Cys Glu Arg Gly Ala Arg Asn 100 105 110 Val Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro 115 120 125 Pro Glu Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val 130 135 140 Thr Asp Thr Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg 145 150 155 160 Val Gly Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Tyr 165 170 175 Val Leu Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu 180 185 190 Tyr Glu Leu Cys Ala Ala Thr Gln Ala Arg Pro Ala Pro His Ala Ser 195 200 205 Gly Thr Arg Arg Gly Leu Gly Cys Glu Arg Ala Trp Asn Gly Ser Val 210 215 220 Arg Glu Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg 225 230 235 240 Arg Arg Gly Ser Ala Gly Arg Ser Pro Pro Leu Ala Lys Arg Pro Arg 245 250 255 Arg Gly Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser 260 265 270 Trp Ala His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys 275 280 285 Val Val Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly 290 295 300 Ala Leu Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His 305 310 315 320 His Ala Gly Pro Pro Ser Thr Ser Arg Pro Pro Ser Pro Trp Asp Thr 325 330 335 Pro Cys Pro Leu Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Cys Ser 340 345 350 Gly Asp Lys Glu Arg Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg 355 360 365 Pro Ser Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly 370 375 380 Ser Arg Pro Trp Met Pro Gly Thr Pro Arg Arg Pro Pro Arg Leu Pro 385 390 395 400 Gln Arg Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn 405 410 415 His Ala Arg Cys Pro Tyr Gly Ala Leu Leu Arg Thr His Cys Pro Leu 420 425 430 Arg Ala Ala Ala Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro 435 440 445 Gln Gly Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg 450 455 460 Leu Val Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly 465 470 475 480 Phe Leu Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly 485 490 495 Ser Arg His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile 500 505 510 Ser Leu Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys 515 520 525 Met Ser Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly 530 535 540 Cys Val Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys 545 550 555 560 Phe Leu His Trp Leu Met Gly Val Tyr Val Val Glu Leu Leu Arg Ser 565 570 575 Phe Phe Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Tyr Leu Phe Phe 580 585 590 Tyr Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln 595 600 605 His Leu Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg 610 615 620 Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe 625 630 635 640 Leu Pro Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val 645 650 655 Val Gly Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr 660 665 670 Ser Arg Val Lys Thr Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg 675 680 685 Arg Pro Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His 690 695 700 Arg Ala Trp Arg Ala Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro 705 710 715 720 Pro Glu Leu Tyr Phe Val Lys Val Ala Val Thr Gly Ala Tyr Asp Thr 725 730 735 Ile Pro Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro 740 745 750 Gln Asn Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Gln Lys Ala Ala 755 760 765 His Gly His Val Arg Lys Thr Phe Lys Lys His Val Ser Thr Leu Thr 770 775 780 Asp Leu Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr 785 790 795 800 Ser Ser Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn 805 810 815 Glu Ala Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Val Cys Asn 820 825 830 His Val Val Arg Ile Gly Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile 835 840 845 Pro Gln Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly 850 855 860 Asp Met Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp Gly Leu Leu 865 870 875 880 Leu Arg Leu Val Ala Ala Phe Leu Leu Val Thr Pro His Leu Thr His 885 890 895 Ala Lys Ala Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly 900 905 910 Cys Val Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp 915 920 925 Glu Ala Leu Gly Gly Ala Ala Phe Val Gln Leu Pro Ala His Gly Leu 930 935 940 Phe Pro Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln 945 950 955 960 Ser Asp Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr 965 970 975 Phe Asn Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe 980 985 990 Gly Val Leu Arg Leu Lys Cys His Ser Leu Phe Leu Tyr Leu Gln Val 995 1000 1005 Asn Ser Leu Gln Thr Val Cys Thr Asn Val Tyr Lys Ile Phe Leu 1010 1015 1020 Leu Gln Ala Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe 1025 1030 1035 Asn Gln Gln Val Trp Lys Asn Pro Ala Phe Phe Leu Arg Val Ile 1040 1045 1050 Ser Asp Thr Ala Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn 1055 1060 1065 Ala Gly Met Ser Leu Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro 1070 1075 1080 Ser Glu Ala Val Gln Trp Leu Cys His Gln Ala Phe Leu Leu Lys 1085 1090 1095 Leu Thr Arg His Arg Val Thr Tyr Val Pro Leu Leu Gly Ser Leu 1100 1105 1110 Arg Thr Ala Gln Thr Gln Leu Ser Arg Lys Leu Pro Gly Thr Thr 1115 1120 1125 Leu Ala Ala Leu Glu Ala Ala Ala Asn Pro Ala Leu Pro Ser Asp 1130 1135 1140 Phe Lys Thr Ile Leu Asp 1145 <210> 55 <211> 3393 <212> DNA <213> Artificial Sequence <220> <223> Synthetic consensus rhTERT nucleic acid sequence (pGX1473) <400> 55 ccaagagccc cacgctgtag agctgtgaga gccctgctga ggtccagata cagggaggtg 60 ctgccactgg ccaccttcgt gaggagactg ggacctgagg gccggcgcct ggtgcagagg 120 ggcgaccccg cagccttccg cgccctggtg gcccagtgcc tggtgtgcgt gccatgggac 180 gccaggcccc ctccagcagc accatccttc agacaggtga gctgcctgaa ggagctggtg 240 gccagggtgg tgcagagact gtgcgagagg ggcgccagga acgtgctggc cttcggcttc 300 gcactgctgg acggagccag gggcgggccc cctgaggcct tcaccacctc cgtgagaagc 360 tacctgccta acaccgtgac cgacaccctg aggggctccg gagcatgggg cctgctgctg 420 aggagagtgg gggacgacgt gctggtgcac ctgctggcaa ggtgcgccct gtacgtgctg 480 gtggcaccaa gctgcgcata ccaggtgtgc ggcccacccc tgtacgagct gtgcgcagca 540 acccaggcca acccagcccc tcacgcatcc ggaccagga ggggactggg ctgcgagagg gcctggaacg gaagcgtgag agaggcagga gtgccactgg gactgcctgc accaggggcc 660 aggagacggc gcgggtctgc cggacggtcc cctccactgg caaagcgccc taggaga 720 gccgcaccag agcctgagag gaccccagtg gggcaggga gctgggcaca ccctggaagg 780 accagggggc catccgacag gggattctgc gtggtgagcc cagccaggcc cgcagaggag 840 gccacctctc tggagggagc cctgtccgga accaggcact ctcacccatc cgtgggaaga 900 cagcaccacg caggccctcc cagcacctct aggccaccct ccccatggga caccccatgc 960 ccactggtgt acgcagagac aaagcacttc ctgtactgca gcggagacaa ggagagactg 1020 cggccatctt tcctgctgtc cagcctgcgc ccctccctga ccggagcacg gcgcctggtg 1080 gagacaatct tcctgggaag caggccttgg atgccaggaa cccccaggag gcctcccagg 1140 ctgccacaga ggtactggca gatgcgccct ctgttcctgg agctgctggg aaaccacgca 1200 aggtgcccat acggagccct gctgcggacc cactgccctc tgagggcagc agcaacccca 1260 gcagcaggcg tgtgcgccag ggagaagccc caggggagcg tggccgcccc tgaggaggag 1320 gacaccgacc cacggcgcct ggtgcagctg ctgagacagc actcttcccc ctggcaggtg 1380 tacggattcc tgagggcatg cctgaggaga ctggtgcccc ctggcctgtg gggctccagg 1440 cacaacgagc ggcgcttcct gcgcaacacc aagaagttca tctctctggg caagcacgcc 1500 aagctgtccc tgcaggagct gacctggaag atgtctgtga gggactgcgc ctggctgagg 1560 agatcccccg gagtgggatg cgtgcctgca gcagagcaca ggctgaggga ggagatcctg 1620 gccaagttcc tgcactggct gatgggggtg tacgtggtgg agctgctgag gtctttcttc 1680 tacgtgaccg agacaacctt ccagaagaac tacctgttct tctaccgcaa gagcgtgtgg 1740 tctaagctgc agtctatcgg aatcaggcag cacctgaaga gggtgcagct gagagagctg 1800 tccgaggccg aggtgagaca gcacagggag gcccgccccg ccctgctgac ctccagactg 1860 cggttcctgc ctaagccaga cggcctgagg cccatcgtga acatggacta cgtggtggga 1920 gcacggacct tccggaggga gaagagggcc gagagactga ccagccgcgt gaagaccctg 1980 ttctctgtgc tgaactacga gagggcaagg aggcccggac tgctgggagc cagcgtgctg 2040 ggcctggacg acatccacag ggcatggagg gccttcgtgc tgcgcgtgag ggcacaggac 2100 ccaccccctg agctgtactt cgtgaaggtg gcagtgaccg gagcatacga caccatccca 2160 caggacaggc tgaccgaggt catcgcctct atcatcaagc ctcagaacac ctactgcgtg 2220 cggcgctacg cagtggtgca gaaggcagca cacggacacg tgaggaagac cttcaagaag 2280 cacgtgtcca ccctgaccga cctgcagccc tacatgagac agttcgtggc ccacctgcag 2340 gagacatcct ccctgaggga cgcagtggtc atcgagcagt ccagctctct gaacgaggcc 2400 tccagcggcc tgttcgacgt gttcctgagg ttcgtgtgca accacgtggt gagaatcgga 2460 ggcaagagct acgtgcagtg ccagggcatc ccccagggct ccatcctgag caccctgctg 2520 tgctctctgt gctacgggga catggagaac aagctgttcg ccggaatcag gagagacggc 2580 ctgctgctga gactggtggc agccttcctg ctggtgaccc ctcacctgac ccacgcaaag 2640 gccttcctgc ggaccctggt gcgcggggtg ccagagtacg gatgcgtggt gaacctgcgg 2700 aagaccgtgg tgaacttccc agtggaggac gaggccctgg gcggcgccgc cttcgtgcag 2760 ctgccagcac acgggctgtt cccatggtgc ggactgctgc tggacaccag aaccctggag 2820 gtgcagtccg actactcttc ctacgccagg accagcatca gagcctctct gaccttcaac 2880 aggggcttca aggccgggag aaacatgcgg cgcaagctgt tcggggtgct gaggctgaag 2940 tgccacagcc tgttcctgta cctgcaggtg aactctctgc agaccgtgtg cactaacgtg 3000 3060. Tacaagatct tcctgctgca ggcctacaga ttccacgcct gcgtgctgca gctgcctttc aaccagcaag tgtggaagaa cccagccttc ttcctgagag tgatctccga caccgccagc ctgtgctact ctatcctgaa ggcaaagaac gcaggaatga gcctgggagc aaagggagca 3180. gcaggaccac tgccttctga ggcagtgcag tggctgtgcc accaggcctt cctgctgag 3240 ctgaccagac accgggtgac ctacgtgcct ctgctgggct ccctgaggac cgcacagacc 3300 cagctgagcc gcaagctgcc agggaccacc ctggccgctc tggaagccgc cgccaacccc 3360 gccctcccat ccgatttcaa aaccattctg gac <210> 56 <211> 1131 <212> PRT <213> Artificial Sequence <220> <223> Protein rhTERT promoter (pGX1473) <400> 56 Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ala Leu Leu Arg Ser Arg 1 5 10 15 Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly Pro 20 25 30 Glu Gly Arg Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg Ala 35 40 45 Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro Pro 50 55 60 Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu Val 65 70 75 80 Ala Arg Val Val Gln Arg Leu Cys Glu Arg Gly Ala Arg Asn Val Leu 85 90 95 Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro Glu 100 105 110 Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr Asp 115 120 125 Thr Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val Gly 130 135 140 Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Tyr Val Leu 145 150 155 160 Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr Glu 165 170 175 Leu Cys Ala Ala Thr Gln Ala Arg Pro Ala Pro His Ala Ser Gly Thr 180 185 190 Arg Arg Gly Leu Gly Cys Glu Arg Ala Trp Asn Gly Ser Val Arg Glu 195 200 205 Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg Arg Arg 210 215 220 Gly Ser Ala Gly Arg Ser Pro Pro Leu Ala Lys Arg Pro Arg Arg Gly 225 230 235 240 Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser Trp Ala 245 250 255 His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys Val Val 260 265 270 Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly Ala Leu 275 280 285 Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His His Ala 290 295 300 Gly Pro Pro Ser Thr Ser Arg Pro Pro Ser Pro Trp Asp Thr Pro Cys 305 310 315 320 Pro Leu Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Cys Ser Gly Asp 325 330 335 Lys Glu Arg Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg Pro Ser 340 345 350 Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly Ser Arg 355 360 365 Pro Trp Met Pro Gly Thr Pro Arg Arg Pro Pro Arg Leu Pro Gln Arg 370 375 380 Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His Ala 385 390 395 400 Arg Cys Pro Tyr Gly Ala Leu Leu Arg Thr His Cys Pro Leu Arg Ala 405 410 415 Ala Ala Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln Gly 420 425 430 Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg Leu Val 435 440 445 Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe Leu 450 455 460 Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser Arg 465 470 475 480 His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser Leu 485 490 495 Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met Ser 500 505 510 Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly Cys Val 515 520 525 Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe Leu 530 535 540 His Trp Leu Met Gly Val Tyr Val Val Glu Leu Leu Arg Ser Phe Phe 545 550 555 560 Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Tyr Leu Phe Phe Tyr Arg 565 570 575 Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His Leu 580 585 590 Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Gln His 595 600 605 Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Leu Pro 610 615 620 Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val Gly 625 630 635 640 Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr Ser Arg 645 650 655 Val Lys Thr Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg Arg Pro 660 665 670 Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His Arg Ala 675 680 685 Trp Arg Ala Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro Pro Glu 690 695 700 Leu Tyr Phe Val Lys Val Ala Val Thr Gly Ala Tyr Asp Thr Ile Pro 705 710 715 720 Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro Gln Asn 725 730 735 Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Gln Lys Ala Ala His Gly 740 745 750 His Val Arg Lys Thr Phe Lys Lys His Val Ser Thr Leu Thr Asp Leu 755 760 765 Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr Ser Ser 770 775 780 Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn Glu Ala 785 790 795 800 Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Val Cys Asn His Val 805 810 815 Val Arg Ile Gly Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile Pro Gln 820 825 830 Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly Asp Met 835 840 845 Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp Gly Leu Leu Leu Arg 850 855 860 Leu Val Ala Ala Phe Leu Leu Val Thr Pro His Leu Thr His Ala Lys 865 870 875 880 Ala Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly Cys Val 885 890 895 Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp Glu Ala 900 905 910 Leu Gly Gly Ala Ala Phe Val Gln Leu Pro Ala His Gly Leu Phe Pro 915 920 925 Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln Ser Asp 930 935 940 Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr Phe Asn 945 950 955 960 Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe Gly Val 965 970 975 Leu Arg Leu Lys Cys His Ser Leu Phe Leu Tyr Leu Gln Val Asn Ser 980 985 990 Leu Gln Thr Val Cys Thr Asn Val Tyr Lys Ile Phe Leu Leu Gln Ala 995 1000 1005 Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe Asn Gln Gln 1010 1015 1020 Val Trp Lys Asn Pro Ala Phe Phe Leu Arg Val Ile Ser Asp Thr 1025 1030 1035 Ala Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala Gly Met 1040 1045 1050 Ser Leu Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro Ser Glu Ala 1055 1060 1065 Val Gln Trp Leu Cys His Gln Ala Phe Leu Leu Lys Leu Thr Arg 1070 1075 1080 His Arg Val Thr Tyr Val Pro Leu Leu Gly Ser Leu Arg Thr Ala 1085 1090 1095 Gln Thr Gln Leu Ser Arg Lys Leu Pro Gly Thr Thr Leu Ala Ala 1100 1105 1110 Leu Glu Ala Ala Ala Asn Pro Ala Leu Pro Ser Asp Phe Lys Thr 1115 1120 1125 Ile Leu Asp 1130 <210> 57 <211> 3393 <212> DNA <213> Artificial Sequence <220> <223> mut rhTERT smooth muscle(pGX1447) <400> 57 cctcgcgccc cacgctgtag agccgtcagg tctctgctgc gcagccggta cagagaggtg ctgccactgg ccacctttgt gcagcggctg ggacctgagg gatggagact ggtgcagagg 120 ggcgaccctg cagccttcag agccctggtg gcacagtgcc tggtgtgcgt gccatgggat 180 gccagacccc ctccagcagc accatctttt aggcaggtga gctgcctgaa ggagctggtg 240 gcccgcgtgc tgcagcggct gtgcgagagg ggcgcccgca acgtgctggc cttcggcttt 300 gccctgctgg acggagcccg gggcggccct cccgaggcct tcaccacatc cgtgcggtct 360 tatctgccca ataccgtgac agatgccctg agaggcagcg gagcatgggg cctgctgctg aggagagtgg gcgacgatgt gctggtgcac ctgctggcaa ggtgcgcact gtttgtgctg 480 gtggcacctt cctgcgcata ccaggtgtgc ggcccacccc tgtatgagct gggagcagca 540 acacagggcc gcccagcagc ccacgcctcc ggcaccaggc gcggcctggg ctgtgagctg 600 gcctggaacc ggtctgtgag agaggcagga gtgccaatgg gcctgccagc acctggcgcc 660 cggagaaggc gcggctctgc caatcgcagc ctgccactgc caaagcggcc taggagaggc 720 gccgcacctg agccagagag gacaccagtg ggacagggca gctgggcaca cccagacagg 780 acccgcggcc cttctgatag gggattctgc gtggtgagcc ctgcccggcc agcagaggag 840 gccacctccc tggagggcgc cctgtctggc acaagacaca gccacccatc cgtgggcagg 900 cagcaccacg caggccctcc aagcaccagc cggcctccct ccccatggga cacacggtgt 960 cccctggtgt acgccgagac aaagcacttt ctgtatagct ccggcgataa ggagcagctg 1020 cggccctcct tcctgctgaa ctccctgagg ccctctctga ccggagcaag gcgcctggtg 1080 gagacaatct ttctgggctc taggccctgg atgcctggaa cccccagacg gcctccccgg 1140 ctgccacaga ggtactggca gatgcgccct ctgttcctgg agctgctggg caatcacgcc 1200 cagtgcccat atggcgccct gctgaagaca cactgtccac tgagggcagc agtgacccca 1260 gcagcaggcg tgtcgcccg cgagaagcct cagggctctg tggcagcacc agaggaggag 1320 gacaccgata ggcgccggct ggtgcagctg ctgaggcagc actctagccc ctggcaggtg 1380 tacggcttcg tgagagcctg tctgagaagg ctggtgcctc caggcctgtg gggctccaga 1440 cacaaccagc gccggtttct gaggaataca aagaagttca tctccctggg caagcacgcc 1500 aagctgtctc tgagggagct gacctggaag atgagcgtgc gcgactgcgc ctggctgcgg 1560 aagtcccctg gagtgggatg cgtgccagca gcagagcacc ggctgagaga ggagatcctg 1620 gccaagtttc tgcactggct gatgagcgtg tacgtggtgg agctgctgcg gtccttcttt 1680 tatgtgaccg agacaacctt ccagaagaac tacctgttct tttataggaa gagcgtgtgg 1740 agcaagctgc agagcatcgg catcagacag cacctgaagc gcgtgcagct gcgggagctg 1800 tccgaggcag aggcaaggca gcacagggag gcccggccaa cactgctggc cagcaggctg 1860 cgcttcctgc caaagcctga cggcctgcgg cccatcgtga atatggatta cgtggtgggc 1920 gccagaacct ttagaaggga gaagagagca gagaggctgg ccagcagggt gaaggccctg 1980 ttctccgtgc tgaactatga gagggcaaga cggcccggcc tgctgggagc cagcgtgctg ggcctggacg atatccacag ggcatggcgg aatttttgtgc tgcgggtgag agcacaggac cctcccccaa agctgtactt cgtgaaggtg gatgtgatgg gcgcctatga caccatcccc caggatcgcc tgacagaagt gatcgcctcc atcatcaagc ctcagaacac atactgcgtg agaaggtatg cagtggtgcg caaggcagca cacggacacg tgcggaagac ctttaagtcc cacgtgtcta ccctgacaga cctgcagcca tacatgaggc agttcgtggc acacctgcag gagacaagcc ccctgaggga cgcagtggtc atcgagcagt cctctagcct gaacgagaca agcagcggcc tgttcgacgt gttcctgaga ttcgtgtgcc accacgccgt gaggatcggc 2460 ggcaagtctt acgtgcagtg tcagggcatc ccccagggca gcatcctgtc caccctgctg tgcagcctgt gctatggcga catggagat aagctgttcg caggatgag gagggatggc ctgctgctga ggctggtgga cgattttctg ctggtgaccc ctcacctgac acacgccaag gccttcctga gaacactggt gaggggcgtg cctgagtacg gctgcgtggt gaacctgcgc aagaccgtgg tgaattttcc agtggaggat gaggccctgg gcggcgccgc ctttgtgcag 2760 ctgccagcac acggcctgtt cccttggtgt ggcctgctgc tggacacccg gacactggag 2820 gtgcagtccg attacagctc ctatgcacgc accagcatca gggcatccct gaccttcaac 2880 agaggcttca aggccggcag gaatatgaga aggaagctgt ttggcgtgct gagactgaag 2940 tgccactctc tgttcctgta cctgcaggtg aacagcctgc agaccgtgtg cacaaacgtg 3000 tacaagatcc tgctgctgca ggcctatcgg tttcacgcct gcgtgctgca gctgcctttc 3060 caccagcaag tgtggaagaa cccagccttc tttctgagag tgatctctga taccgccagc 3120 ctgtgctact ccatcctgaa ggccaagaat gccggcatgt ctctgggagc aaagggagca 3180 gcaggaccac tgccaagcga ggcagtgcag tggctgtgcc accaggcctt cctgctgaag 3240 ctgacccagc acagagtgac atatgtgcca ctgctgggct ccctgaggac cgcacagaca 3300 cagctgtctc ggaagctgcc tggcaccaca ctggccgctc tggaggctgc tgctaatccc 3360 gccctgccat ccgacttcaa aacaatcctg gac 3393 <210> 58 <211> 1131 <212> PRT <213> Artificial Sequence <220> <223> mut rhTERT amino acid sequence(pGX1447) <400> 58 Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser Arg 1 5 10 15 Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Gln Arg Leu Gly Pro 20 25 30 Glu Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg Ala 35 40 45 Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro Pro 50 55 60 Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu Val 65 70 75 80 Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Arg Asn Val Leu 85 90 95 Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro Glu 100 105 110 Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr Asp 115 120 125 Ala Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val Gly 130 135 140 Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Phe Val Leu 145 150 155 160 Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr Glu 165 170 175 Leu Gly Ala Ala Thr Gln Gly Arg Pro Ala Ala His Ala Ser Gly Thr 180 185 190 Arg Arg Gly Leu Gly Cys Glu Leu Ala Trp Asn Arg Ser Val Arg Glu 195 200 205 Ala Gly Val Pro Met Gly Leu Pro Ala Pro Gly Ala Arg Arg Arg Arg 210 215 220 Gly Ser Ala Asn Arg Ser Leu Pro Leu Pro Lys Arg Pro Arg Arg Gly 225 230 235 240 Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser Trp Ala 245 250 255 His Pro Asp Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys Val Val 260 265 270 Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly Ala Leu 275 280 285 Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His His Ala 290 295 300 Gly Pro Pro Ser Thr Ser Arg Pro Pro Ser Pro Trp Asp Thr Arg Cys 305 310 315 320 Pro Leu Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Ser Ser Gly Asp 325 330 335 Lys Glu Gln Leu Arg Pro Ser Phe Leu Leu Asn Ser Leu Arg Pro Ser 340 345 350 Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly Ser Arg 355 360 365 Pro Trp Met Pro Gly Thr Pro Arg Arg Pro Pro Arg Leu Pro Gln Arg 370 375 380 Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His Ala 385 390 395 400 Gln Cys Pro Tyr Gly Ala Leu Leu Lys Thr His Cys Pro Leu Arg Ala 405 410 415 Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln Gly 420 425 430 Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Arg Arg Arg Leu Val 435 440 445 Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe Val 450 455 460 Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser Arg 465 470 475 480 His Asn Gln Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser Leu 485 490 495 Gly Lys His Ala Lys Leu Ser Leu Arg Glu Leu Thr Trp Lys Met Ser 500 505 510 Val Arg Asp Cys Ala Trp Leu Arg Lys Ser Pro Gly Val Gly Cys Val 515 520 525 Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe Leu 530 535 540 His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe Phe 545 550 555 560 Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Tyr Leu Phe Phe Tyr Arg 565 570 575 Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His Leu 580 585 590 Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Ala Arg Gln His 595 600 605 Arg Glu Ala Arg Pro Thr Leu Leu Ala Ser Arg Leu Arg Phe Leu Pro 610 615 620 Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val Gly 625 630 635 640 Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Ala Ser Arg 645 650 655 Val Lys Ala Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg Arg Pro 660 665 670 Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His Arg Ala 675 680 685 Trp Arg Asn Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro Pro Lys 690 695 700 Leu Tyr Phe Val Lys Val Asp Val Met Gly Ala Tyr Asp Thr Ile Pro 705 710 715 720 Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro Gln Asn 725 730 735 Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Arg Lys Ala Ala His Gly 740 745 750 His Val Arg Lys Thr Phe Lys Ser His Val Ser Thr Leu Thr Asp Leu 755 760 765 Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr Ser Pro 770 775 780 Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn Glu Thr 785 790 795 800 Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Val Cys His His Ala 805 810 815 Val Arg Ile Gly Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile Pro Gln 820 825 830 Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly Asp Met 835 840 845 Glu Asn Lys Leu Phe Ala Gly Met Arg Arg Asp Gly Leu Leu Leu Arg 850 855 860 Leu Val Asp Asp Phe Leu Leu Val Thr Pro His Leu Thr His Ala Lys 865 870 875 880 Ala Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly Cys Val 885 890 895 Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp Glu Ala 900 905 910 Leu Gly Gly Ala Ala Phe Val Gln Leu Pro Ala His Gly Leu Phe Pro 915 920 925 Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln Ser Asp 930 935 940 Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr Phe Asn 945 950 955 960 Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe Gly Val 965 970 975 Leu Arg Leu Lys Cys His Ser Leu Phe Leu Tyr Leu Gln Val Asn Ser 980 985 990 Leu Gln Thr Val Cys Thr Asn Val Tyr Lys Ile Leu Leu Leu Gln Ala 995 1000 1005 Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe His Gln Gln 1010 1015 1020 Val Trp Lys Asn Pro Ala Phe Phe Leu Arg Val Ile Ser Asp Thr 1025 1030 1035 Ala Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala Gly Met 1040 1045 1050 Ser Leu Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro Ser Glu Ala 1055 1060 1065 Val Gln Trp Leu Cys His Gln Ala Phe Leu Leu Lys Leu Thr Gln 1070 1075 1080 His Arg Val Thr Tyr Val Pro Leu Leu Gly Ser Leu Arg Thr Ala 1085 1090 1095 Gln Thr Gln Leu Ser Arg Lys Leu Pro Gly Thr Thr Leu Ala Ala 1100 1105 1110 Leu Glu Ala Ala Ala Asn Pro Ala Leu Pro Ser Asp Phe Lys Thr 1115 1120 1125 Ile Leu Asp 1130 <210> 59 <211> 2202 <212> DNA <213> Artificial Sequence <220> <223> Synthetic consensus FAP nucleic acid sequence <400> 59 ctgaggcctt ctagagtgca caactccgag ggcccaacca gagccctgac actgaaggac 60 atcctgaatg gcaccttttc ttacaagaca ttctttccca actggatctc tggccaggag 120 tatctgcacc agagcgccga taacaacatc atcctgtaca acatcgagac aggcgagagc 180 tacacaatcc tgtccaactc taccatgaag agcgtgaacg cctccaatta cggcctgagc 240 cctgacaggc agttcgccta cctggagtct gattatagca agctgtggag atactcctat accgccacat accacatcta tgatctgatc aatggcgagt ttgtgcggga gaacgagctg 360 cccggcccta tccagtacct gtgctggagc cccgtgggca gcaagctggc atacgtgtat 420 cagaacaata tctatctgaa gcagaggccc agggaccctc ccttccagat cacatccaac ggcaaggaga ataagatctt taacggcatc cccgattggg tgtacgagga ggagatgctg 540 gccaccaagt atgccctgtg gtggagccct aatggcaagt tcctggccta cgccgagttt 600 aacgacacag atatcccagt gatcgcctat tcctactatg gcgacgagca gtacccccgg 660 accatcaata tcccatatcc caaggcagga gcaaagaacc caacagtgcg cgtgttcatc atcgatacca catacccaga gcacgtggga ccaaaggagg tgcctgtgcc agccatgatc 780 gccagctccg actactactt cagctggctg acctgggtga cagatgagag gatctgtctg 840 cagtggctga agagaatcca gaacgtgagc gtgctgtcta tctgcgactt cagggaggat tggaacacct gggactgtcc taagacacag gagcacatcg aggagagcag aaccggatgg gccggcggct tcttcgtgag cacaccagtg ttctctagcg acgccatcag ctactataag 1020 atctttccg acaaggatgg ctacaagcac atccactata tcaaggatac cgtggagaat 1080 gccatccaga tcacatctgg caagtgggag gccatcaaca tcttcagggt gacccaggac 1140 agcctgttct actcctaa tgagtttgag ggctacccag gcaggagaaa catctataga 1200 atcagcatcg gctcctaccc acccagcaag aagtgcgtga cctgtcacct gcggaaggag 1260 aggtgccagt actatacagc cagcttttcc gattacgcca agtactatgc cctgatctgt 1320 tatggccccg gcatccctat ctccaccctg cacgacggcc ggacagatca ggagatcaag 1380 atcctggagg agaataagga gctggagaat gcctgaaga acatccagct gcctaaggag 1440 gagatcaaga agctggaggt ggacggcatc accctgtggt acaagatgat cctgcctcca 1500 cagttcgatc ggtctaagaa gtatcccctg ctgatccagg tgtacggcgg accttgctct 1560 cagagcgtgc gcagcgtgtt ttccatctct tggatctcct acctggcctc taaggagggc 1620 atcgtggtgg ccctggtgga cggaagggga accgccttcc agggcgataa gctgctgtac 1680 gccgtgtatc gcaagctggg cgtgtacgag gtggaggacc agatcacagc cgtgcggaag 1740 ttcatcgaga tgggctttat cgatgagaag aggatcgcaa tctggggatg ggcatacggc ggatatgtga gctccctggc cctggcatct ggaaccggcc tgttcaagtg tggcatcgcc 1860. gtggccccag tgtctagctg ggagtactat gcctccatct acaccgagag gttcatgggc 1920 ctgcccacaa agtccgacaa tctggagcac tataagaact ctaccgtgat ggccagggcc gagtacttca gaaacgtgga ttatctgctg atccacggca cagccgacga taatgtgcac ttccagaact ccgcccagat cgccaaggcc ctggtgaatg cccaggtgga ctttcaggcc atgtggtact ctgatcagaa ccacggcatc tctggcctga gcaccaagca cctgtatacc cacatgacac acttcctgaa gcagtgcttt agcctgtccg ac <210> 60 <211> 734 <212> PRT <213> Artificial Sequence <220> <223> Even if you have a FAP license plate <400> 60 Leu Arg Pro Ser Arg Val His Asn Ser Glu Gly Pro Thr Arg Ala Leu 1 5 10 15 Thr Leu Lys Asp Ile Leu Asn Gly Thr Phe Ser Tyr Lys Thr Phe Phe 20 25 30 Pro Asn Trp Ile Ser Gly Gln Glu Tyr Leu His Gln Ser Ala Asp Asn 35 40 45 Asn Ile Ile Leu Tyr Asn Ile Glu Thr Gly Glu Ser Tyr Thr Ile Leu 50 55 60 Ser Asn Ser Thr Met Lys Ser Val Asn Ala Ser Asn Tyr Gly Leu Ser 65 70 75 80 Pro Asp Arg Gln Phe Ala Tyr Leu Glu Ser Asp Tyr Ser Lys Leu Trp 85 90 95 Arg Tyr Ser Tyr Thr Ala Thr Tyr His Ile Tyr Asp Leu Ile Asn Gly 100 105 110 Glu Phe Val Arg Glu Asn Glu Leu Pro Arg Pro Ile Gln Tyr Leu Cys 115 120 125 Trp Ser Pro Val Gly Ser Lys Leu Ala Tyr Val Tyr Gln Asn Asn Ile 130 135 140 Tyr Leu Lys Gln Arg Pro Arg Asp Pro Pro Phe Gln Ile Thr Ser Asn 145 150 155 160 Gly Lys Glu Asn Lys Ile Phe Asn Gly Ile Pro Asp Trp Val Tyr Glu 165 170 175 Glu Glu Met Leu Ala Thr Lys Tyr Ala Leu Trp Trp Ser Pro Asn Gly 180 185 190 Lys Phe Leu Ala Tyr Ala Glu Phe Asn Asp Thr Asp Ile Pro Val Ile 195 200 205 Ala Tyr Ser Tyr Tyr Gly Asp Glu Gln Tyr Pro Arg Thr Ile Asn Ile 210 215 220 Pro Tyr Pro Lys Ala Gly Ala Lys Asn Pro Thr Val Arg Val Phe Ile 225 230 235 240 Ile Asp Thr Thr Tyr Pro Glu His Val Gly Pro Lys Glu Val Pro Val 245 250 255 Pro Ala Met Ile Ala Ser Ser Asp Tyr Tyr Phe Ser Trp Leu Thr Trp 260 265 270 Val Thr Asp Glu Arg Ile Cys Leu Gln Trp Leu Lys Arg Ile Gln Asn 275 280 285 Val Ser Val Leu Ser Ile Cys Asp Phe Arg Glu Asp Trp Asn Thr Trp 290 295 300 Asp Cys Pro Lys Thr Gln Glu His Ile Glu Glu Ser Arg Thr Gly Trp 305 310 315 320 Ala Gly Gly Phe Phe Val Ser Thr Pro Val Phe Ser Ser Asp Ala Ile 325 330 335 Ser Tyr Tyr Lys Ile Phe Ser Asp Lys Asp Gly Tyr Lys His Ile His 340 345 350 Tyr Ile Lys Asp Thr Val Glu Asn Ala Ile Gln Ile Thr Ser Gly Lys 355 360 365 Trp Glu Ala Ile Asn Ile Phe Arg Val Thr Gln Asp Ser Leu Phe Tyr 370 375 380 Ser Ser Asn Glu Phe Glu Gly Tyr Pro Gly Arg Arg Asn Ile Tyr Arg 385 390 395 400 Ile Ser Ile Gly Ser Tyr Pro Pro Ser Lys Lys Cys Val Thr Cys His 405 410 415 Leu Arg Lys Glu Arg Cys Gln Tyr Tyr Thr Ala Ser Phe Ser Asp Tyr 420 425 430 Ala Lys Tyr Tyr Ala Leu Ile Cys Tyr Gly Pro Gly Ile Pro Ile Ser 435 440 445 Thr Leu His Asp Gly Arg Thr Asp Gln Glu Ile Lys Ile Leu Glu Glu 450 455 460 Asn Lys Glu Leu Glu Asn Ala Leu Lys Asn Ile Gln Leu Pro Lys Glu 465 470 475 480 Glu Ile Lys Lys Leu Glu Val Asp Gly Ile Thr Leu Trp Tyr Lys Met 485 490 495 Ile Leu Pro Pro Gln Phe Asp Arg Ser Lys Lys Tyr Pro Leu Leu Ile 500 505 510 Gln Val Tyr Gly Gly Pro Cys Ser Gln Ser Val Arg Ser Val Phe Ser 515 520 525 Ile Ser Trp Ile Ser Tyr Leu Ala Ser Lys Glu Gly Ile Val Val Ala 530 535 540 Leu Val Asp Gly Arg Gly Thr Ala Phe Gln Gly Asp Lys Leu Leu Tyr 545 550 555 560 Ala Val Tyr Arg Lys Leu Gly Val Tyr Glu Val Glu Asp Gln Ile Thr 565 570 575 Ala Val Arg Lys Phe Ile Glu Met Gly Phe Ile Asp Glu Lys Arg Ile 580 585 590 Ala Ile Trp Gly Trp Ala Tyr Gly Gly Tyr Val Ser Ser Leu Ala Leu 595 600 605 Ala Ser Gly Thr Gly Leu Phe Lys Cys Gly Ile Ala Val Ala Pro Val 610 615 620 Ser Ser Trp Glu Tyr Tyr Ala Ser Ile Tyr Thr Glu Arg Phe Met Gly 625 630 635 640 Leu Pro Thr Lys Ser Asp Asn Leu Glu His Tyr Lys Asn Ser Thr Val 645 650 655 Met Ala Arg Ala Glu Tyr Phe Arg Asn Val Asp Tyr Leu Leu Ile His 660 665 670 Gly Thr Ala Asp Asp Asn Val His Phe Gln Asn Ser Ala Gln Ile Ala 675 680 685 Lys Ala Leu Val Asn Ala Gln Val Asp Phe Gln Ala Met Trp Tyr Ser 690 695 700 Asp Gln Asn His Gly Ile Ser Gly Leu Ser Thr Lys His Leu Tyr Thr 705 710 715 720 His Met Thr His Phe Leu Lys Gln Cys Phe Ser Leu Ser Asp 725 730 <210> 61 <211> 2034 <212> DNA <213> Artificial Sequence <220> <223> Synthetic consensus FSHR nucleic acid sequence <400> 61 tgtcatcata ggatttgtca ttgctctaat agggtgttcc tgtgccagga gtccaaggtc 60 actgaaatcc catctgacct gccccggaat gctgtggagc tgagatttgt cctgaccaag 120 ctgagagtga tccctaaagg cgcattcagt ggctttgggg acctggagaa aatcgaaatt 180 tcacagaacg atgtgctgga ggtcatcgaa gctaacgtgt tcagcaacct gccaaaagctg 240 cacgagatcc gcattgaaaa agctaacaat ctgctgtaca ttgatcccga agcatttcag 300 aatctgccta acctgcgata tctgctgatc agcaataccg gcattaagca cctgcccgcc 360 gtgcataaga ttcagtccct gcagaaagtc ctgctggaca tccaggataa tatcaacatt 420 cacacagtgg agaaacag cttcatgggg ctgtcctttg aatctgtcat cctgtggctg 480 aataagaacg gcatccagga gattcataat tgcgcattca acgggacaca gctggacgaa 540 600 agcggaccag tcatcctgga tatttcccga acaagaatcc acagtctgcc ttcatacggc 660 ctggagaatc tgaagaact gagagccagg tcaacttata acctgaagaa actgccaagc 720 ctggagaagt tcgtggccct gatggaagct tcactgacct accccagcca ctgctgtgct 780 tttgcaaatt ggcggagaca gatctccgag ctgcatccaa tctgtaacaa atctattctg 840 cggcaggaag tggacgatat gacccaggca cgcgggcagc gagtctccct ggccgaggac 900 gatgaaagct cctactctag aggattcgac atgatgtata gtgagttcga ctttgatctg 960 tgcaatgaag tggtcgatgt gacttgttct cccaagcctg acgccttcaa tccctgcgag 1020 gatatcatgg gctataacat tctgagggtg ctgatctggt ttatctctat tctggctatc 1080 accgggaata tcattgtgct ggtcatcctg attactagtc agtacaagct gaccgtgcct 1140 cgcttcctga tgtgcaacct ggcctttgct gacctgtgca tcgggatcta cctgctgctg 1200 attgccagtg tggatatcca cacaaaatca fótccata actatgccat cgactggcag 1260 acaggagctg gctgtgatgc cgctggattc tttaccgtgt tcgccagcga gctgtccgtc 1320 tacaccctga cagctattac tctggcaaga gcccacacta tcacccatgc catgcagctg 1380 gactgcaagg tgcagctgag gcagctcagcc agcgtgatgc tggtcggatg gatcttcgct 1440 tttgcagtgg ccctgttccc aatctttggc atttctagtt acatgaaagt gagcatttgt 1500 ctgcctatgg acatcgattc tccactgagt cagctgtatg tgatgtccct gctggtgctg 1560 aacgtcctgg cttttgtggt catttgcggc tgttacaccc atatctatct gacagtgcga 1620 aatcccaaca tcgtctcaag ctcctctgac accaagattg caaaacggat ggccatgctg 1680 atcttcacag attttctgtg catggccccc attagcttct ttgctatctc tgcaagtctg 1740 aaggtgcctc tgattacagt ctcaaagagc aaaatcctgc tggtgctgtt ctacccaatt 1800 aattcttgcg ctaacccctt tctgtatgca atcttcacta agaactttag gcgcgacttc 1860 tttattctgc tgagcaaatt cggatgttac gagatgcagg cacagatcta taggacagaa 1920 actagttcaa ccgcccacaa tagccatcct cgcaacggcc actgcagctc cgccccaaga 1980 gtcactaatg gaagcaacta caccctggtc ccactgtctc acctggctca gaac 2034 <210> 62 <211> 678 <212> PRT <213> Artificial Sequence <220> <223> Synthetic consensus FSHR amino acid sequence <400> 62 Cys His His Arg Ile Cys His Cys Ser Asn Arg Val Phe Leu Cys Gln 1 5 10 15 Glu Ser Lys Val Thr Glu Ile Pro Ser Asp Leu Pro Arg Asn Ala Val 20 25 30 Glu Leu Arg Phe Val Leu Thr Lys Leu Arg Val Ile Pro Lys Gly Ala 35 40 45 Phe Ser Gly Phe Gly Asp Leu Glu Lys Ile Glu Ile Ser Gln Asn Asp 50 55 60 Val Leu Glu Val Ile Glu Ala Asn Val Phe Ser Asn Leu Pro Lys Leu 65 70 75 80 His Glu Ile Arg Ile Glu Lys Ala Asn Asn Leu Leu Tyr Ile Asp Pro 85 90 95 Glu Ala Phe Gln Asn Leu Pro Asn Leu Arg Tyr Leu Leu Ile Ser Asn 100 105 110 Thr Gly Ile Lys His Leu Pro Ala Val His Lys Ile Gln Ser Leu Gln 115 120 125 Lys Val Leu Leu Asp Ile Gln Asp Asn Ile Asn Ile His Thr Val Glu 130 135 140 Arg Asn Ser Phe Met Gly Leu Ser Phe Glu Ser Val Ile Leu Trp Leu 145 150 155 160 Asn Lys Asn Gly Ile Gln Glu Ile His Asn Cys Ala Phe Asn Gly Thr 165 170 175 Gln Leu Asp Glu Leu Asn Leu Ser Asp Asn Asn Asn Leu Glu Glu Leu 180 185 190 Pro Asn Asp Val Phe Gln Gly Ala Ser Gly Pro Val Ile Leu Asp Ile 195 200 205 Ser Arg Thr Arg Ile His Ser Leu Pro Ser Tyr Gly Leu Glu Asn Leu 210 215 220 Lys Lys Leu Arg Ala Arg Ser Thr Tyr Asn Leu Lys Lys Leu Pro Ser 225 230 235 240 Leu Glu Lys Phe Val Ala Leu Met Glu Ala Ser Leu Thr Tyr Pro Ser 245 250 255 His Cys Cys Ala Phe Ala Asn Trp Arg Arg Gln Ile Ser Glu Leu His 260 265 270 Pro Ile Cys Asn Lys Ser Ile Leu Arg Gln Glu Val Asp Asp Met Thr 275 280 285 Gln Ala Arg Gly Gln Arg Val Ser Leu Ala Glu Asp Asp Glu Ser Ser 290 295 300 Tyr Ser Arg Gly Phe Asp Met Met Tyr Ser Glu Phe Asp Phe Asp Leu 305 310 315 320 Cys Asn Glu Val Val Asp Val Thr Cys Ser Pro Lys Pro Asp Ala Phe 325 330 335 Asn Pro Cys Glu Asp Ile Met Gly Tyr Asn Ile Leu Arg Val Leu Ile 340 345 350 Trp Phe Ile Ser Ile Leu Ala Ile Thr Gly Asn Ile Ile Val Leu Val 355 360 365 Ile Leu Ile Thr Ser Gln Tyr Lys Leu Thr Val Pro Arg Phe Leu Met 370 375 380 Cys Asn Leu Ala Phe Ala Asp Leu Cys Ile Gly Ile Tyr Leu Leu Leu 385 390 395 400 Ile Ala Ser Val Asp Ile His Thr Lys Ser Gln Tyr His Asn Tyr Ala 405 410 415 Ile Asp Trp Gln Thr Gly Ala Gly Cys Asp Ala Ala Gly Phe Phe Thr 420 425 430 Val Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu Thr Ala Ile Thr Leu 435 440 445 Ala Arg Ala His Thr Ile Thr His Ala Met Gln Leu Asp Cys Lys Val 450 455 460 Gln Leu Arg His Ala Ala Ser Val Met Leu Val Gly Trp Ile Phe Ala 465 470 475 480 Phe Ala Val Ala Leu Phe Pro Ile Phe Gly Ile Ser Ser Tyr Met Lys 485 490 495 Val Ser Ile Cys Leu Pro Met Asp Ile Asp Ser Pro Leu Ser Gln Leu 500 505 510 Tyr Val Met Ser Leu Leu Val Leu Asn Val Leu Ala Phe Val Val Ile 515,520,525 How To How To Turn Thr His Ile Type With Thr Val Arg Asn Pro Asn Ile 530 535 540 Val Ser Ser Ser Ser Asp Thr Lys Ile Ala Lys Arg Met Ala Met Leu 545 550 555 560 Ile Phe Thr Asp Phe Leu Cys Met Ala Pro Ile Ser Phe Phe Ala Ile 565,570,575 To Be To Be Lys To Be Lys To Be Lys Ile 580,585,590 Leu Leu Val Leu Phe Tyr Pro Ile Asn Ser Cys Ala Asn Pro Phe Leu 595,600,605 Tyr Ala Ile Phe Thr Lys Asn Phe Arg Arg Asp Phe Phe Ile Leu Leu 610 615 620 Serving Lys Phe Gly Cys Tyr Glu Met Gln Ala Gln With Tyr Arg Glu 625 630 635 640 Thr Ser Ser Thr Ala His Asn Ser His Pro Arg Asn Gly His Cys Ser 645,650,655 Ser Ala Pro Arg Val Thr Asn Gly Ser Asn Tyr Thr Leu Val Pro Leu 660 665 670 Ser His Leu Ala Gln Asn 675 <210> 63 <211> 780 <212> DNA <213> Artificial Sequence <220> <223> Synthetic consensus PSA nucleic acid sequence <400> 63 tgggtcctgg tggtgttcct gactctgagc gtcacatgga tcggcgccgc tccactgatt 60 ctgagccgcc tggtgggcgg gtgggagtgc gaaaagcact cccagccatg gcaggtgctg 120 gtcgcttcta ggggccgagc agtgtgcgga ggcgtgctgg tccaccctca gtgggtcctg 180 accgcagccc attgtatccg acagaagagc gtgattctgc tggggcgaca ccagccattc 240 taccccgagg acacaggaca ggtgttccag gtctctcaca gttttcccca tcctctgtac 300 aacatgagcc tgctgaaaaa cagatatctg ggacctggcg acgatagctc ccatgatctg 360 atgctgctga ggctgtccga gccagccgaa ctgactgacg ctgtgcaggt cctggatctg 420 cccacccagg agcctgccct gggaaccaca tgttatgctt caggctgggg gagcatcgaa 480 ccagaggaac atctgactcc caagaaactg cagtgcgtgg acctgcacct gattagtaac 540 gatgtgtgtg cacaggtcca ttcacagaag gtgacaaagt tcatgctgtg cgccggctct 600 tggatgggcg gcaagtcaac ttgcagcggg gactccggcg ggccactggt gtgtgatgga 660 gtcctgcagg gcatcacctc ttggggcagt cagccttgtg ccctgcctcg gagaccaagt 720 ctgtacacta aggtggtccg gtataggaaa tggattcagg acactattgc cgctaacccc 780 <210> 64 <211> 260 <212> PRT <213> Artificial Sequence <220> <223> Synthetic consensus PSA amino acid sequence <400> 64 Trp Val Leu Val Val Phe Leu Thr Leu Ser Val Thr Trp Ile Gly Ala 1 5 10 15 Ala Pro Leu Ile Leu Ser Arg Leu Val Gly Gly Trp Glu Cys Glu Lys 20 25 30 His Ser Gln Pro Trp Gln Val Leu Val Ala Ser Arg Gly Arg Ala Val 35 40 45 Cys Gly Gly Val Leu Val His Pro Gln Trp Val Leu Thr Ala Ala His 50 55 60 Cys Ile Arg Gln Lys Ser Val Ile Leu Leu Gly Arg His Gln Pro Phe 65 70 75 80 Tyr Pro Glu Asp Thr Gly Gln Val Phe Gln Val Ser His Ser Phe Pro 85 90 95 His Pro Leu Tyr Asn Met Ser Leu Leu Lys Asn Arg Tyr Leu Gly Pro 100 105 110 Gly Asp Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu Pro 115 120 125 Ala Glu Leu Thr Asp Ala Val Gln Val Leu Asp Leu Pro Thr Gln Glu 130 135 140 Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser Ile Glu 145 150 155 160 Pro Glu Glu His Leu Thr Pro Lys Lys Leu Gln Cys Val Asp Leu His 165 170 175 Leu Ile Ser Asn Asp Val Cys Ala Gln Val His Ser Gln Lys Val Thr 180 185 190 Lys Phe Met Leu Cys Ala Gly Ser Trp Met Gly Gly Lys Ser Thr Cys 195 200 205 Ser Gly Asp Ser Gly Gly Pro Leu Val Cys Asp Gly Val Leu Gln Gly 210 215 220 Ile Thr Ser Trp Gly Ser Gln Pro Cys Ala Leu Pro Arg Arg Pro Ser 225 230 235 240 Leu Tyr Thr Lys Val Val Arg Tyr Arg Lys Trp Ile Gln Asp Thr Ile 245 250 255 Ala Ala Asn Pro 260 <210> 65 <211> 2274 <212> DNA <213> Artificial Sequence <220> <223> Synthetic consensus PSMA nucleic acid sequence <400> 65 tggaacgcac tgcatgagac tgattctgct gtcgcactgg gacggagacc ccggtggctg 60 tgcgctggag cactggtgct ggccggcggg ggattcctgc tgggattcct gtttggctgg 120 tttatcaaaa gctccagcga ggctaccaat attaccccta agcacaataa gaaagcattc 180 ctggatgaac tgaaagccga gaacatcaag aaattcctgt acaacttcac aagaattcca 240 catctggctg gcactgagca gaacttccag ctggcaaaac agatccagag tcagtggaag 300 gaatttgggc tggactcagt ggagctgacc cactacgatg tcctgctgtc ctatccaaat 360 aagactcatc ccaactacat ctctatcatt aacgaagacg gaaatgagat tttcaacacc 420 tctctgtttg aaccccctcc acccggctat gagaatgtca gtgacgtggt ccctccattc 480 tcagccttca gcccccaggg gatgcctgag ggagatctgg tgtacgtcaa ttatgctaga 540 acagaagact tctttaagct ggagagggat atgaaaatca actgttccgg caagatcgtg 600 attgcccggt acgggaaggt gttcagagga aataaggtca aaaacgctca gctggccgga 660 gctaccggcg tgatcctgta cagcgacccc gctgattatt ttgcacctgg cgtgaagtcc 720 tatccagacg gatggaatct gcccggcggg ggagtgcaga ggggaaacat cctgaacctg 780 aatggagccg gcgatcctct gactccagga taccccgcca acgaatacgc ttatcgccgg 840 ggaattgcag aggccgtggg cctgcctagc atcccagtcc atcccattgg ctattacgat 900 gcccagaagc tgctggagaa aatgggcggg agcgctcccc ctgactctag ttggaagggc 960 tccctgaaag tgccttacaa tgtcgggcca ggattcactg ggaacttttc tacccagaag 1020 gtgaaaatgc acatccatag taccagcgag gtgacacgaa tctacaacgt cattggcacc 1080 ctgagaggcg ccgtggagcc tgatcgctat gtcattctgg gaggccacag agactcatgg 1140 gtgttcgggg gaatcgatcc acagagcgga gcagctgtgg tccatgaaat tgtgcgcagc 1200 tttgggaccc tgaagaaga gggatggcga cccaggcgca caatcctgtt cgcatcctgg 1260 gacgccgagg aatttgggct gctgggcagc acagaatggg ccgaggaaaa ttccgcctg 1320 ctgcaggagc gaggggtggc ttacatcaat gcagactca gcattgagg aaactatacc 1380 ctgcgggtgg attgcacc cctgatgtac agtctggtct atacctgac aaggagctg 1440 aaatcacctg acgaggctt cgaagggaaa agcctgtacg aatcctggac tgagagagc 1500 ccatccccg attcagcgg catgcctagg atctctaagc tgggcagtgg gaacgatttt 1560 gaggtgttct tcagcgcct gggaattgcc tctggccgag ctcggtacac aaaaaatttgg 1620 gagactaca agttctccctc ttaccactg tatcacagcg tgtacgagac ttagactg 1680 gtcgagaaat tcaccgaccc cactttaag tatcatctga ccgtggcaca ggtcaggggc 1740 gggatggtgt tcgaactggc caatagcatc gtcctgccat ttgactgtcg agattacgct 1800 gtggtcctgc ggaagtacgc agacagatc tataacatct ccatgaagca cccccaggag 1860 atgaaggcct attctgtgag ttcgattcc ctgttttctg ccgtcaaaa ttcaccgaa 1920 atcgctagta agttttcaga gcgcctgcag gacctggata agtccaatcc catcctgctg 1980 cggattatga acgatcagct gatgttcctg gaaagagcct ttatcgaccc tctgggcctg 2040 cctgatagac cattctacag gcacgtgatc tacgcaccta gttcacataa caagtacgcc 2100 ggcgagtctt tcccagggat ctatgacgct ctgtttgata ttgaatcaaa ggtggacccc 2160 agcaaagcat ggggcgaggt caagagacag atcagcattg cagcctttac agtgcaggcc 2220 gccgccgaaa ccctgtccga agtcgcttac ccatacgatg tccccgatta cgca 2274 <210> 66 <211> 749 <212> PRT <213> Artificial Sequence <220> <223> Synthetic consensus PSMA amino acid sequence <400> 66 Trp Asn Ala Leu His Glu Thr Asp Ser Ala Val Ala Leu Gly Arg Arg 1 5 10 15 Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Gly Phe 20 25 30 Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ser Ser Glu Ala 35 40 45 Thr Asn Ile Thr Pro Lys His Asn Lys Lys Ala Phe Leu Asp Glu Leu 50 55 60 Lys Ala Glu Asn Ile Lys Lys Phe Leu Tyr Asn Phe Thr Arg Ile Pro 65 70 75 80 His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile Gln 85 90 95 Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Thr His Tyr 100 105 110 Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn Tyr Ile Ser 115 120 125 Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn Thr Ser Leu Phe Glu 130 135 140 Pro Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Val Val Pro Pro Phe 145 150 155 160 Ser Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr Val 165 170 175 Asn Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met Lys 180 185 190 Ile Asn Cys Ser Gly Lys Ile Val Ile Ala Arg Tyr Gly Lys Val Phe 195 200 205 Arg Gly Asn Lys Val Lys Asn Ala Gln Leu Ala Gly Ala Thr Gly Val 210 215 220 Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val Lys Ser 225 230 235 240 Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly Val Gln Arg Gly Asn 245 250 255 Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu Thr Pro Gly Tyr Pro 260 265 270 Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala Glu Ala Val Gly Leu 275 280 285 Pro Ser Ile Pro Val His Pro Ile Gly Tyr Tyr Asp Ala Gln Lys Leu 290 295 300 Leu Glu Lys Met Gly Gly Ser Ala Pro Pro Asp Ser Ser Trp Lys Gly 305 310 315 320 Ser Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn Phe 325 330 335 Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Ser Glu Val Thr 340 345 350 Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu Pro Asp 355 360 365 Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp Val Phe Gly Gly 370 375 380 Ile Asp Pro Gln Ser Gly Ala Ala Val Val His Glu Ile Val Arg Ser 385 390 395 400 Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr Ile Leu 405 410 415 Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Gly Ser Thr Glu 420 425 430 Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln Glu Arg Gly Val Ala Tyr 435 440 445 Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val Asp 450 455 460 Cys Thr Pro Leu Met Tyr Ser Leu Val Tyr Asn Leu Thr Lys Glu Leu 465 470 475 480 Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser Trp 485 490 495 Thr Glu Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile Ser 500 505 510 Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu Gly 515,520,525 I Have Only Ser Gly Arg Only Arg Tyr Thr Lys Asn To Glu Thr Lys Asn 530 535 540 Phe Ser Ser Tyr Pro Leu Tyr His Ser Val Tyr Glu Thr Tyr Glu Leu 545 550 555 560 Val Glu Lys Phe Tyr Asp Pro Thr Phe Lys Tyr His Leu Thr Val Ala 565,570,575 Gln Val Arg Gly Gly Met Val Phe Glu Leu Ala Asn Ser Ile Val Leu 580,585,590 Pro Phe Asp Cys Arg Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala Asp 595,600,605 Lys Ile Tyr Asn Ile Ser Met Lys Pro Gln Glu Met Lys Ala Tyr 610 615 620 Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Glu 625 630 635 640 Lys Ser Ser Glu Arg Leu Gln Asp Leu Asp Lys Ser Asn 645,650,655 Pro with Arg and Asn Asp with Gln and Phe with Glu Arg 660,665,670 Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg His 675 680 685 Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser Phe 690 695 700 Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp Pro 705 710 715 720 Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Ser Ile Ala Ala Phe 725 730 735 Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala 740 745 <210> 67 <211> 1014 <212> DNA <213> Artificial Sequence <220> <223> Synthetic consensus STEAP nucleic acid sequence <400> 67 gagagccgca aggacatcac aaatcaggaa gagctgtgga agatgaaacc acggagaaac 60 ctggaggaag acgattacct gcacaaggac accggcgaaa caagtatgct gaaaagacca 120 gtgctgctgc acctgcatca gactgctcat gcagacgagt ttgattgccc ctctgaactg 180 cagcacaccc aggagctgtt cccacagtgg catctgccca tcaagattgc cgctatcatt 240 gcttcactga catttctgta tactctgctg agagaagtga tccaccctct ggccaccagc 300 catcagcagt acttctataa gatccctatt ctggtcatca acaaggtcct gccaatggtg 360 agcatcacac tgctggccct ggtctacctg cctggcgtga tcgcagccat tgtccagctg 420 cacaacggaa caaagtacaa gaagttccca cattggctgg ataagtggat gctgactagg 480 aaacagttcg ggctgctgtc cttctttttc gccgtgctgc acgctatcta cagcctgtcc 540 tatcccatga ggcgctctta ccgatataag ctgctgaact gggcttacca gcaggtgcag 600 cagaacaagg aggacgcatg gattgaacac gatgtgtggc ggatggaaat ctatgtgtct 660 ctgggcattg tcgggctggc catcctggct ctgctggcag tgaccagtat cccttctgtc 720 agtgactcac tgacatggcg cgagtttcac tacattcaga gcaagctggg aatcgtgtcc 780 ctgctgctgg gcaccatcca tgcactgatt tttgcctgga ataagtggat cgatatcaag 840 cagttcgtgt ggtatactcc ccctaccttt atgattgccg tcttcctgcc catcgtggtc 900 ctgattttta agtccatcct gttcctgcct tgtctgcgaa agaaaatcct gaaaatccga 960 catgggtgg aagacgtgac aaaaatcaat aagaccgaaa tctcaagcca gctg 1014 <210> 68 <211> 338 <212> PRT <213> Artificial Sequence <220> <223> Synthesis of STEAP amino acid sequence <400> 68 Glu Ser Arg Lys Asp Ile Thr Asn Gln Glu Glu Leu Trp Lys Met Lys 1 5 10 15 Pro Arg Arg Asn Leu Glu Glu Asp Asp Tyr Leu His Lys Asp Thr Gly 20 25 30 Glu Thr Ser Met Leu Lys Arg Pro Val Leu Leu His Leu His Gln Thr 35 40 45 Ala His Ala Asp Glu Phe Asp Cys Pro Ser Glu Leu Gln His Thr Gln 50 55 60 Glu Leu Phe Pro Gln Trp His Leu Pro Ile Lys Ile Ala Ala Ile Ile 65 70 75 80 Ala Ser Leu Thr Phe Leu Tyr Thr Leu Leu Arg Glu Val Ile His Pro 85 90 95 Leu Ala Thr Ser His Gln Gln Tyr Phe Tyr Lys Ile Pro Ile Leu Val 100 105 110 Ile Asn Lys Val Leu Pro Met Val Ser Ile Thr Leu Leu Ala Leu Val 115 120 125 Tyr Leu Pro Gly Val Ile Ala Ala Ile Val Gln Leu His Asn Gly Thr 130 135 140 Lys Tyr Lys Lys Phe Pro His Trp Leu Asp Lys Trp Met Leu Thr Arg 145 150 155 160 Lys Gln Phe Gly Leu Leu Ser Phe Phe Phe Ala Val Leu His Ala Ile 165 170 175 Tyr Ser Leu Ser Tyr Pro Met Arg Arg Ser Tyr Arg Tyr Lys Leu Leu 180 185 190 Asn Trp Ala Tyr Gln Gln Val Gln Gln Asn Lys Glu Asp Ala Trp Ile 195 200 205 Glu His Asp Val Trp Arg Met Glu Ile Tyr Val Ser Leu Gly Ile Val 210 215 220 Gly Leu Ala Ile Leu Ala Leu Leu Ala Val Thr Ser Ile Pro Ser Val 225 230 235 240 Ser Asp Ser Leu Thr Trp Arg Glu Phe His Tyr Ile Gln Ser Lys Leu 245 250 255 Gly Ile Val Ser Leu Leu Leu Gly Thr Ile His Ala Leu Ile Phe Ala 260 265 270 Trp Asn Lys Trp Ile Asp Ile Lys Gln Phe Val Trp Tyr Thr Pro Pro 275 280 285 Thr Phe Met Ile Ala Val Phe Leu Pro Ile Val Val Leu Ile Phe Lys 290 295 300 Ser Ile Leu Phe Leu Pro Cys Leu Arg Lys Lys Ile Leu Lys Ile Arg 305 310 315 320 His Gly Trp Glu Asp Val Thr Lys Ile Asn Lys Thr Glu Ile Ser Ser 325 330 335 Gln Leu <210> 69 <211> 390 <212> DNA <213> Artificial Sequence <220> <223> Synthetic consensus PSCA nucleic acid sequence <400> 69 gactggacat ggattctgtt tctggtcgcc gccgcaaccc gcgtgcattc tgctggcctg 60 gcactgcagc ctggaaccgc cctgctgtgc tactcttgta aggcccaggt gagtaacgag 120 gactgcctgc aggtcgaaaa ttgtactcag ctgggagagc agtgctggac cgcacggatc 180 agagcagtgg gactgctgac agtcattagc aaagggtgct ccctgaactg tgtggacgat 240 agccaggatt actatgtcgg aaagaaaaac atcacctgct gtgacacaga tctgtgtaat 300 gcttctggcg cccacgctct gcagcccgca gccgctattc tggctctgct gcccgctctg 360 ggactgctgc tgtggggacc cggacagctg 390 <210> 70 <211> 130 <212> PRT <213> Artificial Sequence <220> <223> Synthetic consensus PSCA amino acid sequence <400> 70 Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val His 1 5 10 15 Ser Ala Gly Leu Ala Leu Gln Pro Gly Thr Ala Leu Leu Cys Tyr Ser 20 25 30 Cys Lys Ala Gln Val Ser Asn Glu Asp Cys Leu Gln Val Glu Asn Cys 35 40 45 Thr Gln Leu Gly Glu Gln Cys Trp Thr Ala Arg Ile Arg Ala Val Gly 50 55 60 Leu Leu Thr Val Ile Ser Lys Gly Cys Ser Leu Asn Cys Val Asp Asp 65 70 75 80 Ser Gln Asp Tyr Tyr Val Gly Lys Lys Asn Ile Thr Cys Cys Asp Thr 85 90 95 Asp Leu Cys Asn Ala Ser Gly Ala His Ala Leu Gln Pro Ala Ala Ala 100 105 110 Ile Leu Ala Leu Leu Pro Ala Leu Gly Leu Leu Leu Trp Gly Pro Gly 115 120 125 Gln Leu 130 BRIEF DESCRIPTION OF THE DRAWINGS
[0024] FIG. 1 , comprising FIGS. 1A to 1E , depicts the construction of pTyr.
[0025] FIG. 2 , comprising 2A to 2B , depicts experimental results showing the immunization strategy and induction of cell-mediated immune responses by Tyr DNA vaccination, respectively.
[0026] Figure 3 Depicted are experimental results showing flow fluorescence activated cell sorting (FACS) of control and immunized mice.
[0027] FIG. 4 , comprising FIGS. 4A-4B , depicts experimental results showing the induction of tyrosinase-specific antibodies in immunized mice.
[0028] FIG. 5 , comprising FIGS. 5A-5B , depicts experimental results showing Kaplan-Meier survival curves and tumor volume curves after tumor challenge in control mice and immunized mice, respectively.
[0029] Figure 6, including FIG. 6A to FIG. 6B , depicts experimental results showing MDSC cell populations in immunized and non-immunized mice.
[0030] Figure 7 Depicted are the results of an experiment showing staining for MDSCs in mice immunized with pVax1 and pTyr.
[0031] FIG. 8 , comprising FIGS. 8A to 8B , depicts the results of an experiment showing MCP-1 secretion by MDSCs.
[0032] Fig. 9 Depicted are experimental results showing the phylogenetic relationships of Tyr nucleotide sequences among the indicated organisms.
[0033] Figure 10, including Fig. 10A 10C , depicted are experimental results showing: (A) a schematic diagram showing the plasmid map of pPRAME (also referred to herein as pGX1411); (B) staining of the nuclei of RD and 293T cells and staining for the shared PRAME antigen using DAPI; and (C) western blot of the shared PRAME antigen in lysates from untransfected cells (“control”), cells transfected with pVAX (“pVAX”), and cells transfected with pPRAME (“PRAME-pVAX”).
[0034] FIG. 11 , comprising FIGS. 11A to 11B , depicts the results of an experiment showing that groups of mice were treated with plaque forming units (SFU) / 10 against interferon gamma (IFN-γ). 6 Results of the splenocyte mapping experiment.
[0035] Figure 12, including Fig. 12A 12C , depicted are experimental results showing: (A) a schematic diagram showing the plasmid map of pNY-ESO-1 (also referred to herein as pGX1409); (B) staining of the nuclei of cells with DAPI and staining for the consensus NY-ESO-1 antigen; and (C) western blots of the consensus NY-ESO-1 antigen in RD and 293T lysates from untransfected cells (“control”), cells transfected with pVAX (“pVAX”), and cells transfected with pNY-ESO-1 (“pNY-ESO-1”).
[0036] Fig.13 Figure 3. Groups of mice were challenged with plaque forming units (SFU) / 10 against interferon gamma (IFN-γ). 6 Figure 3. Schematic diagram of the mapping of spleen cells.
[0037] Fig.14 Figure 3. Groups of mice were challenged with plaque forming units (SFU) / 10 against interferon gamma (IFN-γ). 6 Figure 3. Schematic diagram of the mapping of spleen cells.
[0038] Fig.15 Depicted is a schematic diagram showing various cancers and some of their associated cancer antigens.
[0039] Fig.16 Schematic design of TERT constructs is depicted. Synthetic consensus hTERT was designed for human TERT with 5 mutations to eliminate its function. Native RhTERT encodes rhesus TERT with 2 mutations. Both constructs were optimized. The table shows the protein homology between optimized TERT and native TERT identified in humans, rhesus monkeys and mice.
[0040] FIG. 17, including FIG. 17A to FIG. Fig. 17B , depicting characterization of mouse TERT-specific IFN-γ responses to rhesus native peptides. ( FIG. 17A ) Immunization schedule. Mice (n=8 / group) were immunized with native RhTERT and synthetic consensus hTERT by IM / electroporation at weeks 0, 2, and 4. ( Fig. 17B ) The frequency of TERT-specific IFN-γ plaque forming units (SFU) per million splenocytes isolated from vaccinated mice was determined by IFN-γ ELISpot assay using rhesus monkey peptide.
[0041] Figure 18, including 18A to 18C , depicting the characterization of TERT-specific IFN-γ responses in rhesus macaques. ( Fig.18A ) Immunization schedule. Rhesus macaques (n=5 / group) were immunized with native RhTERT or synthetic consensus hTERT and rhIL-12 by IM / electroporation at weeks 0, 4, 8, and 12. (Figure 18B and Fig. 18C ) The frequency of TERT-specific IFN-γ plaque forming units (SFU) per million splenocytes isolated from vaccinated mice was determined by IFN-γ ELISpot assay using native rhesus peptide and synthetic consensus hTERT peptide.
[0042] Fig.19 Depicted are experimental results showing that synthetic consensus hTERT (pGX1434) induces a strong T cell response in mice and slows TC-1 tumor growth. (Left) Mice received three immunizations (with 0 μg, 20 μg, 40 μg, or 60 μg of pGX1434) separated by 2 weeks. T cell responses in mice were assessed at 5 weeks, showing that pGX1434 induces a strong T cell response. (Right) Mice were implanted with 25 x 10 4 TC-1 cells. They were then immunized 4 times with 25 μg of pGX1434, one week apart. Tumor volume was measured over 32 days, showing that mice treated with pGX1434 had reduced tumor volume compared to naive mice.
[0043] Fig. 20 Depicted are the results of experiments showing the immunogenicity of SynCon hTERT (pGX1434) in mice.
[0044] FIG. 21, including FIG. 21A to FIG. Fig.21B , depicts experimental results showing that SyCon hTERT (pGX1434) and mut-hTERT (pGX1406) provide similar control of TC-1 tumor growth.
[0045] FIG. 22, including FIG. 22A to FIG. Fig. 22B , depicts the experimental design for experiments showing the immunogenicity of hTERT in non-human primates (NHPs). FIG22A depicts an exemplary immunization schedule. Fig. 22B A table showing the constructs administered to the different groups is depicted. pGX1434: hTERT; pGX1406: Mut-hTERT; pGX1447: Mut-rhTERT; pGX1404: WT-1; pGX1108: PSMA; pGX6006: rhIL-12.
[0046] FIG. 23, including FIG. 23A to FIG. Fig. 23B , depicts the results of experiments showing that SynCon hTERT breaks self-tolerance in NHPs. FIG. 23A depicts the results of experiments showing that responses to native rhesus TERT were detected at PD3 and PD4 in Group 1 animals. Fig. 23B Depicted are the results of experiments showing that responses to native rhesus TERT were detected at PD3 and PD4 in Group 2 animals.
[0047] FIG. 24, including FIG. 24A to FIG. Fig.24C , depicts experimental results showing that SynCon design enables breaking of self-tolerance. FIG. 24A depicts a table showing the percent identity of different constructs to the native sequence. FIG. 24B depicts experimental results showing TERT-specific IFNγ responses. Fig.24C Depicted are the results of an experiment showing a TERT-specific IFNγ response in rhesus macaques.
[0048] FIG. 25, including FIG. 25A to FIG. Fig.25B , depicts the results of experiments showing the NHP immunogenicity of SynCon hTERT. FIG. 25A depicts the results of experiments showing the TERT response generated using a combination of SynCon hTERT, PSMA, WT-1, and IL-12. Fig.25B Depicted are the results of experiments showing TERT responses generated using a combination of mut-hTERT, PSMA, WT-1, and IL-12.
[0049] FIG. 26, including FIG. 26A to FIG. Fig.26C , depicts experimental results showing the NHP immunogenicity of SynCon hTERT. FIG26A depicts experimental results showing TERT responses generated using a combination of TERT, PSMA, WT-1, and IL-12. FIG26B depicts experimental results showing PSMA responses generated using a combination of TERT, PSMA, WT-1, and IL-12. Fig.26C Depicted are the results of experiments showing WT-1 responses generated using a combination of TERT, PSMA, WT-1, and IL-12.
[0050] FIG. 27, including FIG. 27A to FIG. Fig.27B , depicts experimental results showing the breadth of the multivalent SynCon vaccine. Figure 27A depicts the immunization schedule used. Fig.27B The percentage of antigen-specific T cells identified after immunization is depicted.
[0051] FIG. 28, including FIG. 28A to FIG. Fig.28B, depicts experimental results showing that multivalent SynCon vaccines reduce tumor burden and increase survival. Figure 28A depicts the immunization schedule used. Fig.28B Depicted are the mean tumor volume and % survival of animals immunized with a combination of WT1, PSMA, and SynCon mTERT.
[0052] Details
[0053] The present invention relates to an immunogenic composition comprising a synthetic consensus TERT antigen alone or in combination with an inhibitor of at least one other cancer antigen or immune checkpoint protein, and a method for treating a disease or condition using the composition. In one embodiment, the immunogenic composition comprises TERT and at least one other cancer antigen consensus sequence. The cancer antigen consensus sequence that may be included in the immunogenic composition includes but is not limited to tyrosinase (Tyr) (preferentially expressed antigen in melanoma (PRAME)), tyrosinase-related protein 1 (Tyrp1), cancer testis antigen (NY-ESO-1), hepatitis B virus antigen, prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), prostate six transmembrane epithelial antigen (STEAP), prostate stem cell antigen (PSCA), fibroblast activation protein (FAP), follicle stimulating hormone receptor (FSHR) and Wilms tumor 1 antigen (WT-1). In one embodiment, the immunogenic composition of the present invention can provide a combination of cancer antigens for preventing or treating cancer in a subject in need.
[0054] One way to design the nucleic acid of recombinant cancer antigens and the corresponding encoded amino acid sequence is to introduce mutations that change specific amino acids in the complete amino acid sequence of natural cancer antigens. The introduction of mutations will not change the cancer antigen so much that it cannot be generally applied across mammalian subjects (such as human or dog subjects), but the antigen is changed enough to break tolerance or be treated as an exogenous antigen to produce an immune response. Another way can be to produce a common recombinant cancer antigen with at least 85% and up to 99% amino acid sequence identity, at least 90% and up to 98% sequence identity, at least 93% and up to 98% sequence identity, or at least 95% and up to 98% sequence identity with the corresponding natural cancer antigen. In some cases, the recombinant cancer antigen has 95%, 96%, 97%, 98% or 99% amino acid sequence identity with the corresponding natural cancer antigen. The natural cancer antigen is an antigen that is generally associated with a specific cancer or cancer tumor. Depending on the cancer antigen, the consensus sequence of the cancer antigen can be across mammalian species or within a subtype of a species or across virus strains or serotypes. Some cancer antigens will not vary greatly with the wild-type amino acid sequence of cancer antigens. Some cancer antigens have nucleic acid / amino acid sequences that have such a large difference between species that consensus sequences cannot be produced. In these cases, recombinant cancer antigens that can break tolerance and produce immune responses are produced, and the recombinant cancer antigens have at least 85% and up to 99% amino acid sequence identity, at least 90% and up to 98% sequence identity, at least 93% and up to 98% sequence identity, or at least 95% and up to 98% sequence identity with the corresponding natural cancer antigen. In some cases, the recombinant cancer antigen has 95%, 96%, 97%, 98% or 99% amino acid sequence identity with the corresponding natural cancer antigen. The aforementioned methods can be combined so that the final recombinant cancer antigen has the percentage similarity with the natural cancer antigen amino acid sequence as discussed above.
[0055] The recombinant cancer antigen can induce antigen-specific T cells and / or high-titer antibody responses, thereby inducing or inducing an immune response to a cancer or tumor expressing the antigen or to the cancer or tumor reaction. In some embodiments, the induced or triggered immune response can be a cell, a humoral, or a cell and humoral immune response. In some embodiments, the induced or triggered cellular immune response may include the induction or secretion of interferon-γ (IFN-γ) and / or tumor necrosis factor α (TNF-α). In other embodiments, the induced or triggered immune response can reduce or inhibit one or more immunosuppressive factors that promote the growth of tumors or cancers expressing the antigen, for example, but not limited to factors that downregulate MHC presentation, factors that upregulate antigen-specific regulatory T cells (Treg), PD-L1, FasL, cytokines such as IL-10 and TFG-β, tumor-associated macrophages, tumor-associated fibroblasts, soluble factors produced by immunosuppressive cells, CTLA-4, PD-1, MDSC, MCP-1, and immune checkpoint molecules.
[0056] The immunogenic composition can be further combined with antibodies for checkpoint inhibitors such as PD-1 and PDL-1 to enhance the stimulation of cellular and humoral immune responses. Anti-PD-1 or anti-PDL-1 antibodies are used to prevent PD-1 or PDL-1 from inhibiting T cells and / or B cell responses. In general, by designing cancer antigens to be recognized by the immune system, it can help overcome other forms of immunosuppression produced by tumor cells, and these immunogenic compositions can be used in combination with suppression or inhibition therapy (such as anti-PD-1 and anti-PDL-1 antibody therapy) to further enhance T cells and / or B cell responses.
[0057] 1. Definition
[0058] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art. In the event of a conflict, this document (including definitions) shall prevail. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in the implementation or testing of the present invention. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods and embodiments disclosed herein are merely illustrative and are not intended to be limiting. The terms used herein are only for the purpose of describing specific embodiments and are not intended to be limiting.
[0059] As used herein, the terms "comprises," "including," "having," "having," "may," "containing," and variations thereof are intended to be open transitional phrases, terms, or words that do not exclude the possibility of additional actions or structures. The singular forms "a," "and," and "the" include plural references unless the context clearly dictates otherwise. The present disclosure also encompasses other embodiments that "comprise," "consist of," and "consist essentially of" the embodiments or components set forth herein, whether or not explicitly set forth.
[0060] For the citation of numerical ranges herein, every intervening number therebetween is expressly included with equal precision. For example, for the range of 6-9, in addition to 6 and 9, the values 7 and 8 are included, and for the range of 6.0-7.0, the values 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 and 7.0 are expressly included.
[0061] As used herein, "adjuvant" means any molecule added to the immunogenic compositions described herein to enhance the immunogenicity of the antigens encoded by the nucleic acid molecules and encoding nucleic acid sequences described below.
[0062] As used herein, "antibody" means an antibody of the class IgG, IgM, IgA, IgD or IgE or a fragment or derivative thereof, including Fab, F(ab')2, Fd and single-chain antibodies, diabodies, bispecific antibodies, bifunctional antibodies and derivatives thereof. The antibody may be an antibody isolated from a serum sample of a mammal, a polyclonal antibody, an affinity-purified antibody or a mixture thereof, the antibody exhibiting sufficient binding specificity to a desired epitope or a sequence derived therefrom.
[0063] As used herein, "coding sequence" or "coding nucleic acid" means a nucleic acid (RNA or DNA molecule) comprising a nucleotide sequence encoding a protein. The coding sequence may also include start and stop signals operably linked to regulatory elements (including promoters and polyadenylation signals) capable of directing expression in cells of an individual or mammal to which the nucleic acid is administered.
[0064] As used herein, "complementary" or "complementary" refers to nucleic acids and can refer to Watson-Crick (eg, AT / U and CG) or Hoogsteen base pairing between nucleotides or nucleotide analogs of a nucleic acid molecule.
[0065] As used herein, "consensus" or "consensus sequence" means a polypeptide sequence based on an analysis of an alignment of multiple sequences of the same gene from different organisms. Nucleic acid sequences encoding the consensus polypeptide sequence can be prepared. Immunogenic compositions comprising proteins containing the consensus sequence and / or nucleic acids encoding such proteins can be used to induce broad immunity against the antigen.
[0066] "Electroporation," "electroperization," or "electrokinetic enhancement" ("EP") as used interchangeably herein means the use of transmembrane electric field pulses to induce microscopic passages (pores) in biological membranes; their presence allows biomolecules such as plasmids, oligonucleotides, siRNA, drugs, ions, and water to pass from one side of the cell membrane to the other.
[0067] As used herein for nucleic acid sequences, "fragment" means a nucleic acid sequence or portion thereof encoding a polypeptide capable of eliciting an immune response in a mammal, the polypeptide cross-reacting with an antigen disclosed herein. The fragment may be a DNA fragment selected from at least one of the various nucleotide sequences encoding protein fragments described below. A fragment may contain at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of one or more nucleic acid sequences described below. In some embodiments, a fragment may comprise at least 20 nucleotides or more, at least 30 nucleotides or more, at least 40 nucleotides or more, at least 50 nucleotides or more, at least 60 nucleotides or more, at least 70 nucleotides or more, at least 80 nucleotides or more, at least 90 nucleotides or more, at least 100 nucleotides or more, at least 150 nucleotides or more, at least 200 nucleotides or more, at least 250 nucleotides or more, at least 300 nucleotides or more, at least 350 nucleotides or more, at least 400 nucleotides or more, at least 450 nucleotides or more, at least 500 nucleotides or more, at least 550 nucleotides or more, at least 600 nucleotides or more, at least 650 nucleotides or more, at least 700 nucleotides or more, at least 750 nucleotides or more, at least 800 nucleotides or more, at least 850 nucleotides or more, at least 900 nucleotides or more, at least 950 nucleotides or more, or at least 1000 nucleotides or more of at least one of the nucleic acid sequences described below.
[0068] With respect to polypeptide sequences, "fragment" or "immunogenic fragment" means a polypeptide capable of eliciting an immune response in a mammal, said polypeptide cross-reacting with an antigen disclosed herein. A fragment may be a polypeptide fragment selected from at least one of the various amino acid sequences described below. A fragment of a common protein may comprise at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the common protein. In some embodiments, a fragment of a consensus protein may comprise at least 20 amino acids or more, at least 30 amino acids or more, at least 40 amino acids or more, at least 50 amino acids or more, at least 60 amino acids or more, at least 70 amino acids or more, at least 80 amino acids or more, at least 90 amino acids or more, at least 100 amino acids or more, at least 110 amino acids or more, at least 120 amino acids or more, at least 130 amino acids or more, at least 140 amino acids or more, at least 150 amino acids or more, at least 160 amino acids or more, at least 170 amino acids or more, at least 180 amino acids or more amino acids of a protein sequence disclosed herein.
[0069] As used herein, "genetic construct" refers to a DNA or RNA molecule comprising a nucleotide sequence encoding a protein. The coding sequence includes start and stop signals operably linked to regulatory elements (including promoters and polyadenylation signals) that can direct expression in the cells of an individual to which the nucleic acid molecule is administered. As used herein, the term "expressible form" refers to a gene construct containing the necessary regulatory elements operably linked to the coding sequence encoding the protein so that when present in the cells of the individual, the coding sequence will be expressed.
[0070] As used herein, the term "homology" refers to the degree of complementarity. Partial homology or complete homology (i.e., identity) may exist. A partially complementary sequence that at least partially inhibits hybridization of a completely complementary sequence to a target nucleic acid is referred to as using the functional term "substantially homologous". When used to refer to a double-stranded nucleic acid sequence such as a cDNA or genomic clone, as used herein, the term "substantially homologous" refers to a probe that can hybridize with the chain of a double-stranded nucleic acid sequence under conditions of low stringency. When used to refer to a single-stranded nucleic acid sequence, as used herein, the term "substantially homologous" refers to a probe that can hybridize with a single-stranded nucleic acid template sequence (i.e., be complementary to it) under conditions of low stringency.
[0071] As used herein in the context of two or more nucleic acid or polypeptide sequences, "identical" or "identity" means that the sequence has a specified percentage of residues that are identical over a specified region. Percentages can be calculated as follows: the two sequences are optimally aligned, the two sequences are compared over a specified region, the number of positions where identical residues are present in the two sequences is determined to obtain the number of matching positions, the number of matching positions is divided by the total number of positions in the specified region, and the result is multiplied by 100 to obtain the percentage of sequence identity. In the case where the two sequences have different lengths or the alignment produces one or more staggered ends and the specified comparison region includes only a single sequence, the residues of the single sequence are included in the denominator of the calculation rather than the numerator. When comparing DNA and RNA, thymine (T) and uracil (U) can be considered to be equivalent. Identity is obtained artificially or by using a computer sequence algorithm such as BLAST or BLAST 2.0.
[0072] As used herein, "immune response" means the activation of a host's immune system, such as a mammal's immune system, in response to the introduction of an antigen. The immune response can be in the form of a cellular response or a humoral response, or both.
[0073] As used herein, "nucleic acid" or "oligonucleotide" or "polynucleotide" means at least two nucleotides covalently linked together. The description of a single strand also defines the sequence of the complementary strand. Therefore, nucleic acid also includes the complementary strand of the described single strand. Many variants of nucleic acid can be used for the same purpose as a given nucleic acid. Therefore, nucleic acid also includes substantially identical nucleic acids and their complementary sequences. The single strand provides a probe that can hybridize with a target sequence under stringent hybridization conditions. Therefore, nucleic acid also includes probes that hybridize under stringent hybridization conditions.
[0074] Nucleic acids can be single-stranded or double-stranded, or can contain portions of double-stranded and single-stranded sequences. Nucleic acids can be DNA (genomic DNA and cDNA), RNA, or hybrids, wherein nucleic acids can contain a combination of deoxyribonucleotides and ribonucleotides, and a combination of bases (including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, and isoguanine). Nucleic acids can be obtained by chemical synthesis or by recombinant methods.
[0075] As used herein, "operably linked" means that the expression of a gene is under the control of a promoter to which it is spatially linked. A promoter may be located 5' (upstream) or 3' (downstream) of a gene under its control. The distance between a promoter and a gene may be about the same as the distance between the promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variations in this distance may be tolerated without loss of promoter function.
[0076] As used herein, "peptide," "protein," or "polypeptide" may mean a linked sequence of amino acids, and may be natural, synthetic, or modified, or a combination of natural and synthetic.
[0077] As used herein, "promoter" means a molecule of synthetic or natural origin that can confer, activate or enhance the expression of a nucleic acid in a cell. A promoter may contain one or more specific transcriptional regulatory sequences to further enhance the expression of the sequence and / or change its spatial expression and / or temporal expression. A promoter may also contain distal enhancer or repressor elements up to several thousand base pairs away from the transcription start site. Promoters may be derived from sources including viruses, bacteria, fungi, plants, insects and animals. A promoter may constitutively or differentially regulate the expression of a genomic component for cells, tissues or organs where expression occurs or for the developmental stage at which expression occurs, or in response to external stimuli (such as physiological stress, pathogens, metal ions or inducers). Representative examples of promoters include bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator-promoter, tac promoter, SV40 late promoter, SV40 early promoter, RSV-LTR promoter, CMV IE promoter, SV40 early promoter or SV 40 late promoter and CMV IE promoter.
[0078] "Signal peptide" and "leader sequence" are used interchangeably herein and refer to an amino acid sequence that can be attached to the amino terminus of a protein described herein. The signal peptide / leader sequence generally directs the localization of the protein. The signal peptide / leader sequence used herein can promote secretion of a protein from a cell that produces it. After secretion from the cell, the signal peptide / leader sequence is generally cleaved from the rest of the protein (generally referred to as the mature protein). The signal peptide / leader sequence is attached to the amino terminus (i.e., N terminus) of the protein.
[0079] As used herein, "stringent hybridization conditions" means conditions under which a first nucleic acid sequence (e.g., a probe) will hybridize to a second nucleic acid sequence (e.g., a target) (such as in a complex mixture of nucleic acids). Stringent conditions are sequence-dependent and are different in different situations. Stringent conditions may be selected to be about 5-10°C lower than the thermal melting point (Tm) of a specific sequence at a defined ionic strength pH. Tm may be the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (due to the presence of an excess of the target sequence, 50% of the probes are occupied at equilibrium at Tm). Stringent conditions may be those conditions at pH 7.0 to 8.3 where the salt concentration is less than about 1.0 M sodium ions, such as a sodium ion concentration of about 0.01-1.0 M (or other salts), and a temperature of at least about 30°C (for short probes (e.g., about 10-50 nucleotides)) and at least about 60°C (for long probes (e.g., greater than about 50 nucleotides)). Stringent conditions can also be achieved by adding destabilizing agents such as formamide. For selective or specific hybridization, a positive signal can be at least 2 to 10 times the background hybridization. Exemplary stringent hybridization conditions include the following conditions: 50% formamide, 5x SSC and 1% SDS, incubated at 42°C, or 5x SSC, 1% SDS, incubated at 65°C, washed in 0.2x SSC and 0.1% SDS at 65°C.
[0080] As used herein, "subject" may refer to a mammal that wants or needs to be immunized with the immunogenic composition described herein. The mammal may be a human, chimpanzee, dog, cat, horse, cow, mouse or rat.
[0081] As used herein, "substantially complementary" means that a first sequence is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 180, 270, 360, 97%, 98%, or 99% identity over a region of 450, 540 or more nucleotides or amino acids, or the two sequences hybridize under stringent hybridization conditions.
[0082] As used herein, "substantially identical" means that if the first sequence is substantially complementary to the complement of the second sequence, then the first and second sequences are 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over a region or with respect to a nucleic acid of 100, 180, 270, 360, 450, 540 or more nucleotides or amino acids.
[0083] As used herein, "treating" or "treatment" may mean protecting an animal from a disease by preventing, inhibiting, suppressing, or completely eliminating the disease. Preventing a disease includes administering the immunogenic composition of the present invention to an animal prior to the onset of the disease. Suppressing a disease includes administering the immunogenic composition of the present invention to an animal after the onset of the disease but before its clinical manifestation. Suppressing a disease includes administering the immunogenic composition of the present invention to an animal after the clinical manifestation of the disease.
[0084] "Variant" as used herein with respect to nucleic acids means (i) a portion or fragment of a reference nucleotide sequence; (ii) a complementary sequence to a reference nucleotide sequence or a portion thereof; (iii) a nucleic acid substantially identical to a reference nucleic acid or its complementary sequence; or (iv) a nucleic acid that hybridizes to a reference nucleic acid, its complementary sequence, or a sequence substantially identical thereto under stringent conditions.
[0085] For a peptide or polypeptide, "variant" refers to a peptide or polypeptide that differs in amino acid sequence by insertion, deletion or conservative substitution of amino acids, but retains at least one biological activity. Variant may also mean a protein having an amino acid sequence that is substantially identical to a reference protein having an amino acid sequence that retains at least one biological activity. Conservative substitution of amino acids, i.e., replacing amino acids with different amino acids having similar properties (e.g., hydrophobicity, degree and distribution of charged regions), is generally considered in the art to include minor changes. As understood in the art, these minor changes may be identified in part by considering the hydropathic index of amino acids. Kyte et al., J. Mol. Biol. 157: 105-132 (1982). The hydropathic index of amino acids is based on considerations of their hydrophobicity and charge. It is known in the art that amino acids with similar hydropathic indexes may be substituted and still retain protein function. In one aspect, amino acids with hydropathic indexes of ± 2 are substituted. The hydrophilicity of amino acids may also be used to reveal substitutions that may produce proteins that retain biological function. Considering the hydrophilicity of amino acids in the context of peptides allows calculation of the maximum local average hydrophilicity of the peptides, which is a useful metric that has been reported to be closely related to antigenicity and immunogenicity. U.S. Patent No. 4,554,101 is fully incorporated herein by reference. As understood in the art, substitution of amino acids with similar hydrophilicity values can produce peptides that retain biological activity, such as immunogenicity. Amino acids with hydrophilicity values that differ from each other within ± 2 can be used for substitution. The hydrophobicity index and hydrophilicity value of amino acids are affected by the specific side chains of the amino acids. Consistent with this observation, amino acid substitutions that are compatible with biological functions are considered to depend on amino acids, and specifically the relative similarity of the side chains of those amino acids, as revealed by hydrophobicity, hydrophilicity, charge, size, and other properties.
[0086] Variant can be the nucleic acid sequence that is substantially identical on the full gene sequence of total length or its fragment. Nucleic acid sequence can have 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homogeneity on the gene sequence of total length or its fragment. Variant can be the amino acid sequence that is substantially identical on the amino acid sequence of total length or its fragment. Amino acid sequence can have 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homogeneity on the amino acid sequence of total length or its fragment.
[0087] As used herein, "vector" means a nucleic acid sequence containing a replication origin. The vector may be a viral vector, a bacteriophage, a bacterial artificial chromosome, or a yeast artificial chromosome. The vector may be a DNA or RNA vector. The vector may be an autonomously replicating extrachromosomal vector, and in one embodiment, an expression plasmid. The vector may contain or include one or more heterologous nucleic acid sequences.
[0088] 2. Synthetic consensus TERT
[0089] The present invention provides an optimized consensus sequence of a TERT antigen. In one embodiment, an antigen encoded by the optimized consensus sequence is capable of eliciting an immune response in a mammal. In one embodiment, an antigen encoded by the optimized consensus sequence may contain one or more epitopes that make it particularly effective as an immunogen that can induce an immune response against it.
[0090] The optimized consensus sequence can be a consensus sequence derived from two or more natural TERT antigens. The optimized consensus sequence may include a consensus sequence and / or one or more modifications for improving expression. Modifications may include codon optimization, RNA optimization, the addition of a kozak sequence to increase translation initiation, and / or the addition of an immunoglobulin leader sequence to enhance immunogenicity. The TERT antigen encoded by the optimized consensus sequence may include a signal peptide, such as an immunoglobulin signal peptide, for example, but not limited to an immunoglobulin E (IgE) or an immunoglobulin (IgG) signal peptide. In some embodiments, the antigen encoded by the optimized consensus sequence may include a hemagglutinin (HA) tag. The TERT antigen encoded by the optimized consensus sequence can be designed to elicit a stronger cellular and / or humoral immune response than the corresponding natural antigen. The TERT antigen encoded by the optimized consensus sequence can be designed to break tolerance and synergize with anticancer immunotherapy.
[0091] In one embodiment, the optimized consensus TERT is designed to break tolerance to native human TERT. In one embodiment, the human optimized consensus TERT coding sequence is as shown in SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53 or SEQ ID NO:55. In one embodiment, the human optimized consensus TERT encoded antigen has an amino acid sequence as shown in SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54 or SEQ ID NO:56.
[0092] In one embodiment, the optimized consensus TERT is designed to break tolerance to native mouse TERT. In one embodiment, the mouse optimized consensus TERT coding sequence is as shown in SEQ ID NO:49 or SEQ ID NO:51. In one embodiment, the mouse optimized consensus TERT encoded antigen has an amino acid sequence as shown in SEQ ID NO:50 or SEQ ID NO:52.
[0093] In one embodiment, the optimized consensus TERT is designed to break tolerance to native rhesus TERT. In one embodiment, the rhesus optimized consensus TERT coding sequence is as shown in SEQ ID NO:53 or SEQ ID NO:55. In one embodiment, the rhesus optimized consensus TERT encoded antigen has an amino acid sequence as shown in SEQ ID NO:54 or SEQ ID NO:56.
[0094] In one embodiment, the optimized consensus sequence encoding the TERT antigen is operably linked to one or more regulatory elements. In one embodiment, the regulatory element is a leader sequence. In one embodiment, the optimized consensus DNA sequence operably linked to the IgE leader sequence encoding sequence is shown in SEQ ID NO: 45, SEQ ID NO: 49 and SEQ ID NO: 53. In one embodiment, the optimized consensus sequence encoding the TERT antigen operably linked to the IgE leader sequence is as shown in SEQ ID NO: 46, SEQ ID NO: 50 and SEQ ID NO: 54.
[0095] In one embodiment, the regulatory element is a start codon. Therefore, in one embodiment, the present invention relates to a nucleic acid sequence as shown in SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:55, or a fragment or homologue thereof, operably linked to a nucleotide sequence comprising a start codon at the 5' end. In one embodiment, the present invention relates to an amino acid sequence as shown in SEQ ID NO:48, SEQ ID NO:52 or SEQ ID NO:56, or a fragment or homologue thereof, operably linked to an amino acid (e.g., methionine) encoded by a start codon at the N-terminus.
[0096] In one embodiment, the regulatory element is at least one stop codon. Therefore, in one embodiment, the present invention relates to the nucleic acid sequence shown in SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53 or SEQ ID NO:55, or a fragment or homologue thereof, operably linked to a nucleotide sequence comprising at least one stop codon at the 3' end. In one embodiment, the nucleotide sequence is operably linked to two stop codons to increase the efficiency of translation termination.
[0097] In one embodiment, the optimized consensus sequence encoding the TERT antigen may encode a peptide having an amino acid sequence as shown in SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, or SEQ ID NO: 56. In one embodiment, the optimized consensus sequence may have a nucleotide sequence as shown in SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, or SEQ ID NO: 55. In some embodiments, the sequence may be a nucleotide sequence having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity over the entire length of the nucleotide sequence as shown in SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, or SEQ ID NO: 55. In other embodiments, the sequence can be a nucleotide sequence that encodes an amino acid sequence that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical over the entire length of the amino acid sequence shown in SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54 or SEQ ID NO:56.
[0098] In some embodiments, the optimized consensus TERT antigen may be encoded by an RNA from a DNA sequence having at least about 96%, 97%, 98%, 99% or 100% identity over the entire length of the nucleic acid sequence shown in SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, or SEQ ID NO: 55. In some embodiments, the optimized consensus TERT antigen may be encoded by an RNA encoding an amino acid sequence having at least about 96%, 97%, 98%, 99% or 100% identity over the entire length of the amino acid sequence shown in SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, or SEQ ID NO: 56.
[0099] The TERT antigen encoded by the optimized consensus sequence can be a peptide having the amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8. In some embodiments, the antigen can have an amino acid sequence that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the entire length of the amino acid sequence shown in SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, or SEQ ID NO: 56.
[0100] Immunogenic fragments of proteins having amino acid sequences homologous to immunogenic fragments of SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, or SEQ ID NO:56 can be provided. Such immunogenic fragments can comprise at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of a protein having 95% homology to SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, or SEQ ID NO:56. Some embodiments relate to immunogenic fragments having 96% homology to immunogenic fragments of the consensus protein sequences herein. Some embodiments relate to immunogenic fragments having 97% homology to immunogenic fragments of the consensus protein sequences herein. Some embodiments relate to immunogenic fragments with 98% homology to the immunogenic fragments of the consensus protein sequences herein. Some embodiments relate to immunogenic fragments with 99% homology to the immunogenic fragments of the consensus protein sequences herein. In some embodiments, the immunogenic fragments include a leader sequence, such as, for example, an immunoglobulin leader sequence, such as an IgE leader sequence. In some embodiments, the immunogenic fragments do not contain a leader sequence.
[0101] In one embodiment, the immunogenic fragment of the optimized consensus TERT antigen encodes at least one immunodominant or subimmunodominant epitope of the full-length optimized consensus TERT antigen.
[0102] Some embodiments relate to immunogenic fragments of SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, or SEQ ID NO:55 that comprise at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the full length of SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, or SEQ ID NO:55. The immunogenic fragment may have at least 96%, at least 97%, at least 98%, or at least 99% homology to a fragment of SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, or SEQ ID NO:55. In some embodiments, the immunogenic fragment includes a sequence encoding a leader sequence, such as, for example, an immunoglobulin leader sequence, such as an IgE leader sequence. In some embodiments, the fragment does not contain a coding sequence encoding a leader sequence.
[0103] 3. Immunogenic compositions
[0104] In one embodiment, the immunogenic composition of the present invention may include a synthetic consensus TERT antigen, a fragment thereof, or a variant thereof. In one embodiment, the TERT antigen is a human TERT antigen (hTERT). hTERT is a human telomerase reverse transcriptase that synthesizes a TTAGGG tag at the end of telomerase to prevent cell death caused by the shortening of chromosomes. Hyperproliferative cells may have abnormally high hTERT expression. Abnormal expression of hTERT may also occur in hyperproliferative cells infected with HCV and HPV. Therefore, the immunotherapy of HPV and HCV can be enhanced by targeting cells expressing hTERT at abnormal levels. HPV and HCV antigens are discussed in more detail below. In one aspect, the hTERT cancer antigen may be further defined by U.S. Patent Application No. 14 / 139,660, filed December 23, 2013, which is incorporated by reference in its entirety.
[0105] In one embodiment, the TERT antigen is a non-human TERT antigen. Non-human TERT antigens include, but are not limited to, mouse TERT (mTERT) and rhesus monkey TERT (rhTERT).
[0106] TERT expression in dendritic cells transfected with TERT gene can induce CD8 + Cytotoxic T cells and induce CD4+ T cells. Thus, the use of hTERT expression in antigen presenting cells (APCs) to delay senescence and maintain their ability to present selected antigens can be used in immunotherapy approaches such as those described herein.
[0107] TERT antigens may be associated with or expressed in a variety of cancers, including, but not limited to, melanoma, prostate cancer, liver cancer, cervical cancer, recurrent respiratory papillomatosis (RRP), anal cancer, head and neck cancer, and blood cancers. Thus, when including the TERT antigens described herein, the vaccine may be used to treat subjects with a variety of cancers, including, but not limited to, melanoma, prostate cancer, liver cancer, cervical cancer, recurrent respiratory papillomatosis (RRP), anal cancer, head and neck cancer, and blood cancers.
[0108] TERT antigens can induce antigen-specific T cells and / or high-titer antibody responses, thereby inducing or inducing an immune response to a cancer or tumor expressing the antigen or to the cancer or tumor reaction. In some embodiments, the induced or triggered immune response can be a cellular immune response, a humoral immune response, or both a cellular and humoral immune response. In some embodiments, the induced or triggered cellular immune response may include the induction or secretion of interferon-γ (IFN-γ) and / or tumor necrosis factor α (TNF-α). In other embodiments, the induced or triggered immune response can reduce or inhibit one or more immunosuppressive factors that promote the growth of tumors or cancers expressing the antigen, for example, but not limited to factors that downregulate MHC presentation, factors that upregulate antigen-specific regulatory T cells (Treg), PD-L1, FasL, cytokines such as IL-10 and TFG-β, tumor-associated macrophages, tumor-associated fibroblasts, soluble factors produced by immunosuppressive cells, CTLA-4, PD-1, MDSC, MCP-1, and immune checkpoint molecules, described in more detail below.
[0109] TERT antigens may comprise protein epitopes that make them particularly effective as immunogens against which an anti-TERT immune response may be induced. TERT antigens may comprise full-length translation products, variants thereof, fragments thereof, or combinations thereof. TERT antigens may comprise a common protein.
[0110] The nucleic acid sequence encoding TERT antigen or a common TERT antigen can be optimized for codon usage and corresponding RNA transcripts. The nucleic acid encoding TERT antigen or a common TERT antigen can be codons and RNA optimized for expression. In some embodiments, the nucleic acid sequence encoding TERT antigen or a common TERT antigen may include a Kozak sequence (e.g., GCCACC) to enhance the efficiency of translation. The nucleic acid encoding TERT antigen or a common TERT antigen may include multiple stop codons (e.g., TGA TGA) to enhance the efficiency of translation termination.
[0111] The nucleic acid encoding the TERT antigen or the shared TERT antigen may also encode an immunoglobulin E (IgE) leader sequence. The nucleic acid encoding the TERT antigen or the shared TERT antigen may further encode an IgE leader sequence so that the amino acid sequence of the IgE leader sequence is connected to the amino acid sequence of the TERT antigen or the shared TERT antigen by a peptide bond, respectively. The nucleic acid encoding the TERT antigen or the shared TERT antigen may also include a nucleotide sequence encoding the IgE leader sequence. In some embodiments, the nucleic acid encoding the TERT antigen or the shared TERT antigen does not have or does not contain a nucleotide sequence encoding the IgE leader sequence.
[0112] In some embodiments, the nucleic acid encoding the TERT antigen or the shared TERT antigen may be a heterologous nucleic acid sequence and / or contain one or more heterologous nucleic acid sequences. The nucleic acid encoding the TERT antigen or the shared TERT antigen may be mutated relative to the wild-type TERT antigen so that one or more amino acids or residues in the amino acid sequence of the TERT antigen or the shared TERT antigen are replaced or substituted by another amino acid or residue, respectively. The nucleic acid encoding the TERT antigen or the shared TERT antigen may be mutated relative to the wild-type TERT antigen so that one or more residues in the amino acid sequence of the TERT antigen or the shared TERT antigen are replaced or substituted by another residue, respectively, so that the immune system of the mammal administered with the nucleic acid encoding the TERT antigen or the shared TERT antigen, the TERT antigen or the shared TERT antigen or a combination thereof is no longer tolerant to TERT. The nucleic acid encoding the TERT antigen or the shared TERT antigen may be mutated relative to the wild-type TERT antigen so that arginine 589, aspartic acid 1005, or arginine 589 and aspartic acid 1005 in the amino acid sequence of the TERT antigen or the shared TERT antigen are replaced or substituted by a tyrosine residue.
[0113] In one aspect, the TERT antigen can be a nucleic acid sequence of SEQ ID NO: 23 or SEQ ID NO: 57, which can encode amino acid sequences of SEQ ID NO: 24 and SEQ ID NO: 58, respectively. SEQ ID NO: 23 and SEQ ID NO: 57 encode a TERT antigen linked to an IgE leader sequence. In one embodiment, the TERT antigen can be linked to an IgE leader sequence and an HA tag. In other embodiments, the TERT antigen can be free of or not linked to an IgE leader sequence and / or an HA tag.
[0114] In some embodiments, the TERT antigen can be a nucleic acid sequence that is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the entire length of the nucleic acid sequence shown in SEQ ID NO:23 or SEQ ID NO:57. In other embodiments, the TERT antigen can be a nucleic acid sequence encoding an amino acid sequence that is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical over the entire length of the amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. The TERT antigen can be an amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity over the entire length of the amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58.
[0115] Some embodiments relate to nucleic acid sequences encoding proteins homologous to TERT antigens, immunogenic fragments of TERT antigens, and immunogenic fragments of homologous proteins. Such nucleic acid molecules encoding immunogenic proteins having up to 95% homology to the sequence, up to 96% homology to the sequence, up to 97% homology to the sequence, up to 98% homology to the sequence, and up to 99% homology to the sequence can be provided. Similarly, nucleic acid sequences encoding immunogenic fragments as set forth herein and immunogenic fragments of proteins homologous to the proteins set forth herein are also provided.
[0116] Some embodiments relate to nucleic acid molecules encoding immunogenic proteins with 95% homology to the nucleic acid coding sequences herein. Some embodiments relate to nucleic acid molecules encoding immunogenic proteins with 96% homology to the nucleic acid coding sequences herein. Some embodiments relate to nucleic acid molecules encoding immunogenic proteins with 97% homology to the nucleic acid coding sequences herein. Some embodiments relate to nucleic acid molecules encoding immunogenic proteins with 98% homology to the nucleic acid coding sequences herein. Some embodiments relate to nucleic acid molecules encoding immunogenic proteins with 99% homology to the nucleic acid coding sequences herein. In some embodiments, nucleic acid molecules having coding sequences disclosed herein that are homologous to the coding sequences of the common proteins disclosed herein include sequences encoding IgE leader sequences connected to the 5' end of the coding sequences encoding the homologous protein sequences disclosed herein.
[0117] Some embodiments relate to nucleic acid sequences encoding proteins having a specific percentage of identity with the full-length TERT antigen, immunogenic fragments of the TERT antigen, and immunogenic fragments of proteins having identity with the TERT antigen. Such nucleic acid molecules encoding immunogenic proteins having up to 80% identity with the full-length TERT sequence, up to 85% identity with the full-length sequence, up to 90% identity with the full-length TERT sequence, up to 91% identity with the full-length TERT sequence, up to 92% identity with the full-length TERT sequence, up to 93% identity with the full-length TERT sequence, up to 94% identity with the full-length TERT sequence, up to 95% identity with the full-length TERT sequence, up to 96% identity with the full-length TERT sequence, up to 97% identity with the full-length TERT sequence, up to 98% identity with the full-length TERT sequence, and up to 99% identity with the full-length TERT sequence can be provided. Likewise, nucleic acid sequences encoding immunogenic fragments set forth herein and immunogenic fragments of proteins having similar percent identities to the TERT antigens set forth herein as specified above are also provided.
[0118] In some embodiments, the nucleic acid sequence does not contain a coding sequence encoding a leader sequence. In some embodiments, the nucleic acid sequence does not contain a coding sequence encoding an IgE leader sequence.
[0119] Some embodiments relate to fragments of SEQ ID NO: 23 or SEQ ID NO: 57. The fragments may be at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of SEQ ID NO: 23 or SEQ ID NO: 57. The fragments may have at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology to a fragment of SEQ ID NO: 23 or SEQ ID NO: 57. The fragment may be at least 80%, at least 85%, at least 90% at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a fragment of SEQ ID NO: 23 or SEQ ID NO: 57. In some embodiments, the fragment includes a sequence encoding a leader sequence, such as, for example, an immunoglobulin leader sequence, such as an IgE leader sequence. In some embodiments, the fragment does not contain a coding sequence encoding a leader sequence. In some embodiments, the fragment does not contain a coding sequence encoding a leader sequence, such as, for example, an IgE leader sequence.
[0120] In addition, the amino acid sequence of the TERT antigen is SEQ ID NO: 24 or SEQ ID NO: 58. The amino acid sequence of the TERT antigen linked to the IgE leader sequence is SEQ ID NO: 24 or SEQ ID NO: 58. The amino acid sequence of the TERT antigen linked to the IgE leader sequence may be linked to an HA tag.
[0121] Some embodiments relate to proteins homologous to SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having 95% homology to the protein sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having 96% homology to the protein sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having 97% homology to the protein sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having 98% homology to the protein sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having 99% homology to the protein sequence shown in SEQ ID NO:24 or SEQ ID NO:58.
[0122] Some embodiments relate to proteins identical to SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 80% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 85% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 90% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 91% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 92% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 93% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 94% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 95% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 96% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 97% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 98% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58. Some embodiments relate to immunogenic proteins having an amino acid sequence that is 99% identical to the full-length amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:58.
[0123] In some embodiments, the protein does not contain a leader sequence. In some embodiments, the protein does not contain an IgE leader sequence. A fragment of a protein may comprise at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the protein. An immunogenic fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may be provided. The immunogenic fragment may comprise at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of SEQ ID NO: 24 or SEQ ID NO: 58. In some embodiments, the fragment includes a leader sequence, such as, for example, an immunoglobulin leader sequence, such as an IgE leader sequence. In some embodiments, the fragment does not contain a leader sequence. In some embodiments, the fragment does not contain a leader sequence, such as, for example, an IgE leader sequence.
[0124] Immunogenic fragments of proteins having amino acid sequences homologous to immunogenic fragments of SEQ ID NO:24 or SEQ ID NO:58 can be provided. Such immunogenic fragments may comprise at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of a protein having 95% or greater homology to SEQ ID NO:18. Some embodiments relate to immunogenic fragments having 96% homology to immunogenic fragments of the protein sequences herein. Some embodiments relate to immunogenic fragments having 97% homology to immunogenic fragments of the protein sequences herein. Some embodiments relate to immunogenic fragments with 98% homology to the immunogenic fragments of the protein sequences herein. Some embodiments relate to immunogenic fragments with 99% homology to the immunogenic fragments of the protein sequences herein. In some embodiments, the fragments include a leader sequence, such as, for example, an immunoglobulin leader sequence, such as an IgE leader sequence. In some embodiments, the fragments do not contain a leader sequence. In some embodiments, the fragments do not contain a leader sequence, such as, for example, an IgE leader sequence.
[0125] Immunogenic fragments of proteins having the same amino acid sequence as an immunogenic fragment of SEQ ID NO: 24 or SEQ ID NO: 58 can be provided. Such immunogenic fragments can comprise at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of a protein having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence shown in SEQ ID NO: 24 or SEQ ID NO: 58. In some embodiments, the fragment includes a leader sequence, such as, for example, an immunoglobulin leader sequence, such as an IgE leader sequence. In some embodiments, the fragment does not contain a leader sequence. In some embodiments, the fragment does not contain a leader sequence, such as, for example, an IgE leader sequence.
[0126] As indicated herein with respect to attachment of a signal peptide or leader sequence to the N-terminus of a protein, the signal peptide / leader sequence replaces the N-terminal methionine of the protein encoded by the start codon of the nucleic acid sequence encoding the protein without the signal peptide encoding sequence.
[0127] A fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 30 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 45 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 60 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 75 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 90 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 120 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 150 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 180 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 210 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 240 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 270 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 300 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 360 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 420 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 480 or more nucleotides, including a sequence encoding an immunodominant epitope.In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 540 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 600 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 300 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 660 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 720 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 780 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 840 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 900 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 960 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1020 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1080 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1140 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1200 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1260 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1320 or more nucleotides, including a sequence encoding an immunodominant epitope.In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1380 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1440 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1500 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1560 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1620 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1680 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1740 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1800 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1860 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1920 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 1980 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2040 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2100 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2160 or more nucleotides, including a sequence encoding an immunodominant epitope.In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2220 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2280 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2340 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2400 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2460 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2520 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2580 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2640 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2700 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2760 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2820 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2880 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 2940 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 3000 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 3060 or more nucleotides, including a sequence encoding an immunodominant epitope.In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 3120 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 3180 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 3240 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 3300 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 3360 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 3420 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, the fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain 3480 or more nucleotides, including a sequence encoding an immunodominant epitope. In some embodiments, the fragment of SEQ ID NO:23 or SEQ ID NO:57 may contain a coding sequence for an IgE leader sequence. In some embodiments, the fragment of SEQ ID NO:23 or SEQ ID NO:57 does not contain a coding sequence for an IgE leader sequence.
[0128] A fragment may comprise less than 60 nucleotides, in some embodiments less than 75 nucleotides, in some embodiments less than 90 nucleotides, in some embodiments less than 120 nucleotides, in some embodiments less than 150 nucleotides, in some embodiments less than 180 nucleotides, in some embodiments less than 210 nucleotides, in some embodiments less than 240 nucleotides, in some embodiments less than 270 nucleotides, in some embodiments less than 300 nucleotides, in some embodiments less than 360 nucleotides, in some embodiments less than 420 nucleotides, in some embodiments less than 480 nucleotides, in some embodiments less than 540 nucleotides, in some embodiments less than 560 nucleotides. In some embodiments, less than 600 nucleotides, in some embodiments less than 660 nucleotides, in some embodiments less than 720 nucleotides, in some embodiments less than 780 nucleotides, in some embodiments less than 840 nucleotides, in some embodiments less than 900 nucleotides, in some embodiments less than 960 nucleotides, in some embodiments less than 1020 nucleotides, in some embodiments less than 1080 nucleotides, in some embodiments less than 1140 nucleotides, in some embodiments less than 1200 nucleotides, in some embodiments less than 1260 nucleotides, in some embodiments less than 1320 nucleotides, in some embodiments less than 1380 nucleotides. In some embodiments, the present invention provides a polypeptide having a molecular weight of at least 100 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, at least 10 nucleotides, in some embodiments less than 2220 nucleotides, in some embodiments less than 2280 nucleotides, in some embodiments less than 2340 nucleotides, in some embodiments less than 2400 nucleotides, in some embodiments less than 2460 nucleotides, in some embodiments less than 2520 nucleotides, in some embodiments less than 2580 nucleotides, in some embodiments less than 2640 nucleotides, in some embodiments less than 2700 nucleotides, in some embodiments less than 2760 nucleotides, in some embodiments less than 2820 nucleotides, in some embodiments less than 2860 nucleotides, in some embodiments less than 2940 nucleotides,In some embodiments less than 3000 nucleotides, in some embodiments less than 3060 nucleotides, in some embodiments less than 3120 nucleotides, in some embodiments less than 3180 nucleotides, in some embodiments less than 3240 nucleotides, in some embodiments less than 3300 nucleotides, in some embodiments less than 3360 nucleotides, in some embodiments less than 3420 nucleotides, in some embodiments less than 3480 nucleotides, and in some embodiments less than 3510 nucleotides.
[0129] A fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 15 or more amino acids, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 18 or more amino acids, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 21 or more amino acids, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 24 or more amino acids, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 30 or more amino acids, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 36 or more amino acids, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 42 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 48 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 54 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 60 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 66 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 72 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 90 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 120 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 150 or more amino acids, including sequences encoding immunodominant epitopes.In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 180 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 210 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 240 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 270 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 300 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 330 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 360 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 390 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 420 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 450 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 480 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 510 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 540 or more amino acids, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 570 or more amino acids, including a sequence encoding an immunodominant epitope. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 600 or more amino acids, including a sequence encoding an immunodominant epitope.In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 630 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 660 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 690 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 720 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 750 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 780 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 810 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 840 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 870 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 900 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 930 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 960 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 990 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 1020 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO: 24 or SEQ ID NO: 58 may contain 1050 or more amino acids, including sequences encoding immunodominant epitopes.In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1080 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1110 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1140 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1170 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1200 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1230 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1260 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1290 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1320 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1350 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1380 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1410 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1440 or more amino acids, including sequences encoding immunodominant epitopes. In some embodiments, a fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1470 or more amino acids, including sequences encoding immunodominant epitopes.In some embodiments, the fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain 1500 or more amino acids, including a sequence encoding an immunodominant epitope. In some embodiments, the fragment of SEQ ID NO:24 or SEQ ID NO:58 may contain a coding sequence for an IgE leader sequence. In some embodiments, the fragment of SEQ ID NO:24 or SEQ ID NO:58 does not contain a coding sequence for an IgE leader sequence.
[0130] Fragments may comprise less than 24 amino acids, in some embodiments less than 30 amino acids, in some embodiments less than 36 amino acids, in some embodiments less than 42 amino acids, in some embodiments less than 48 amino acids, in some embodiments less than 54 amino acids, in some embodiments less than 60 amino acids, in some embodiments less than 72 amino acids, in some embodiments less than 90 amino acids, in some embodiments less than 120 amino acids, in some embodiments less than 150 amino acids, in some embodiments less than 180 amino acids, in some embodiments less than 210 amino acids, in some embodiments less than 240 amino acids, in some embodiments less than 260 amino acids, in some embodiments less than 290 amino acids, in some embodiments less than 320 amino acids, in some embodiments less than 350 amino acids, in some embodiments less than 380 amino acids, in some embodiments less than 410 amino acids, in some embodiments less than 440 amino acids, in some embodiments less than 470 amino acids, in some embodiments less than 500 amino acids, in some embodiments less than 530 amino acids, in some embodiments less than 560 amino acids, in some embodiments less than 590 amino acids, in some embodiments less than 620 amino acids, in some embodiments less than 640 amino acids, In some embodiments, the present invention comprises less than 650 amino acids, in some embodiments less than 680 amino acids, in some embodiments less than 710 amino acids, in some embodiments less than 740 amino acids, in some embodiments less than 770 amino acids, in some embodiments less than 800 amino acids, in some embodiments less than 830 amino acids, in some embodiments less than 860 amino acids, in some embodiments less than 890 amino acids, in some embodiments less than 920 amino acids, in some embodiments less than 950 amino acids, in some embodiments less than 980 amino acids, in some embodiments less than 1010 amino acids, in some embodiments less than In some embodiments, the present invention comprises less than 1040 amino acids, less than 1070 amino acids, less than 1200 amino acids, less than 1230 amino acids, less than 1260 amino acids, less than 1290 amino acids, less than 1320 amino acids, less than 1350 amino acids, less than 1380 amino acids, less than 1410 amino acids, less than 1440 amino acids, less than 1470 amino acids, and less than 1500 amino acids.
[0131] In one embodiment, the TERT antigen is a synthetic consensus TERT antigen. In certain embodiments, the synthetic consensus TERT comprises 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 15 or more, 20 or more, 30 or more, or 50 or more amino acid mutations relative to the natural TERT antigen.
[0132] In one embodiment, the shared hTERT antigen may be a nucleic acid sequence of SEQ ID NO: 45, which encodes an amino acid sequence of SEQ ID NO: 46. SEQ ID NO: 45 encodes a shared hTERT antigen linked to an IgE leader sequence. The shared hTERT antigen may be linked to an IgE leader sequence and an HA tag. In other embodiments, the shared hTERT antigen may not contain an IgE leader sequence and / or an HA tag or may not be linked to it. In one embodiment, the shared hTERT antigen may be a nucleic acid sequence of SEQ ID NO: 47, which encodes an amino acid sequence of SEQ ID NO: 48. SEQ ID NO: 47 encodes a shared hTERT antigen that does not contain an IgE leader sequence and / or an HA tag or may not be linked to it.
[0133] In one embodiment, the shared mTERT antigen may be a nucleic acid sequence of SEQ ID NO: 49, encoding an amino acid sequence of SEQ ID NO: 50. SEQ ID NO: 49 encodes a shared mTERT antigen linked to an IgE leader sequence. The shared mTERT antigen may be linked to an IgE leader sequence and an HA tag. In other embodiments, the shared mTERT antigen may not contain an IgE leader sequence and / or an HA tag or may not be linked to it. In one embodiment, the shared mTERT antigen may be a nucleotide sequence of SEQ ID NO: 51, encoding an amino acid sequence of SEQ ID NO: 52. SEQ ID NO: 51 encodes a shared mTERT antigen that does not contain an IgE leader sequence and / or an HA tag or may not be linked to it.
[0134] In one embodiment, the consensus rhTERT antigen may be a nucleic acid sequence of SEQ ID NO:53, which encodes an amino acid sequence of SEQ ID NO:54. SEQ ID NO:53 encodes a consensus rhTERT antigen linked to an IgE leader sequence. The consensus rhTERT antigen may be linked to an IgE leader sequence and an HA tag. In other embodiments, the consensus rhTERT antigen may not contain an IgE leader sequence and / or an HA tag or is not linked to it. In one embodiment, the consensus rhTERT antigen may be a nucleotide sequence of SEQ ID NO:55, which encodes an amino acid sequence of SEQ ID NO:56. SEQ ID NO:55 encodes a consensus rhTERT antigen that does not contain an IgE leader sequence and / or an HA tag or is not linked to it.
[0135] In some embodiments, the consensus TERT antigen can be a nucleic acid sequence that is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the entire length of the nucleic acid sequence shown in SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, or SEQ ID NO:55. In other embodiments, the consensus TERT antigen can be a nucleic acid sequence encoding an amino acid sequence that is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical over the entire length of the amino acid sequence shown in SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54 or SEQ ID NO:56. The consensus TERT antigen can be an amino acid sequence that is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical over the entire length of the amino acid sequence shown in SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54 or SEQ ID NO:56.
[0136] Some embodiments relate to nucleic acid sequences encoding proteins homologous to the common TERT antigen, immunogenic fragments of the common TERT antigen, and immunogenic fragments of homologous proteins. Such nucleic acid molecules encoding immunogenic proteins having up to 95% homology to the sequence, up to 96% homology to the sequence, up to 97% homology to the sequence, up to 98% homology to the sequence, and up to 99% homology can be provided. Likewise, nucleic acid sequences encoding immunogenic fragments set forth herein and immunogenic fragments of proteins homologous to the proteins set forth herein are also provided.
[0137] Some embodiments relate to nucleic acid molecules encoding immunogenic proteins with 95% homology to the nucleic acid coding sequences herein. Some embodiments relate to nucleic acid molecules encoding immunogenic proteins with 96% homology to the nucleic acid coding sequences herein. Some embodiments relate to nucleic acid molecules encoding immunogenic proteins with 97% homology to the nucleic acid coding sequences herein. Some embodiments relate to nucleic acid molecules encoding immunogenic proteins with 98% homology to the nucleic acid coding sequences herein. Some embodiments relate to nucleic acid molecules encoding immunogenic proteins with 99% homology to the nucleic acid coding sequences herein. In some embodiments, nucleic acid molecules having coding sequences disclosed herein that are homologous to the coding sequences of the common proteins disclosed herein include sequences encoding IgE leader sequences connected to the 5' end of the coding sequences encoding the homologous protein sequences disclosed herein.
[0138] Some embodiments relate to nucleic acid sequences encoding proteins having a specific percent identity to the full-length consensus TERT antigen, immunogenic fragments of the consensus TERT antigen, and immunogenic fragments of proteins having identity to the consensus TERT antigen. Such nucleic acid molecules encoding immunogenic proteins having up to 80% identity to the full-length consensus TERT sequence, up to 85% identity to the full-length consensus sequence, up to 90% identity to the full-length consensus TERT sequence, up to 91% identity to the full-length consensus TERT sequence, up to 92% identity to the full-length consensus TERT sequence, up to 93% identity to the full-length consensus TERT sequence, up to 94% identity to the full-length consensus TERT sequence, up to 95% identity to the full-length consensus TERT sequence, up to 96% identity to the full-length consensus TERT sequence, up to 97% identity to the full-length consensus TERT sequence, up to 98% identity to the full-length consensus TERT sequence, up to 99% identity to the full-length consensus TERT sequence can be provided. Likewise, nucleic acid sequences encoding immunogenic fragments set forth herein and immunogenic fragments of proteins having similar identity percentages as specified above to the consensus TERT antigens set forth herein are also provided.
[0139] In some embodiments, the nucleic acid sequence does not contain a coding sequence encoding a leader sequence. In some embodiments, the nucleic acid sequence does not contain a coding sequence encoding an IgE leader sequence.
[0140] Some embodiments relate to fragments of SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, or SEQ ID NO: 55. The fragment can be at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, or SEQ ID NO: 55. The fragment may have at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology with a fragment of SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, or SEQ ID NO:55. The fragment may have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with a fragment of SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, or SEQ ID NO:55. In some embodiments, the fragment includes a sequence encoding a leader sequence, such as, for example, an immunoglobulin leader sequence, such as an IgE leader sequence. In some embodiments, the fragment does not contain a coding sequence encoding a leader sequence. In some embodiments, the fragment does not contain a coding sequence encoding a leader sequence such as, for example, an IgE leader sequence.
[0141] In addition, in one embodiment, the amino acid sequence of the consensus TERT antigen is SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, or SEQ ID NO: 56. The amino acid sequence of the consensus TERT antigen linked to the IgE leader sequence is SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, or SEQ ID NO: 56. The amino acid sequence of the consensus TERT antigen linked to the IgE leader sequence can be linked to an HA tag.
[0142] Some embodiments relate to proteins homologous to SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, or SEQ ID NO:56. Some embodiments relate to immunogenic proteins having 95% homology to the protein sequence shown in SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52...
Claims
1. An immunogenic composition comprising a nucleic acid molecule encoding a consensus TERT antigen, wherein the consensus TERT antigen comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 46 and SEQ ID NO:
48.
2. The immunogenic composition of claim 1, wherein the immunogenic composition further comprises one or more nucleotide sequences encoding one or more amino acid sequences selected from the group consisting of: a) an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70; b) an amino acid sequence having 98% or greater identity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, and ... c) a fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, wherein the fragment comprises at least 98% of the full-length amino acid sequence.
3. The immunogenic composition of claim 1, further comprising a nucleic acid encoding one or more antigens selected from the group consisting of MAGE A1, gp100, viral antigens, and combinations thereof.
4. The immunogenic composition of claim 3, wherein the viral antigen is an antigen from hepatitis B virus (HBV), hepatitis C virus (HCV) or human papillomavirus (HPV).
5. The immunogenic composition of claim 4, wherein the HBV antigen is HBV core antigen or HBV surface antigen or a combination thereof.
6. The immunogenic composition of claim 5, wherein the HCV antigen is HCV NS34A antigen, HCV NS5A antigen, HCV NS5B antigen, HCV NS4B antigen, or a combination thereof.
7. The immunogenic composition of claim 4, wherein the HPV antigen is HPV type 6 E6 antigen, HPV type 6 E7 antigen, HPV type 11 E6 antigen, HPV type 11 E7 antigen, HPV type 16 E6 antigen, HPV type 16 E7 antigen, HPV type 18 E6 antigen, HPV type 18 E7 antigen, or a combination thereof.
8. The immunogenic composition of claim 1, further comprising an immune checkpoint inhibitor.
9. The immunogenic composition of claim 1, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: a) a nucleotide sequence selected from the group consisting of SEQ ID NO:45 and SEQ ID NO:47, b) a nucleotide sequence having 98% or greater identity with a nucleotide sequence selected from the group consisting of SEQ ID NO:45 and SEQ ID NO:47, and c) a fragment of a nucleotide sequence selected from the group consisting of SEQ ID NO: 45 and SEQ ID NO: 47, wherein the fragment comprises at least 98% of the full-length nucleotide sequence.
10. The immunogenic composition of claim 2, wherein the immunogenic composition comprises one or more nucleotide sequences selected from the group consisting of: a) a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67 and SEQ ID NO: 69; b) a nucleotide sequence having 98% or greater identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69, and c) a fragment of a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67 and SEQ ID NO:69, wherein the fragment comprises at least 98% of the full-length nucleotide sequence.
11. The immunogenic composition of claim 1, wherein the nucleic acid is a plasmid.
12. The immunogenic composition of claim 1, wherein the composition comprises one or more plasmids.
13. The immunogenic composition of claim 1, further comprising an adjuvant.
14. The immunogenic composition of claim 13, wherein the adjuvant is IL-12, IL-15, IL-28 or RANTES.
15. Use of the immunogenic composition of claim 1 in the preparation of a medicament for treating or preventing cancer in a subject in need thereof, the treatment or prevention comprising administering the immunogenic composition to the subject.
16. Use according to claim 15, wherein the administration comprises an electroporation step.
17. The use according to claim 15, wherein the treatment or prevention further comprises administering an immune checkpoint inhibitor to the subject.
18. The use according to claim 17, wherein the immunogenic composition and the immune checkpoint inhibitor are administered to the subject in a single formulation.
19. The use according to claim 17, wherein the immunogenic composition and the immune checkpoint inhibitor are administered to the subject separately.
20. The use according to claim 15, wherein the cancer is selected from the group consisting of melanoma, head and neck cancer, prostate cancer, liver cancer, cervical cancer, recurrent respiratory papillomatosis (RRP), anal cancer, blood cancer, ovarian cancer, and combinations thereof.
21. A nucleic acid molecule comprising one or more nucleotide sequences selected from the group consisting of: SEQ ID NO:45 and SEQ ID NO:
47.
22. The nucleic acid molecule according to claim 21, further comprising one or more nucleotide sequences selected from the group consisting of: a) a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67 and SEQ ID NO: 69; b) a nucleotide sequence having 98% or greater identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69, and c) a fragment of a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67 and SEQ ID NO:69, wherein the fragment comprises at least 98% of the full-length nucleotide sequence.
23. The nucleic acid molecule of claim 21, wherein the nucleic acid molecule is a plasmid.
24. An amino acid molecule comprising one or more amino acid sequences selected from the group consisting of: SEQ ID NO: 46 and SEQ ID NO:
48.
25. The amino acid molecule of claim 24, further comprising one or more amino acid sequences selected from the group consisting of: a) an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70; b) an amino acid sequence having 98% or greater identity to an amino acid selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, and ... c) a fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, wherein the fragment comprises at least 98% of the full-length amino acid sequence.
